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8 | Chapter 1 
 
Over the past few years, the Dutch newspapers paid a lot of attention to the introduction of 
non-invasive prenatal testing (NIPT) for Down’s syndrome, Edwards’ syndrome and Patau’s 
syndrome. They fuelled the debate about the introduction of this promising test, which will 
provide much more reliable test results compared to existing prenatal screening tests and 
prevent uncertainty for women. The newspapers also published articles headed like for 
example “Born, despite the NIP-test” or “Who chooses for a child with Down’s syndrome” 
addressing ethical and social issues of NIPT.(1, 2) The first mentioned article draws a portrait 
of three couples with a child with Down’s syndrome who made different decisions about 
prenatal screening for Down’s syndrome. Two couples did not accept NIPT and one couple 
accepted it after an indication from the 20 weeks ultrasound. One couple did not opt for 
NIPT because, as the parents explained, they had no reasons for having prenatal screening: 
she was doing well and moreover, they thought that every child should be welcomed. The 
news that their new-born son has Down’s syndrome was thus totally unexpected and the 
parents began to doubt their decision to decline NIPT. They explained that it felt as if they 
had chosen for a child with Down’s syndrome by declining NIPT: “It was not something that 
just happened to us. You cannot go back to a sort of innocence.” Nevertheless, they are not 
sure whether they will opt for NIPT in a next pregnancy and they question what they would 
do in case of an abnormal result, also because they still, after six months have to adapt to 
the new unexpected situation: “I love him but still I rather would have a child without 
Down’s syndrome. It feels very tricky to say this”. The other couple declined NIPT because 
they would welcome every child. The second article reports the dialogue between a mother 
who decided to terminate the pregnancy after receiving the diagnosis of Down’s syndrome 
and a mother of a son with Down’s syndrome. Both mothers explained how difficult it  is to 
talk about your choice, because there are always people who have judgements about it . 
Nevertheless there are also people who are helped with sharing these opinions. These 
mothers therefore thought that it is important to have such dialogues, to create 
understanding for both decisions to accept or decline prenatal screening and terminate or 
continue the pregnancy after a diagnosis of Down’s syndrome. 
These newspaper articles reported parents’ personal considerations concerning prenatal 
screening and termination of pregnancy and how they deal with the decision. The articles 
also pointed at the social dilemmas concerning the availability of prenatal screening: does 





create this availability a certain responsibility for having a healthy child? Is it still accepted to 
give birth to a child with a disability? The Dutch social debate in newspapers and on 
television about the pros and cons of prenatal screening and the introduction of the 
relatively new non-invasive prenatal test (NIPT) are supported by these personal stories 
about deciding about prenatal screening as well as deciding about termination of a 
pregnancy of a child with Down’s syndrome in order to make the related dilemmas concrete.  
In the media these pros and cons of particularly NIPT are strongly contrasted and sometimes 
inflated. The reasons to learn about possible abnormalities, including psychological and 
practical preparation for the birth of a disabled child or the option to terminate the 
pregnancy, are contrasted with the negative consequences of a prenatal screening offer, 
including the a lack of freedom of choice and stigmatization or discrimination of people with 
the relevant disabilities. Firm statements about a lack of informed decision-making, 
routinisation, societal pressure to test and an expanded scope mark the debate. Also in the 
scientific debate these benefits and possible disadvantages of NIPT are mentioned, discussed 
and analysed. However, in both the social and scientific debate the reflection on the validity 
of the several arguments and concerns is limited. This thesis aims to clarify and justify these 
issues and related arguments, inform and nuance the scientific and social debate about 
prenatal screening and contribute to a responsible implementation of NIPT and its possible 
expansion.  
1.1 Aim of prenatal screening  
The aim of prenatal screening for aneuploidies is formulated as promoting reproductive 
choices or reproductive autonomy or providing courses of action to pregnant women and 
couples.(3-5) Prenatal screening enables pregnant women to obtain information about the 
health of their unborn child in order to have the possibility to terminate the pregnancy or to 
prepare for the birth of a child with a disorder in case of an abnormal test-result. This aim is 
formulated as an alternative for the general aim of other population screening programmes 
which is prevention.(3) Prevention-aimed screening intends to promote health and reduce 
morbidity or mortality. Prenatal screening programmes also include preventive screening 
tests to improve pregnancy outcomes and to gain health benefit, for example tests for the 
Rhesus-D status, hepatitis B or HIV. However, with prenatal screening for aneuploidies no 
health benefit can be reached because there are no treatments available for the disorders 
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included in the test. Prevention as an aim of such screening is therefore problematic: 
termination of an affected pregnancy would then be a preventive measure and the success 
rate of the prevention programme would be the amount of terminations. This might 
pressure women to terminate a pregnancy of a child with a disability.(3) Therefore the aim 
of prenatal screening is formulated as promoting reproductive autonomy and termination of 
an affected pregnancy is explicitly mentioned as one course of action among other 
options.(6) The success of the programme should be measured in terms of informed consent 
which is seen as the operationalization of the aim.(3) This aim is underlined in the ongoing 
debate about (selective) abortion as the consequence of prenatal screening. Opponents 
argue against prenatal screening because it provides women with reasons for abortion, 
which they reject for three reasons. Firstly, some people are against abortion because they 
believe that life starts at conception and is therefore from that moment on worth 
protecting. Others rejects abortion because they believe that one should accept life as it 
comes, without having religious convictions as underlying reasons for it. These two groups 
therefore disagree with the starting point of the Dutch Health council and Dutch legislation 
that the protection of unborn life of the foetus increases during the pregnancy. According  to 
this starting point, a foetus is viable from a gestational age of 24 weeks on and in principle 
abortion is allowed until the 24th week.(5)   
A third view opposes prenatal screening because it provokes selective abortion, which sends 
a discriminatory message about lives of people with the conditions included in the prenatal 
test. This is known as the ‘expressivist argument’, held by representatives of the disability 
rights critique, which argues that techniques which lead to prevention of the birth of 
children with disabilities send discriminatory messages about people with disabilities. (7) 
Others refuted this argument with stating that pregnant women and couples do not decide 
for selective abortion to judge the life of disabled people but because of the impact of 
raising a child with a disability on their own lives or to prevent severe suffering for the 
child.(6) However, in practice this argumentation does not take away the parents’ concerns 
that prenatal screening and particularly NIPT affects the life of disabled people. Parents of 
children with Down’s syndrome for example gathered negative experiences of judgment of 
others and of being confronted with critique on having a child with Down’s syndrome in a 
Blackbook.(8) They presented it to the Dutch House of Representatives in order to provide 





an illustration of the negative consequences of prenatal screening for children with Down’s  
syndrome and their family and to feed the debate about the possible consequences of NIPT.  
Informed choice  
To reach the aim of reproductive autonomy, in the practice of prenatal screening 
professionals aim at women’s informed decision-making by providing information about the 
prenatal test and the tested disorders.(3, 9) Informed choice as used in the context of 
prenatal screening is defined as “one that is based on relevant knowledge, consistent with 
the decision-maker’s values and behaviourally implemented”.(10) Information includes the 
conditions tested for, characteristics of the test and the implications of undergoing a  test. A 
woman’s attitude comprises her values concerning prenatal screening. ‘Behaviourally 
implemented’ means the actual choice.(9)   
The multi-dimensional measure of informed choice (MMIC) is the instrument most used in 
the field of prenatal screening to measure the informedness of women’s choices based on a 
self-report questionnaire about someone’s knowledge and attitude.(11) A woman is thought 
to have sufficient knowledge when approximately at least half of the questions about the 
provided information concerning prenatal screening are answered correctly. Attitudes 
towards prenatal screening are assessed with questions such as for example “For me 
prenatal screening for Down’s syndrome would be beneficial/harmful”. Studies measuring 
informed choice showed various percentages of informed choice for first-trimester prenatal 
screening.(12) That 37%(13), 43%, 51%(14), 59%(11), or 68%(15) of the participating women 
made an informed choice for the first-trimester combined test and 75.6(16), 77.9%(17) and 
89.0(18) for NIPT were promising results, although it also indicates that there is room for 
improvement. The recent introduction of NIPT was one of the reasons to start with this 
improvement and to again emphasize the importance of informed choice, also -or 
specifically- for this new practice changing test.  
 
1.2 The introduction of non-invasive prenatal testing (NIPT) 
NIPT is based on the finding that maternal blood contains cell-free DNA of the placenta.(19) 
Testing cell-free DNA was already conducted prenatally for foetal sex determination and 
rhesus D screening.(20) Genome wide sequencing techniques now also enable detection of 
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aneuploidies in this cell-free DNA which led to the introduction of NIPT for trisomy 21, 18 
and 13 into the prenatal screening practice.(21) In 2011 NIPT became available in the United 
States and Western-Europe and thereafter also other in parts of the world. (22) It is proved 
to be an accurate test providing very reliable results compared to the first-trimester 
combined test(21, 23) with 98% sensitivity and a positive predictive value of 96% for Down’s 
syndrome in a general obstetric population.(24) The first-trimester combined test has been 
offered to Dutch women since 2007 and includes a blood test and an ultrasound. The blood 
test measures maternal serum markers (PAPP-A end free betaHCG) and the ultrasound 
examines the nuchal translucency, the nuchal fold thickness. The obtained results, combined 
with the maternal age provide a risk estimate for Down’s syndrome. In the Netherlands the 
cut-off point for a high risk for Down’s syndrome is 1:200. A risk higher than 1:200 is an 
indicator for invasive follow-up testing. Women with a high risk result are eligible for an 
amniocentesis and chorionic villi sampling, both invasive follow-up diagnostic test with a 
very small miscarriage risk. The first-trimester combined test has a considerable amount of 
false positives, leading to unnecessary invasive follow-up diagnostic tests. With NIPT it is 
aimed to reduce the number of false positive screening results and therewith the number of 
unnecessary invasive follow-up tests.(25) NIPT can be introduced as first test or as second 
test after the first-trimester combined test. In case of NIPT as a second-tier screening 
women who received a high risk result from the first-trimester combined test can first opt 
for NIPT before they undergo invasive diagnostics. NIPT as first step replaces the first-
trimester combined test and is also offered to women without an increased risk for Down’s 
syndrome.  
NIPT does not provide a fully reliable result because amongst others a lower foetal fractio n, 
a confined placental mosaicism or a maternal tumour could cause false positive or negative 
results. Therefore an abnormal NIPT result still needs to be confirmed with a diagnostic 
invasive test.(26) According to several studies NIPT’s reliability and easiness are seen by 
women and professionals as advantages, compared to the combined test. Besides, only a 
blood draw from the mother is needed to conduct the test and it can be done earlier in the 
pregnancy, from 9 weeks on.(27-30)  
An expanding scope of prenatal screening    
With whole genome sequencing techniques NIPT technically allows for testing the entire 





genome of the foetus.(24) This enables the expansion of the scope of prenatal screening and 
the detection of an increasing number of lethal, severe and milder chronic disorders, 
including other trisomies like trisomy 8, 9, 15, 16 and 22, microdeletions like for example 
12q or 22q11 deletion causing DiGeorge syndrome, variants of unknown significance (VOUS) 
and placental chromosome aberrations.(24, 31-33) NIPT can also reveal aneuploidies which 
are associated with pregnancy loss or maternal preeclampsia.(34, 35)  
Ethical aspects of NIPT  
The introduction of NIPT and the promising improvement of first-trimester prenatal 
screening for aneuploidies however raised clinical and ethical questions about its impact on  
informed decision-making, about the scope of prenatal screening and about the possible 
negative consequences for freedom of choice in prenatal screening and for giving birth to a 
child with a disability.   
A simple blood draw eases the access to prenatal screening for women. This fuelled the fear 
that NIPT might foster women to routinely accept the prenatal screening offer, without 
thinking about its consequences. This might lead to what is called routinisation of prenatal 
screening which refers to the concern that a prenatal test is offered and accepted 
routinely.(36, 37) A routine uptake might impede informed decision-making and with that 
thus hinders the aim of prenatal screening.  
Another indicated problem for informed choice is the possible expansion o f the scope and 
the technical possibility to detect more abnormalities. The expanded pre-test information 
might hinder a well-informed decision-making and it can be questioned whether women will 
understand the possible rare and unknown test results including unknown phenotypes.(3) 
The possibility to expand the scope of prenatal screening also raises questions and concerns 
regarding how to define the scope ethically. Although it is seen as positive that an expanded 
scope removes the focus on Down’s syndrome, it is questioned where the line should be 
drawn and which disorders would be included and which not. This question includes the 
difficulty that a defining list of disorders is susceptible to discrimination,(5) as explained 
above in the discussion of the purpose of prenatal screening. But the practice of prenatal 
screening needs some guidance to determine the scope and distinguish between serious and 
trivial disorders.  
The indicated questions and concerns are not unique for NIPT but were previously indicat ed 
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in the context of other screening and diagnostic tests.(38-40) This thesis bui lds on previous 
debates and aims to clarify, verify and if necessary rectify several arguments within this 
debate which are raised in the context of the introduction of NIPT. 
1.3 Dutch context of prenatal screening 
Legislation and policy  
First the Dutch context of prenatal screening and related legislation and policy will be 
described. In the Netherlands screening of (a category of) the population is regulated by the 
Population Screening Act (Wet op het Bevolkingsonderzoek, WBO, (1992). This act aims to 
protect citizens against potential physical or psychological risks of screening and requires 
that some screening programmes should have a license, including screening which uses ionic 
radiation, cancer screening and screening for severe disorders or abnormalities for which no 
treatment or prevention is available. Prenatal screening for aneuploidies, for which no 
treatment is available, falls within the latter group and thus needs a license.(41) For this 
license prenatal screening should meet the quality requirements. An important requirement 
concerns the pre-test information about the characteristics of the screening test, its 
consequences and possible follow-up, which is the basis for a well-informed choice. 
Although prenatal screening is not offered by the Dutch government prenatal screening all 
pregnant women receive information about prenatal screening as part of the standard 
healthcare during the pregnancy. The quality of the screening and the information is 
monitored by the RIVM (National Institute for Public Health and Environment) which is 
responsible for the coordination and implementation of the prenatal screening programme. 
In the Netherlands since 2007 first-trimester prenatal screening is offered to women older 
than 38 and later 36. Women younger than 36 had to pay for the screening test. Since 
January 2015 this age limit is abandoned and all pregnant women have to pay €165,- for the 
first-trimester combined test. This age limit was amongst others abandoned because it 
possible might lead to misconceptions about the age-related risks.  
 
NIPT in the Netherlands  
In 2014 NIPT became available within the Netherlands and was offered to high -risk women 
within a nationwide study, the TRIDENT-1 study (Trial by Dutch laboratories for Evaluation of 
Non-Invasive Prenatal Testing). This study aimed to assess the clinical impact of NIPT 





including uptake, test results, test performance and pregnancy outcomes.(25) This study has 
shown promising results concerning the performance of NIPT and the clinical aspects(25) 
and therefore besides TRIDENT-1 since 1 April 2017 TRIDENT-2 started. In the TRIDENT-2 
study NIPT is offered to all pregnant women as an alternative for the first -trimester 
combined test.(24) Both TRIDENT studies not only assess clinical aspects but also study 
women’s preferences and considerations concerning prenatal screening and NIPT as well as 
ethical, social and psychological aspects, including informed choice.(17, 42)  
1.4 The aim and research questions of the thesis  
In the ethical and social debate about prenatal screening and particularly NIPT informed 
choice, routine acceptance of a prenatal screening offer, societal pressure to test, 
reimbursement and the expansion of the scope are recurring and pressing themes. However, 
the related arguments, that NIPT might 1) impede informed choice or lead to routine 
acceptance of prenatal screening, 2) that NIPT might lead to routinisation of prenatal 
screening or societal pressure to test and that 3) reimbursement might lead to better 
informed choices, have limited empirical and ethical support. The aim of this thesis is to 
explicate and clarify these ethical and social arguments concerning prenatal screening an d 
specifically NIPT. Furthermore, it aims to search for empirical and conceptual evidence to 
support or criticize these arguments in order to contribute to the scientific and social debate 
about a responsible implementation of NIPT and the possible expansion of the scope of 
prenatal screening. 
The following research questions are addressed in this thesis.  
Part I: The ethical framework for prenatal screening: theory and practice 
1. What is the ethical framework of prenatal screening and how could this guide the 
expansion of its scope? (Chapter 2) 
2. What do pregnant women think about ethical and social aspects of NIPT and the 
possible expansion of its scope? (Chapter 3) 
3. What do parents of children with Down’s syndrome think about NIPT and the 
possible expansion of its scope? (Chapter 4) 
Part II: Conceptual and empirical analyses of ethical and social issues of prenatal screening. 
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1. How could informed consent and pre-test counselling serve the aim of prenatal 
screening at best? (Chapter 5) 
2. What is meant with the concept of routinisation? Are the related routinisation 
arguments valid? (Chapter 6) 
3. What are the Dutch public’s attitudes towards prenatal screening and could they 
lead to societal pressure? (Chapter 7) 
4. Should prenatal screening be fully reimbursed? (Chapter 8) 
1.5 Methodology  
In this thesis several methodologies are used to answer the research questions including 
ethical analysis of concepts and practices and empirical research methods. Qualitative and 
quantitative methods were used to study the attitudes of pregnant women, partners, 
parents of children with Down’s syndrome and the Dutch public towards non-invasive 
prenatal testing.  
The role of empirical research in ethics could be defined in at least two ways: firstly it can 
inform normative ethics in assessing which ethical questions arise in practice and how to 
deal with these questions. Empirical research could indicate which aspects of a certain 
practice need normative reflection. This approach of empirical ethical research sees 
empirical studies as source of normatively relevant facts not of normative claims as such. 
Secondly, empirical research in practice could be seen as source of moral beliefs or 
“normative-ethical knowledge” and therefore opinions of those working in practice could be 
seen as morally relevant. Practical experiences are then part of the ethical deliberation 
process.(43, 44)   
Authors indicated several levels and categories of empirical research that could inform 
bioethics, ranging from defining current practices to improving care, from finding out who is 
involved in the specific practice to changing ethical norms.(45, 46) Empirical research can for 
example reveal who is the person that is expected to make an ethical decision and who is 
object of the decision.(45)  
In this thesis empirical research is used in both ways and on several levels. Empirical 
information is gathered about stakeholders’ attitudes towards NIPT. Health professionals, 
pregnant women, parents and the public were asked about their moral attitudes in order to 





see which ethical questions arise from the clinical practice, the intended users of NIPT and 
the public. This might contribute to the deliberation about an ethical valid introduction of 
NIPT and about the scope for prenatal screening. Another aspect in ethics of prenatal 
screening are “foreseeable effects”(45): empirical research can help to study what already 
can be known about possible consequences of introducing NIPT, including social pressure or 
consequences for people with for example Down’s syndrome. Precisely in the debate about 
prenatal screening, in which the preferences from pregnant women and professionals and 
also the possible impact of NIPT are highly relevant for the way the tests are offered, 
empirical research can contribute significantly. Therefore I made use of a mixed method 
approach of both conceptual analysis and empirical methods. This app roach aims at giving 
more insight in arguments like slippery slope arguments, routinisation arguments and 
arguments concerning societal pressure to test. It enables the ethical analyses to be more 
explicit and concrete about the possible consequences of NIPT in order to further the 
debate. On the other hand, conceptual analyses will provide clarity in arguments which will 
not come to surface by empirical studies and might provide direction to the debate.  
1.6 Clarifications of words and concepts   
In advance I first will clarify some concepts or notions that are frequently used in the debate 
and in this thesis. Firstly, when it comes to decision-making about prenatal screening often 
only pregnant women were mentioned instead of women and partners or women an d 
couples. Also in studies on prenatal screening mostly women participated and 
measurements of informed choice were conducted amongst women. However, in practice it 
is mostly a decision of both the pregnant woman and her partner which should be kept in 
mind when thinking and writing about informed decision-making and pre-test counselling, 
although the partner is not explicitly mentioned. 
Terms for indicating disorders  
When writing about prenatal screening several words are used to indicate a disorder. In this 
thesis ‘abnormality’, ‘congenital abnormality or disorder’ and ‘disorder’ are interchangeably 
used to indicate the presence of a (chronic) disorder in the foetus.(47) The concept of 
‘disability’ is also used which relates to more than the clinical aspects of having disorder. It 
also includes the (social) context in which people with a disorder live. It comprises the 
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interaction between the social environment and living with a disease including the impact of 
de disorder on major life activities.(48, 49)  
Prenatal screening and diagnosis  
The concept of screening in general is used to indicate an unsolicited test offer to whole 
population groups or selected groups and aims and refers to “the presumptive identification 
of unrecognized disease or defect by the application of tests examinations or other 
procedures”.(50) Prenatal screening for congenital disorders is a selective screening and is 
offered to all pregnant women. In this thesis I use ‘prenatal screening’ or ‘prenatal testing’ to 
indicate the unsolicited offer of a prenatal screening test for congenital disorders.   
Prenatal screening differs from prenatal diagnosis which refers to diagnostic tests that are 
conducted on indication after obtaining an abnormal test result from NIPT or the first 
trimester combined test. Prenatal diagnosis is then offered to women as a follow-up test to 
confirm the prenatal screening result.  
1.7 Outline  
The first part of this thesis discusses the ethical framework for prenatal screening (chapter 
2). The various ethical aspects in this framework were discussed with professionals (chapter 
2) pregnant women (chapter 3) and parents of children with Down’s syndrome (chapter 4) in 
individual interviews and focus groups.  
In the second part of this thesis four specific ethical and societal issues and their related 
arguments are addressed, concerning informed consent (chapter 5) routinisation of prenatal 
screening (chapter 6), societal pressure to test (chapter 7) and reimbursement of prenatal 
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Abstract 
Background: The introduction of non-invasive prenatal testing (NIPT) for foetal aneuploidies 
is currently changing the field of prenatal screening in many countries. As it is non -invasive, 
safe and accurate, this technique allows for a broad implementation of first-trimester 
prenatal screening, which raises ethical issues, related, for instance, to informed choice and 
adverse societal consequences. This article offers an account of a leading international 
ethical framework for prenatal screening, examines how this framework is used by 
professionals working in the field of NIPT, and presents ethical guidance for the expansion of 
the scope of prenatal screening in practice. Methods: A comparative analysis of 
authoritative documents is combined with 15 semi-structured interviews with professionals 
in the field of prenatal screening in the Netherlands. Data were recorded, transcribed 
verbatim and analysed using thematic analysis. Results: The current ethical framework 
consists of four pillars: the aim of screening, the proportionality of the test, justice, and 
societal aspects. Respondents recognised and supported this framework in practice, but 
expressed some concerns. Professionals felt that pregnant women do not always make 
informed choices, while this is seen as central to reproductive autonomy (the aim of 
screening), and that pre-test counselling practices stand in need of improvement. 
Respondents believed that the benefits of NIPT, and of an expansion of its scope, outweigh 
the harms (proportionality), which are thought to be acceptable. They felt that the out -of-
pocket financial contribution currently required by pregnant women constitutes a barrier to 
access to NIPT, which disproportionally affects those of a lower socioeconomic status 
(justice). Finally, professionals recognised but did not share concerns about a rising pressure 
to test or discrimination of disabled persons (societal aspects). Conclusions: Four types of 
limits to the scope of NIPT are proposed: NIPT should generate only test outcomes that are 
relevant to reproductive decision-making, informed choice should be (made) possible 
through adequate pre-test counselling, the rights of future children should be respected, and 
equal access should be guaranteed. Although the focus of the interview study is on the 
Dutch healthcare setting, insights and conclusions can be applied internationally and to 
other healthcare systems. 
 
 





Non-invasive prenatal testing (NIPT) is based on the analysis of cell free foetal DNA for 
chromosomal abnormalities.(1) Non-invasiveness refers to the way the foetal DNA sample is 
obtained: not from the placenta or amniotic fluid, which requires an invasive procedure, but 
from a blood sample of the mother.   
NIPT for chromosomal abnormalities was first offered in 2011, in the United States of 
America, Western-Europe and China.(2) In the Netherlands, prenatal screening for 
untreatable disorders is subjected to licensing under the Population Screening Act. NIPT has 
been offered to high-risk women, exclusively within the context of the TRIDENT-1 study 
(Trial by Dutch laboratories for Evaluation of Non-Invasive Prenatal Testing) since early 
2014.(3) When a woman received a high-risk outcome (chance ≥1:200) from the first 
trimester combined test (FCT) and wanted further testing, she was offered the choice 
between NIPT or invasive testing.(3) Low-risk pregnant women who wanted NIPT could not 
access NIPT in the Netherlands, and went abroad. Since April 2017, NIPT is also offered 
within the TRIDENT-2 study to low-risk pregnant women, who are given a choice between 
FCT and NIPT. The current NIPT-based prenatal test includes detection of trisomy 21 (Down 
syndrome), trisomy 18 (Edwards syndrome) and trisomy 13 (Patau syndrome). Compared to 
the FCT the sensitivity, the specificity and the positive predictive value of NIPT are 
remarkably high for those trisomies.(3) The positive predictive value is slightly lower in low-
risk pregnant women but still higher than the positive predictive value of the FCT.(1, 4, 5) 
However, NIPT is not a diagnostic test. This is because of several factors. First, cell free foetal 
DNA circulating in maternal blood originates from the placenta, not the foetus. The presence 
of a chromosomal anomaly can be limited to the placenta in case of confined placental 
mosaicism without affecting the foetus, thus resulting in a false positive NIPT outcome. 
Furthermore, the presence of maternal chromosomal anomalies, including those originating 
from a maternal tumour, false-negative NIPT due to a low foetal DNA fraction in maternal 
blood, and a vanishing twin (6, 7), may still lead to inconclusive, false positive or false 
negative results.(8) Yet NIPT leads to fewer unnecessary invasive follow-ups tests - through 
amniocentesis and the chorionic villus sampling - than the FCT. These invasive tests have a 
0.1%-0.2% miscarriage risk respectively.(3) To minimize the need for invasive testing – and 
the associated risk of miscarriage – has been one of the major reasons for implementing 
NIPT in current screening programmes.  
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When genome-wide sequencing techniques are used to perform NIPT, they allow for the 
detection of chromosomal abnormalities other than trisomy 13, 18 and 21, and thus for an 
expansion of the current scope of prenatal screening.(3, 9) Several studies have indicated 
that additional findings could include other full trisomies, sex-chromosomal abnormalities,  
and sub-chromosomal aberrations, associated with rare diseases.(3, 10-12) However, the 
possibility to find more abnormalities has raised questions, notably the policy question 
whether the screening offer should be expanded to include all those abnormalities. When 
discussing the question whether or not to include additional conditions, experts have 
brought up considerations of clinical utility and concerns related to the consequences of a 
broader test for informed choice.(13-15) These concerns were raised ten years ago, when 
genome-wide arrays were introduced in prenatal diagnosis, and are raised again with 
renewed urgency in the context of the introduction of NIPT.(16)  
Various statements and position papers about prenatal screening, issued by governmental 
organisations and ethical committees, have addressed ethical issues of prenatal 
screening.(15, 17-24) Together with scholarly studies of ethical issues in prenatal screening 
(25-30) these statements and position papers could be seen as an – unofficial, but broadly 
shared and often referred to – international ethical framework for prenatal screening. An 
ethical framework can be defined as a specification of general principles in a specific context, 
through which the scope of general principles is narrowed by spelling out why and how 
actions should be undertaken or avoided.(31) The aim of an ethical framework is to “provide 
practical guidance for public health professionals and to highlight the defining values of 
public health.”(32)  
The aim of this article is firstly to reconstruct and analyse the main tenets of the ethical 
framework for prenatal screening and then to compare these with the practi ce of prenatal 
screening, by interviewing professionals in the field of prenatal screening. Secondly, this 
article examines whether and how the ethical framework can guide the introduction of an 
expansion of the scope of prenatal screening.  
Methods 
For this study we used a combination of methods, a literature study and a qualitative 
interview study. We conducted a comparative analysis of ethical statements about 




requirements for (non-invasive) prenatal testing formulated by national and international 
organisations or committees. Also, we conducted in-depth interviews with Dutch 
professionals in the field of prenatal screening. The interviews serve to illustrate how the 
ethical framework for prenatal screening is translated into practice, and to offer insigh t into 
professionals’ moral views on recent developments in prenatal screening.  
Document analysis  
To identify important documents that represent an ethical framework we started with an 
authoritative article of the European Society of Human Genetics (ESHG) and the American 
Society of Human Genetics (ASHG), which offers a consensus view of responsible innovation 
in prenatal screening, which is also endorsed by the Human Genetics Society of Australasia 
and other related professional associations in Europe.(15) We built on this consensus view 
and postulated four pillars of an ethical framework: the aim of prenatal screening, 
proportionality of testing, justice, and societal aspects. Other studies and documents – 
notably from the World Health Organisation (WHO), UNESCO International Bioethics 
Committee (IBC), German Ethics Council (Ethikrat) and the Dutch Health Council (GR) – were 
reviewed to corroborate, adapt and complement the ethical framework. We selected these 
four other documents for our analysis because – in contrast to other publications we have 
reviewed – these documents contain discussions of issues related to all four pillars. 
Interviews 
For the qualitative interview study, professionals in the field of prenatal screening and 
follow-up diagnostic testing from six academic centres in the Netherlands were invited. In 
total 15 individual in-depth interviews were conducted with two midwives, seven medical 
specialists (three gynaecologists, four clinical geneticists specialised in prenatal diagnosis), 
two lab specialists working with NIPT, two test developers and two policy makers. The 
interviews were conducted at the respondents’ work places or at Erasmus MC. A semi-
structured interview guide was used. This guide included five themes: informed decision -
making, proportionality, access to NIPT, societal aspects and the scope of prenatal screening. 
Interviews were digitally recorded, transcribed verbatim and analysed with Atlas.ti using 
thematic analysis, based on the five indicated themes.  
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Results 
The documents each point at the four pillars - the aim of screening, the proportionality of 
the test, justice, and societal aspects - but differ in some aspects of their interpretations. 
Table 1 presents an overview of interpretations of the four pillars in the five documents. 
Below we present the four pillars of the ethical framework for the practice of prenatal 
screening, complemented with results from the interviews.  
Aim of prenatal screening   
The first pillar of the ethical framework for prenatal screening pertains to the aim of prenatal 
screening for foetal abnormalities. Prenatal screening differs from other areas of public 
health, where the aim is reduction of morbidity and mortality associated with disorders in 
the population.(15) Translating this aim to prenatal screening might imply that the success of 
a prenatal screening programme would be defined in terms of maximisation of the 
termination rate of foetuses with abnormalities, which would be problematic, as abortion is 
often a point of controversy.(15, 17, 19, 20) Besides, prenatal screening is thought to imply 
discriminatory messages about the value of the lives of people living with the relevant 
conditions.(15, 17-19) The widely supported view therefore is that governments can only 
justifiably offer prenatal screening when the aim is to enable pregnant women and their 
partners to make autonomous reproductive choices.(15, 17, 19)    
Although interviewed professionals recognised informed choice as the aim of prenatal 
screening, some of them pointed out that prenatal screening also provides the opportunity 
to prepare for the birth of a disabled child and to improve the care for it. Several 
respondents thought that the latter should be emphasised more during pre-test counselling 
and that it should be made clear that prenatal screening is not exclusively aimed at offering 
women the opportunity to terminate an affected pregnancy.   
The right not to know about the options of prenatal screening is considered to be very 
important. In the Netherlands, this has been formalised in the obligation of professionals to 
present women with an ‘information offer’ first (33), in order to stress the fact that prenatal 
screening for aneuploidies is not mandatory. When a pregnant woman visits the midwife or 
obstetrician, the professional must first ask whether the woman wants to be informed about 
prenatal screening at all. The woman is free to decline this information offer.  
 









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Not all professionals agreed with this policy, and some argued - contra current policy - that 
this first question should be skipped,  
“because many people actually do not know what it (prenatal screening) entails. How 
could you say ‘yes’ or ‘no’ to this question when you do not exactly know what this 
test is for?” (I3 medical specialist)   
In order to reach the aim of prenatal screening, it is of paramount importance that pregnant 
women or couples can make informed choices for or against a screening offer.(15, 17-20) 
Informed choice is often defined as “a choice that is based on relevant knowledge, 
consistent with the decision maker’s values and behaviourally implemented”.(34, 35) This 
means that women should understand the purpose of the test and its potential risks and 
implications (36), because they may be confronted with “a large number of further decisions 
which (they) might have wished to avoid if (they) had been aware of the consequences 
before screening”.(18) To help women make informed choices pre-test counselling is 
offered. During pre-test counselling women are presented with information about the 
purpose, nature, scope and validity(18) and complete information about diseases, including 
e.g. “name(s) and general characteristics of the major disorder(s)”, possible treatments, 
possible unexpected or unclear findings of the test and kinds of test-outcome.(20) 
Furthermore, pre-test counselling for first-trimester prenatal screening should be conducted 
at a designated moment, clearly separated from information provision about other aspects 
of antenatal care, such as lifestyle, health aspects (e.g. screening for HIV) and birth 
planning.(15)  
Many professionals noticed that when women talked about their reasons for choosing 
prenatal screening, they often mentioned wanting to be reassured about the health of their 
child. Professionals thought that women sometimes do not realise in advance what kinds of 
outcomes they might face and difficult choices they might have to make:  
[women] “have to realise that if [they] opt for NIPT and a congenital disorder is 
found, [they] kind of jump on a train on which [they] might not want to be [… I] hear 
people say that they are in a rollercoaster.” (I8, medical specialist)  
Some professionals thought that especially in the case of NIPT this might be a problem. The 
previous screening programme in the Netherlands was step-wise: the first step was a FCT, 
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which provided only a risk estimate for aneuploidies. Then women had to think carefully 
about invasive follow-up testing, taking into account the risk of miscarriage. Women could 
choose whether or not to undergo invasive testing to obtain a diagnostic result. 
Professionals thought that this step-wise process gradually prepared women for the 
obtaining of an abnormal test result. They thought that, with NIPT, by contrast, women will 
opt for an easy test and – in one single step – may be confronted with an almost ‘diagnostic 
outcome’ at once. NIPT “gives the idea of a decisive outcome.”(I10, midwife) As said, this 
idea is not accurate, as diagnostic follow-up testing is required also with NIPT. The odds that 
the result turns out false positive, however, are much lower.  
In order to protect women from the negative consequences of uninformed choices, 
professionals emphasised that counselling plays a crucial role. Counselling serves to explain 
women’s options and to correct misunderstandings of tests and disabilities, but should also 
explore the norms and values and the attitudes of women towards having a child  with a 
disability. During counselling women should be encouraged to think about their views about 
testing, about having a child with a disability and termination of pregnancy:  
“Yes, I think, that with a few standard questions [the counsellor] will [be able to] 
achieve a lot. Just to trigger [women], let’s say [to think about the consequences of 
NIPT]. That does not necessarily take a lot of time. [… As a counsellor, you could ask 
women:] What does Down syndrome mean to you?” (I3, medical specialist)  
Respondents took the view that the current quality of counselling in the Netherlands is 
moderate, and needs improvement: professionals should pay more attention to and spend 
more time on pre-test counselling. Dedicated counselling sessions will help women 
understand that the aim of prenatal screening for chromosomal abnormalities is different 
from those of antenatal care (i.e. maintaining and/or improving the health of the pregnant 
woman and the foetus). Some respondents, who were medical specialists, feared that 
professionals underestimate the importance of (non-directive) counselling for NIPT and 
should be aware that the ease of the test, requiring only a maternal blood sample, and its 
high reliability may lead to less informed choices. One study suggested that professionals 
might indeed attach less importance to informed consent for a non-invasive test compared 
to an invasive test.(37) 




To conclude, in order to reach the aim of prenatal screening - reproductive autonomy - 
informed choice is of crucial importance. Counselling should be non-directive and of high 
quality, and include deliberation on personal values of women, in order to achieve informed 
choice and promote this aim.   
 
Proportionality  
In the identified ethical framework, the pillar of proportionality of screening programmes 
entails balancing benefits and harms, following the original screening criteria for population 
screening formulated by Wilson and Jungner, complemented with additional criteria from 
the WHO.(15, 19, 38). To assess benefits and harms, the quality of the test and the test offer, 
including the laboratory procedures, counselling and education of professiona ls should be 
evaluated.(15) According to the ESHG/ASHG and the Dutch Health Council, the benefits and 
harms or costs depend on the way NIPT will be offered, as a first-tier screening test or 
second-tier screening test, after FCT.(15, 17) When NIPT would replace FCT as a first-tier 
test, it might have the benefit of fewer false positive results for trisomy 21, 18, and 13, but 
on the other hand might also lead to a loss of other findings that can be identified on 
ultrasound as part of FCT. Experts must decide whether the benefits of a better test 
performance of NIPT regarding the three trisomies will outweigh this loss of diagnostic yield 
when the first-trimester ultrasound is removed from the screening programme.   
For pregnant women or couples, prenatal screening for foetal abnormalities has the benefit 
of offering reproductive choices regarding an affected pregnancy, including termination of 
pregnancy or being able to prepare for the birth of an affected child, relief from anxiety in 
case of a negative test result and the reduction of invasive follow-up tests.(15, 17-20) Harms 
for pregnant women are related to false reassurance, burden of decision making and anxiety 
in case of false-positive outcomes and incidental findings, which can be of unclear clinical 
significance and might cause needless worries.(15) Respondents held that these harms are 
inevitable but acceptable. Yet the possibility of incidental findings needs to be explained 
during pre-test counselling. It has been suggested that making the choice to terminate a 
desired pregnancy after receiving an abnormal test result may be harmful, as well.(20)   
According to professionals, women might be faced with unwanted choices they have to 
make, because they may not have been fully aware of the consequences of prenatal 
screening beforehand, as some medical specialists indicated in the interviews:  
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“But sometimes I see people saying: ‘I never would have wanted this choice. This is a 
horrible choice you’re giving me. I don’t want it. This is a wanted pregnancy. If I had 
not known that this child has Down syndrome I would go for [continuation of this 
pregnancy], I am sure. But now I have a choice and I am going to hesitate’.” (I7, 
medical specialist) 
Justice  
The third pillar of the ethical framework is justice. The principle of justice in prenatal 
screening relates to equal access to prenatal screening for all pregnant women, to policy 
questions concerning reimbursement of prenatal screening, and to equal distribution of 
healthcare resources.(15, 17-20) Equal access to prenatal screening means that differences 
in personal resources may not cause disparities in access to prenatal screening programmes: 
women’s choices not to participate in screening should not be based upon a lack of financial 
resources.(15, 17-20) That would imply that prenatal screening should be offered, especially 
to women with limited financial resources, either free of charge or against a small fee. On 
the other hand, it could be argued that a (small) payment might serve the aim of 
reproductive autonomy as it may “increases awareness that there is truly a choice to be 
made”.(15)   
Professionals recognised this dilemma concerning the reimbursement of prenatal screening. 
Respondents mentioned the impact of payment on the uptake of prenatal screenin g. A 
midwife suggested that the fee that is currently asked for FCT in the Netherlands (165 euros) 
has much impact and might explain the large difference in the uptake of FCT as compared to 
the 20-week ultrasound, which is offered free of charge:  
“I am curious, when [NIPT] will be reimbursed and [as a counsellor] you explain to 
people the possibility of having a NIPT, whether they would say: ‘If it is reimbursed 
and it gives information about the health of my child, of course I want [to use NIPT].’ 
They do the same for the 20 week scan. I really wonder whether the difference (in 
uptake for the FCT and the 20-week ultrasound) is that big because people say: ‘I [do 
want to] give birth to a child with Down syndrome but not to a child with spina 
bifida’. I do not believe that [differences in attitudes explain the] difference between 
30% [the uptake of the FCT] and 95% [the uptake of the 20-week ultrasound].” (I10, 
midwife)  




Some professionals suggested that a financial contribution by women might serve as a 
helpful barrier, making women aware of the importance of the choice. It could prevent 
women from opting for a test ‘just because it is possible and does not cost any money’, and 
thus protect them against ill-considered testing. On the other hand, respondents mentioned 
two objections to payment as a barrier for test uptake. Firstly, professionals thought that 
some women refrain from screening because of lack of money: 
“There are a lot of people for whom [165 euros] is a lot of money that can buy a lot 
of baby clothes.”.(I13, medical specialist)  
They thought that lack of money is not a good reason to decline screening. Professionals 
think that when screening is offered, it should be reimbursed to guarantee unhindered 
access. Secondly, asking a contribution is in contradiction with equality in healthcare:  
“Yes, it is a barrier, but for whom are you creating a barrier? For a specific group of 
people who cannot pay for it.” (I3, medical specialist)  
Experts should understand that while requiring a personal financial contribution may serve a 
purpose (i.e. improving informed choice), it may also, and more importantly, create 
disparities in access to prenatal screening, which is undesirable and contrary to one of the 
moral pillars of prenatal screening: justice.  
Societal aspects  
Self-determination is not only a matter of individual freedom, but also has a societal 
dimension, and it may be threatened by for example group pressure or societal views about 
testing.(18, 19) One of the concerns related to group pressure is that it might lead to less-
autonomous choices among pregnant women. This would be problematic, it is argued, 
because the aim of prenatal screening, reproductive autonomy, will not be reached when 
women fail to make informed choices.(15, 17-20)   
Furthermore, it is thought that the offer of prenatal screening for chromosomal 
abnormalities might also imply a discriminatory message to individuals and groups living 
with specific diseases.(15, 17-20) This objection is known as the ‘disability rights critique’ of 
prenatal screening and holds that discriminatory messages are inseparable from prenatal 
screening.(15, 17) This critique may apply both to the sheer societal availability of prenatal 
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screening programmes and to individual women’s choices. In response, it is underlined that 
the aim of prenatal screening is not preventing the birth of disabled people, but promoting 
reproductive autonomy.(17) Also, studies have shown that women’s reasons for the 
selective termination of their pregnancies include prevention of a life of severe suffering and 
not being able to create the best conditions to care for a child with a disability  (17, 39-43), 
which does not support this critique. However, with the introduction of NIPT, the uptake of 
first-trimester screening might increase and the number of persons with disabilities might 
decrease. This is not in itself problematic, but it might become problematic if a low 
prevalence of disabilities will negatively affect the position of persons with disabilities, and 
render the option to continue an affected pregnancy less attractive. Therefore the practice 
of prenatal screening should be evaluated continuously in comparison to its aim.(17) 
Moreover, a negative perception of people with a disability can be redressed with public 
information and education.(19) The WHO concludes that just non-discriminatory societal 
settings are important for making a free choice: “It is important to prevent discrimination 
and to provide improved support services for individuals and families with genetic 
conditions. The absence of adequate services for people with hereditary disabilities 
undermines the principle of free choice for couples at risk of having children with such 
disabilities.”(20)  
Professionals did not think that the uptake of prenatal screening would increase 
dramatically, although they suggested that an easier test is less likely to be declined and 
might become self-evident. They observed however that the need to participate in pr enatal 
screening is not as self-evident to many pregnant women as the need for other tests in 
pregnancy.  
Besides, “there will always be people who do not want to know [about health risks of 
their foetus], who just want a care-free pregnancy, and (who feel that) every child is 
welcome,”(I13 medical specialist)  
Moreover, professionals think that women will not choose to terminate pregnancies more 
often because women who participate in prenatal screening generally have desired 
pregnancies, and do not wish to undergo termination of pregnancy for trivial reasons.(18) 
Also, according to respondents, specific cultural aspects in the Netherlands might in part 




explain the low uptake of NIPT, as compared to other countries. In the Dutch prenatal 
screening programme, midwives play important roles in pre-test counselling, rather than 
medical specialists.(44) Among midwives, there is a tendency to avoid medical interference 
in the pregnancy. Also, in society, a rather positive public image of Down syndrome prevails. 
Professionals held the opinion that the fear that fewer people with Down syndrome will be 
born when NIPT is introduced, is not justified. Respondents thought that people with a 
disability are accepted in the Netherlands and that there is good care available for 
handicapped people. However, they agreed that care and support should be guaranteed to 
counteract possible negative consequences of prenatal screening, including discrimination. 
  
In sum, societal aspects and concerns such as an increase in test uptake and a decrease in 
people born with disabilities are recognized, but disputed in the literature as well as among 
professionals. However, it is acknowledged that arrangements should be made (i.e. ensuring 
quality of care for the disabled) to counteract possible negative consequences.  
Discussion: the expansion of the scope of prenatal screening  
The four pillars of the ethical framework can be used to evaluate the potential expansion of 
the scope of NIPT. Below, four limits are proposed to the responsible expansion of the scope 
of NIPT in the future. These limits provide ethical guidance for professionals and policy-
makers who are working in the field of NIPT and will be shaping its development and further 
implementation in the future.  
Limits set by the aim of prenatal screening  
In the five documents it is explicitly stated that although the aim of prenatal screening is not 
to maximise reproductive choice indefinitely, there is room for expansion of the screening 
offer.(15, 17, 20) In the interviews several professionals indicated that a broader test will 
contribute to the aim of prenatal screening because an expanded NIPT allows for detecting 
more disorders than trisomy 21, 18 and 13:  
“People do not want a test for Down syndrome, but a test for a healthy child.” (I15) 
  
However, an expanded scope might affect informed choice as a precondition of reproductive 
autonomy. When NIPT includes a high number of diseases, it will be difficult in pre-test 
42 | Chapter 2 
 
counselling to discuss all possible test outcomes in detail, “including the full range of 
variability in the manifestations” of these diseases.(15) Testing for more abnormalities might 
thus “paradoxically undermine rather than serve or enhance reproductive autonomy.”(15) A 
clinical professional feared that 
“People have no idea what the results [of NIPT] can be and what these could mean 
to them. I am sure about this, because for Down syndrome it is already the case [that 
people do not understand what the outcome means to them].” (I7, medical 
specialist)  
This raises the question how to best inform pregnant women prior to the test. It has been 
suggested in documents and by some of our respondents that information about the 
possible outcomes of prenatal screening should be presented as categories of disorders: the 
scope of NIPT can be narrow or broad, with results pertaining to severe or non-severe 
disorders and early- or late-onset disorders. When the scope of NIPT expands to such an 
extent that it becomes impossible to describe in detail all possible test outcomes during pre-
test counselling, the counsellor “should describe the general characteristics of the categories 
of disorders tested for (e.g., mental disability or neurological impairment). Women will 
receive intensive counselling after a foetal diagnosis.”(20) This model of informed choice is 
sometimes referred to as ‘generic consent’, which is thought to be a solution for complex 
counselling and has already been discussed in the context of genetic screening. Generic 
consent aims to prevent ‘information overload’ and to avoid the provision of information 
that is “pointless or counterproductive”.(45) The question arises whether generic consent 
offers enough information to enable people to make a truly informed choices.(46, 47) The 
ESHG/ASHG and the Dutch Health Council have their reservations about generic consent (15, 
17), because “the feasibility of this model has not yet been empirically tested in the prenatal 
context” and it remains unclear how informed generic consent would be.(15) The extent to 
which generic consent can be informed consent should be studied in line with  previous 
studies on informed choice in the context of prenatal screening. These studies showed highly 
variable percentages of women having made informed choices: 89%, 77,9%, 51% and 
44%.(35, 48-50) Some of that variation might be explained by variation in the nature and the 
quality of pre-test counselling practices, which will likely affect the ‘informedness’ of 
women’s choices to a great extent, also in the context of an expanded NIPT. In practice, it is 




not clear whether a sufficient number of professionals will be available to counsel large 
numbers of pregnant women and their partners, and whether they will have enough time to 
explain the details of the test and facilitate informed decision-making. In some countries, 
measures have been put in place to counter this problem, including the use of decision aids 
and the additional training of midwives in NIPT counselling.(51) Another solution might be a 
change in the focus of counselling, from technical-medical aspects to women’s values or 
goals related to screening. As respondents suggested too, counselling is more than providing 
information; women should be triggered to think about why they would want prenatal 
screening and what they would do in case of an abnormal test result, to make them more 
aware of their attitude towards undergoing prenatal screening. Attitude is defined as the 
general feeling of ‘favourableness’ or ‘unfavourableness’ for testing.(34) Triggering women 
to think about testing might lead to a process of deliberation and evaluation of pros a nd 
cons, which, according to several authors, should be part and parcel of an informed 
choice.(49) Professionals could play a role in this deliberation and help women to formulate 
their values, for instance in accordance with the interpretive model of the physician-patient 
relationship, as described by Emanuel and Emanuel.(52) This model entails that the 
healthcare professional helps to elicit the norms and values of a patient.   
We would suggest that in this process, the necessary technical information about the test  
could support or influence the attitude, but is not sufficient or even essential to the quality 
of decision-making. Shifting the focus of counselling from ‘conveying knowledge about 
screening’ to ‘exploring women’s attitude towards screening’ might improve women’s and 
their partners’ decision-making processes, even in the context of an expanded scope of 
screening and, in combination with decision aids, takes away the time pressure to explain all 
clinical and technical details of NIPT.  
Professionals differed in their opinions about whether women should be given a say in 
decisions regarding the scope of the screening offer. Some professionals suggested that a list 
of options should be offered from which women could choose, whereas others believed that 
experts should determine which (categories of) disorders should be included in the test. The 
main reason for preferring a predetermined offer was that women might not have the 
information – or the capacity to understand the information – required to make a decision 
about the adequate scope of NIPT. Another study of opinions of professionals showed that a 
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majority of respondents preferred a predetermined offer or a fixed list of disorders to be 
tested.(53)  
A second category of problems arises with the dual aim of prenatal screening within 
antenatal care systems.(15) Some routinely offered prenatal screening tests are used to 
improve pregnancy outcomes or the health condition of the mother or the baby, such as the 
blood test for rhesus status in RhD-negative women. The rhesus test is currently offered as a 
separate test but could – for reasons of efficiency – be combined in one test with NIPT for 
autosomal aneuploidies. An objection to a combination of this test with screening for 
aneuploidies is the possible confusion in women about what test they should accept or 
decline, and for what reasons. Prenatal screening for aneuploidies is aimed at reproductive 
autonomy and requires non-directive counselling.(15) The term ‘non-directiveness’ refers to 
the absence of coercion or the withholding of advice, in order to respect the autonomy of a 
patient.(54) According to Ten Have, as cited in Oduncu, non-directiveness means that the 
expert who provides information about genetic conditions “should not, in any  respect, try to 
influence the decision made by the persons who are counselled or screened. (…) his aim is 
merely to provide information and to help the patients or clients to work through possible 
options.”(54) For prevention-aimed screening in antenatal care (e.g. screening for 
hypertension or rhesus status), it may not be objectionable for health professionals to 
recommend or insist on participation, because this type of screening promotes the health of 
the mother and the foetus, but for autonomy-aimed screening, directive counselling is not 
appropriate.(15, 55) In sum, one (expanded) NIPT that combines two aims and two - 
opposed - modes of counselling is not desirable.  
NIPT is meant to offer reproductive options, but not to screen foetuses for all kinds  of 
medical problems. For instance, children are usually not allowed to undergo predictive 
testing for (untreatable) late-onset diseases because this might affect their right to an open 
future and their right not to know unwanted predictive information.(15, 17-20) The principle 
to defer testing until adulthood applies to unborn children as well. Prenatal screening is not 
meant as a medical screening of future children: its scope should thus be limited to those 
conditions for which expecting parents may consider terminating the pregnancy. To protect 
the unborn child’s right not to know, ‘conditional access’ models have been proposed for 
women who want information about late-onset diseases: testing for late-onset diseases, 




including some sex chromosomal aneuploidies, will only be offered if women “expressed the 
clear intention to choose abortion if a predisposition for a late-onset diseases is found.”(56) 
However, as termination of a pregnancy is, and should continue to be, the result of a 
voluntary decision, women who change their minds about an earlier expressed intention 
cannot be forced to terminate an affected pregnancy. Therefore, it cannot be excluded that 
children may be born in the knowledge of carrying a mutation for a late-onset disease. 
Further research should focus on the consequences of living with this information for both 
parents and children and on its effects on their relationship.(18, 19)  
NIPT may contribute to the aim of prenatal screening: the promotion of reproductive 
autonomy. On the basis of the first pillar of the ethical framework for prenatal screening, 
however, limits can be set to the morally responsible expansion of the scope of NIPT: NIPT 
should generate only test outcomes that are relevant to reproductive decision -making, and 
informed choice should be (made) possible through adequate pre-test counselling.  
 
Limits set by proportionality   
The expansion of the scope of NIPT also raises questions concerning proportionality. 
According to the Dutch Health Council, proportionality is an important requirement of 
prenatal screening, and benefits of each ‘test’ (for each condition) to be included in the 
screening offer should outweigh the harms.(17) Professionals noted that it may be beneficial 
to include more disorders in a test because that means that more reproductive choices can 
be made:  
“There are children who are born with a severe disorder. Then we do an exome 
analysis to see what the cause is. Then we find, say, in 40% of the cases, a new 
mutation, in a crucial gene, which the parents do not have. In the future it may be 
possible to detect that [mutation] in maternal blood.”(I15, lab specialist)  
Several professionals gave the example of the 22q11 deletion, which is associated with a 
severe phenotype. Studies on the attitudes of pregnant women towards an expanded scope 
of prenatal screening showed that women thought that it may be valuable especially to 
include severe disorders with no or short life expectancy in a screening test.(57, 58) Women 
also wanted to learn about sex chromosomal aneuploidies (59, 60) and about specific other 
aneuploidies, but were hesitant about learning about conditions with unknown or variable 
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phenotypic expression. They were uncertain about what the benefit would be of knowing 
about such conditions.(59) 
Proportionality concerns might limit the expansion of the scope, on at least three points. 
Firstly, when genome-wide analyses are used in NIPT, it might be difficult to assess the 
clinical validity of many among the huge number of abnormalities that can be detected. 
Offering a test for disorders without knowing the validity might lead to false positives and 
false negatives, cause harm to pregnant women, and challenge the proportionality of 
including the disorders.(17) Professionals mentioned that outcomes should be actionable for 
pregnant women. When tests are not reliable (i.e. clinically valid), they provide few 
actionable options. Moreover, uncertain test outcomes might lead to unnecessary anxiety or 
insecurity in pregnant women, which is objectionable:  
“I think that, when you introduce uncertainty in the pregnancy, it will become 
difficult. If you [can say that you] are sure that the child is disabled, then this is 
understandable for people, and they will be able to prepare [for the birth of a 
disabled child] or to decide that they do not want this. But if you say, ‘we actually do 
not know what it means exactly; (…) it can turn out better than expected, but the 
child can also turn out severely disabled.’ Well, what should you do, as parents?”(I3, 
medical specialist)  
Several other professionals stated that in practice this should not pose a big problem, as only 
a small number of abnormalities that are currently being detected in labs are of unknown or 
little-known clinical validity. These will need to be discussed between expecting parents and 
clinical geneticists specialised in prenatal diagnosis.   
A second point that several respondents stressed is that NIPT has shortcomings: NIPT is not a 
diagnostic test, and it still requires invasive follow-up. An expanded scope might lead to  an 
increasing number of positive test results for a wide range of disorders, which will include 
false positive results that need confirmation by (unnecessary) invasive diagnostic testing. 
This is problematic, because a reduction of invasive tests as compared to FCT is seen as one 
of the important benefits of NIPT.(15, 18, 19)   
A third point that might limit the scope of NIPT is the burden of the decision to terminate a 
pregnancy. Some disorders may not be sufficiently severe to justify their inclusion in the 




NIPT; they may not meet the first screening criterion of Wilson and Jungner: “The condition 
sought should be an important health problem.”(61) However, professionals mentioned that 
it is hard to define what ‘serious’ or ‘non-serious’ diseases are. In the documents it is stated, 
for instance, that severity should not be determined at all: “It would be dangerous to create 
medical, legal, or social definitions of "serious", because these could infringe on couples' 
lives in several ways.”(20) Expecting parents are the ones who should indicate whether they 
consider a disorder to be serious or not, in their life situation.(20) Although it will be difficult 
in practice to draw the lines, the seriousness of disorders can serve as an (arguable) limit to 
the expanding scope of NIPT. 
From the pillar of proportionality a few additional limits can be derived for the expansion of 
the scope of NIPT: in order for tests to be included in an expanded scope of NIPT, they 
should be clinically valid. Especially the positive predictive value should be high, as 
confirmatory testing through invasive procedures will still be required and is associated with 
risks, costs and burdens. NIPT should not be offered for trivial conditions.  
 
Limits set by justice aspects   
When using the ethical framework to evaluate an expansion of the scope NIPT, the pillar of 
justice is less prominent than the other three pillars. However, there are three issues that 
arise from the pillar of justice. Firstly, when NIPT is offered as an expanded test, it should be 
available equally for every pregnant woman.(17) Equal access to healthcare is considered to 
be a fundamental right that should preclude the exclusion of specific groups from healthcare 
services.(62) Women should not face restrictions to having reproductive options. Ideally, all 
women should have access to the same information about their foetus, and the scope of 
first-trimester prenatal screening should be equal for all women. When expanded NIPT is 
made available only to women who have an increased risk of trisomy 21, 18 or 13 as a 
second-tier test after FTC, for instance, low-risk pregnant women will not have access to 
information about the foetus other than the three more common trisomies detected 
through FCT, whereas high-risk women will.(17) For this reason, justice would require 
making NIPT available as a first-tier test to all women (or restricting the scope of NIPT as a 
second-tier test). Also, it is important to note that diagnostic follow-up testing should be 
made available to women who have undergone NIPT, in line with the criterion of Wilson and 
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Jungner that in screening programmes, diagnostic follow-up testing should be available to 
those found to be at risk.(38) This is of special importance in countries in which access to 
follow-up testing is not self-evident. 
A second aspect, according to the International Bioethics Committee, is that education is a 
matter of justice: “Persons with a lower education level and lower health literacy are denied 
the information which is required to exercise their freedom and autonomy.”(19) Some 
women may not be able to understand all relevant information pertaining to the screening 
offer, which is necessary to make an informed choice. The expansion of NIPT will only 
exacerbate this inequality (19), it is feared, as the test becomes more elaborate and more 
complex, and decision-making places higher demands on women’s health literacy.  
A third concern is that an expanded NIPT could challenge a justi fiable distribution of 
healthcare resources. As resources are scarce and should be distributed equally, efforts must 
be taken to demarcate the scope of prenatal screening tests to prevent unnecessary follow -
up of clinically insignificant findings. Besides, when prenatal screening is offered within the 
context of a public health programme and is upheld by taxpayers, there should be 
transparency with regard to the utility of the test.(15) This also underlines the importance of 
ensuring the proportionality of a test.   
When considering the costs of prenatal screening it should be noted that a widespread 
implementation and uptake of prenatal screening programmes is likely to lead to the birth of 
fewer affected children, which reduces the costs associated with their healthcare and 
support. Although this should not be an aim of prenatal screening, these long-term costs 
savings are undeniably part of a cost-effectiveness analysis of new screening tests.(15)  
From the pillar of justice another limitation can be derived: expanded NIPT should be 
available for all pregnant women, which may increase the costs of the programme. This 
limitation may change over time as the technology improves and becomes cheaper.  
Limits set by societal aspects   
In discussions on the expansion of the scope of NIPT, concerns are reiterated that have 
already been raised in the context of earlier prenatal screening programmes, such as 
discrimination and stigmatisation of people with chronic diseases. New societal aspects, 
unique to expanded NIPT, are raised as well. Professionals noted in the interviews, for 




instance, that a benefit of an expanded scope could be a removal of the focus of prenatal 
testing on Down syndrome. Down syndrome is the most common of the three trisomies and 
in the Netherlands first-trimester screening for chromosomal abnormalities is often referred 
to as a ‘test for Down syndrome’. By expanding the scope of prenatal screening this focus 
could shift, which might reduce concerns related to discriminatory messages conveyed by 
the screening programme. This benefit of the expansion is also acknowledged by parents of 
children with Down syndrome, who experience the focus on Down as stigmatising for their 
children.(63) On the other hand, the Dutch Health Council mentioned that expanded NIPT is 
not free from the allegation of stigmatisation either, as, for instance, a list of selected 
disorders can be thought of as ‘subjective’ and vulnerable to stigmatisation of specific 
groups, too.(17) According to some professionals, an expanded scope might reduce the 
acceptance of children with a disability:  
“With 22q11 deletion, [children] can be mentally retarded, etc. When people hear a 
story like that, they tend to terminate [the pregnancy]. I find it very hard. Everybody 
wants a healthy child, I understand that. So it is good to have these options. On  the 
other hand, I am afraid that, when more [screening] becomes possible, what space is 
there for children with a disability? I find it terrible that there may be no respect or 
no care [for these children].”(I10, midwife)  
Adverse societal consequences of an expanded scope are also mentioned by pregnant 
women and parents of children with Down syndrome, who fear a loss of diversity in s ociety 
and a ‘slippery slope’, implying that people might want to start testing for increasingly trivial 
abnormalities.(57, 63) However, respondents questioned whether these consequences of an 
expanded scope will occur and denied that society will eventually be without children with a 
disorder or disability. Although it is difficult to predict the societal consequences (if any ) of 
NIPT or how these would limit the expansion of its scope, it is clear that negative 
consequences for people with disabilities should be mitigated, and the practice of prenatal 
screening should be monitored continuously, not only with a focus on the risks and benefits 
for individuals, but also for its wider societal implications.  
Conclusion 
An expansion of the scope of NIPT fits the aim of prenatal screening, as it contributes to 
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more reproductive options for pregnant women and couples. However, drawing on the 
broadly shared ethical framework for prenatal screening as well as on the findings of our 
qualitative study of professionals’ opinions and experiences of the translation of the pillars 
of this framework in practice, we conclude that expansion of the scope of NIPT is not 
unlimited. Four moral limits can be set to demarcate a responsible expansion of the scope of 
NIPT. Firstly, informed choice as a central precondition for prenatal screening should limit its 
scope: when NIPT is expanded to include more chromosomal or sub-microscopic 
abnormalities, and relevant pre-test information about the test becomes more elaborate 
and more complex, counsellors will need to improve pre-test counselling to uphold its 
quality. This requires new models for counselling, with a special focus on generic information 
about possible test outcomes and on expecting parents’ attitudes and values in relation to 
prenatal screening. Secondly, any expansion of NIPT should be proportionate: the test 
should be clinically valid and useful to women. Findings that generate mainly anxiety and for 
which no courses of action are available, do not meet the criterion of proportionality. 
Thirdly, respect for the right of the future child to an open future excludes testing for late-
onset disorders when women or couples know beforehand that they will not terminate the 
pregnancy based on the results. Finally, healthcare resources should be justly distributed: 
when possible, NIPT should be made available to all pregnant women either free of charge 
or for a small sum. At the same time, any expansion of the scope of NIPT should be based 
upon a favourable assessment of the benefits of including additional ‘tests’ for additional 
disorders in proportion to the costs and burdens. Both in the literature and in our interview 
study of professionals’ opinions, we observed differences in the sense of urgency or 
importance that is attributed to each of the four limitations. We contend that the criterion 
of reproductive autonomy as the aim of prenatal screening as well as that of proportionality 
– or a positive balance between the benefits and burdens for pregnant women and their 
future children – should together be guiding in decisions whether particular disorders should 
be tested or communicated to women or couples. This means that for example, depending 
on the test performance, disorders that are comparable to trisomies 13, 18 and 21 in terms 
of severity could be included in the NIPT. Over the next decade, those working in the field of 
NIPT may strive to maximise the potential benefits of NIPT and include more abnormalities 
in the screening test, keeping these moral limits to a justified scope of NIPT in mind.  
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Abstract 
The noninvasive prenatal test (NIPT) as the first trimester prenatal screening (FTS) for 
trisomies 21, 18, and 13 is offered to all pregnant women in the Netherlands. NIPT using 
genome sequencing allows for an expansion of the scope of FTS and the introduction of NIPT 
gives rise to ethical and societal concerns about deliberated decision‐making, pressure to 
engage in screening, and possible lack of equal access due to the financial contr ibution 
(€175) to NIPT. We explored the opinions and experiences of pregnant women, who were 
offered FTS, about these concerns, and the possibility of a broadened scope. Nineteen 
pregnant women representing a diversity of backgrounds were interviewed using a semi‐
structured interview guide. Eight women did not opt for prenatal screening while 11 did 
(NIPT = 4, combined test = 7). Women experienced a free choice to accept or decline 
prenatal screening, despite sometimes receiving advice from others. Prior to pretest 
counseling, some women had already deliberated about what an abnormal test result would 
mean to them. Others accepted or declined FTS without deliberation. The current Dutch 
policy of requiring a co‐payment was acceptable to some, who believed that it functioned as 
a threshold to think carefully about FTS. Others were concerned that a financial threshold 
would lead to unequal access to screening. Finally, pregnant women found it difficult to 
formulate opinions on the scope of FTS, because of lack of knowledge. Life expectancy, 



















The noninvasive prenatal test (NIPT) provides an easy form of first trimester prenatal 
screening (FTS). In the Netherlands, NIPT screens for trisomies 21, 18, and 13 and is offered 
to all pregnant women, costing them €175. When using genome sequencing, NIPT allows for 
an expansion of the scope of FTS. The introduction of NIPT gives rise to ethical an d societal 
concerns about deliberated decision-making, pressure to engage in screening, and possible 
lack of equal access due to the financial costs of NIPT. This study examines to what extent 
these concerns matter to pregnant women and explores their opinions and experiences 
concerning FTS. 
In the Netherlands, all pregnant women can choose to have a screening test  to determine 
their chance of fetal trisomies 21 (Down syndrome), 18 (Edwards syndrome), and 13 (Patau 
syndrome).(1) From 2007 until April 1, 2017 this screening was mainly conducted with the 
first trimester combined test (ftCT). If the ftCT determines an increased likelihood (>1:200) 
of (one of) these common aneuploidies, pregnant women could choose either invasive 
prenatal genetic testing or refrained from further testing.(2, 3) On the April 1, 2014, the 
possibility to opt for the noninvasive prenatal test (NIPT) in a national implementation study 
‘trial by Dutch laboratories for evaluation of non‐invasive prenatal testing’ (TRIDENT‐1) was 
added. 
 
Since April 1, 2017, all pregnant women in the Netherlands have a choice between no first 
trimester screening (FTS), the ftCT, or NIPT within the TRIDENT‐2 study. First (and second) 
trimester screening is mainly offered by primary care midwives, in a separate consultation 
with a funded duration of 30 min.(4) At the moment all pregnant women in the Netherlands 
must pay out of pocket for the ftCT (€170), and NIPT also requires a €175 contribution. 
Second‐trimester screening sonography scans are fully reimbursed.(5) 
 
The introduction of NIPT provides easy accessible FTS using genome sequencing, NIPT allows 
for an expansion of the scope of FTS. Pregnant women opting for the ftCT still have a choice, 
in case of an increased risk, between NIPT or invasive prenatal genetic testing as the follow‐
up test. NIPT entails important benefits for pregnant women: first, it is more sensitive and 
specific as compared to the ftCT. The sensitivity of NIPT is 97% for Down syndrome, 90% for 
Edwards syndrome, and 90% for Patau syndrome, while the combined test has sensitivities 
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of r 85%, 77% and 65% (6) respectively. Second, the use of NIPT will reduce the need for 
invasive procedures and the concurrent risks of miscarriage. However, the introduction of  
NIPT also raises some concerns. 
 
First, it is feared that NIPT as a first‐tier screening test may lead to routinization. The 
routinization argument is a container concept, which has been conceptually and empirically 
unraveled elsewhere.(7) Routinization may refer to: (a) that NIPT may lead pregnant women 
to venture into first trimester prenatal screening less thoughtfully, (b) that in the abs ence of 
a risk of miscarriage, NIPT may lead to societal pressures to participate in prenatal screening 
and to stigmatization of those who 
forego screening (8 2013), and (c) because NIPT can be conducted early in the pregnancy, it 
may result in the trivialization of abortion (9, 10). However, concerns about informed 
decision‐making, pressure to test, and stigmatization lack empirical evidence, which 
questions their validity.(7) 
 
Second, there are concerns about the influence of reimbursement policies on pregnant 
couples’ views and uptake of prenatal screening. Pregnant couples might easily or 
thoughtlessly opt for reimbursed screening, whereas non-reimbursed screening may lead to 
unequal access.(11) As said before, at the moment all pregnant women in the Netherlands 
must pay a contribution for the first trimester screening. In contrast, second trimester 
screening sonography scans are fully reimbursed.(5) The uptake of first trimester screening 
is around 45% whereas over 90% of pregnant women choose the fetal anomaly scan in the 
second trimester. The difference in reimbursement policies might be one of the reasons why 
the uptake of these tests is different, besides the fact that many women opt for an 
ultrasound to see their unborn child.(12) 
 
Third, whole genome NIPT can detect a wide range of fetal chromosome abnormalities in 
addition to trisomies 21, 18, and 13.(13) At the moment, pregnant women in the 
Netherlands can choose for a NIPT that only reveals trisomies 21, 18, and 13, or a NIPT that 
also reveals abnormalities in other chromosomes, indicated as secondary findings. However, 
in the Netherlands fetal sex and sex chromosomal abnormalities are not communicated, 
because the ministerial license does not allow analysis of the sex chromosomes.(2) 




Expanding the scope of NIPT could be beneficial for pregnant couples, be‐ cause more 
pathogenic abnormalities in the fetus can be detected.(14) However, concerns on this 
expanding scope of NIPT have been voiced. Several studies have suggested that an expanded 
scope of NIPT may undermine informed decision‐making because of the increased quantity 
and complexity of pretest information counselors have to offer.(15) Moreover, people fear 
that with an expansion of the scope, prenatal screening is on a ‘slippery‐slope’ towards 
screening for minor abnormalities and cosmetic traits. Different studies have shown that 
both professionals and pregnant women have difficulty deciding where to draw the line for 
an expanded NIPT.(14, 16) In practice, the expansion of NIPT has already started in many 
clinics in many developed countries, including the United States and the Netherlands. (2, 17) 
An expanded NIPT includes other trisomies in addition to trisomies 21, 18, and 13 and also 
subchromosomal aberrations and microdeletions. Professionals indicate an urgent need f or 
ethical guidance to determine an appropriate scope of NIPT.(14) In this context, knowledge 
of women's preferences with regard to the scope of NIPT is indispensable. 
 
The aim of the study at hand is to examine the ethical and societal concerns about 
routinization, societal pressure, reimbursement, and an expanded scope of NIPT. Interviews 
with pregnant women regarding their views about NIPT, its characteristics, its (lack of) 
reimbursement, and its scope were conducted. Previous interview studies on attitudes of 
pregnant women and partners regarding NIPT mainly focused on how pregnant couples view 
NIPT and its different aspects, but remain hypothetical on the aspects of that is, societal 
pressure and reimbursement.(8, 16) Furthermore, most studies were conducted a couple of 
years before the introduction of NIPT as a first‐tier screening test, making the results less 
applicable to present day pregnant couples. This study will give a more in‐depth insight of 
the views and opinions of pregnant women who have made the decisions about whether or 
not to engage in such prenatal screening tests. 
 
Methods 
For this study a qualitative research design was used. Semi‐structured individual interviews 
were held to explore the experiences and opinions of pregnant women regarding first 
trimester pre‐ natal screening and in particular NIPT. Ten interviews were con‐ ducted 
before the availability of NIPT to all pregnant women in the Netherlands, whereas nine 
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interviews were conducted after this implementation. All women provided written informed 
consent be‐ fore participating in this study. The research ethics review commit‐ tee (METC) 
of Erasmus MC, University Medical Centre Rotterdam, exempted this study (MEC‐2016‐399).  
 
Participants 
Individual semi‐structured interviews were conducted with 19 pregnant women from four 
midwifery practices between June 2016 and June 2017. After 19 interviews no new 
information was attained and therefore data saturation was reached, no further interviews 
were conducted. Women were recruited through four different midwifery practices across 
the country. The researchers deliberately sought to include women with different ethnic and 
religious backgrounds, educational levels, and socioeconomic status. However, women who 
signed up for the study were mostly Caucasian, highly educated women. Women were 
interviewed throughout all phases of their pregnancy. All 19 women were offered first 
trimester prenatal screening; 11 of them opted for prenatal screening (NIPT or ftCT), 
whereas eight did not. None of the pregnant women who chose for first trimester prenatal 
screening obtained high‐risk results. Characteristics of the participants can be seen in      
Table 1. 
 
Table 1: Characteristics of interviewed pregnant women 
Characteristic N (%)  
Nationality  
 Dutch 18 (94.7%) 
 Other 1 (5.3%) 
Screening  
 No  8 (42.1%) 
 Yes, ftCT 7 (36.8%) 
 Yes, NIPT 4 (21.1%) 
Education levela  
 Highly educated 12 (63.2%) 
 Lower educated 7 (36.8%) 
Religious  
 Yes 5 (26.3%) 
 No 14 (73.7%) 
Children  
 Yes 10 (52.6%) (mean = 1.8) 
 No 9 (47.4%) 
aEducation level: Highly educated: College educated or higher. 
 





Pregnant women were recruited and interviewed by two of the re‐ searchers (IMB and AKK). 
Nine interviews were held in person and the other 10 by telephone. The interviews were 
guided by an interview guide, and if necessary follow‐up questions were asked. The 
individual interviews lasted between 30 and 60 min. The pregnant women received a €10 
gift card for their participation. 
An interview guide was developed in a multidisciplinary team of clinical geneticists, 
gynecologists, medical ethicists, and medical psychologists. The themes found to be relevant 
for the interviews were discussed and appropriate questions were formulated. The interview 
guide made sure that the interviews entailed a reflection on women's own choices with 
respect to screening, their views on the different screening modalities (ultrasound, 
combined test, NIPT), the appropriate scope of NIPT, and their experiences (if any) of 
societal pressure to undergo prenatal screening or to terminate an affected pregnancy. 
Furthermore, we included questions about the reimbursement policies for the various 
screening tests and asked the pregnant women what influence—if any—the reimbursement 
policy had on their choices for prenatal screening. 
 
Data analysis 
All interviews were audio taped and transcribed verbatim by IMB afterwards. After 
transcription, the interviews were analyzed using Nvivo software. Data analys is was 
conducted using thematic analysis.(18) Responses in the interviews were coded 
independently by AKK and IMB. Afterward, these codes were com‐ pared and any 
discrepancies were discussed until consensus was reached. From these codes topics were 
extracted, and clustered into main topics and subtopics in order to identify important 
themes in the interviews. Representative quotes from the interviews were translated from 
Dutch to English and presented to illustrate the different themes. 
 
Results 
The four themes that were examined during the interviews were pregnant women's: (a) 
reasons for choosing first trimester prenatal screening or not (routinization), (b) experiences 
of pressure from the social environment and society, (c) thoughts and expectations about 
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payment for prenatal screening, and (d) views on the possible expansion of the scope of 
prenatal screening. These four themes will be presented consecutively below. 
 
Women's views regarding prenatal screening and NIPT 
Women who participated in the interviews had various reasons to accept or reject prenatal 
screening. Some women did not opt for screening because they did not think about it at all, 
they believed they were too young and not at risk, or thought the test result of the ftCT is 
difficult to interpret, or a combination of these considerations. Others preferred a worry‐
free pregnancy above knowing the health status of their fetus, or would not take action after 
an abnormal test result. For some, abortion was not an option because of their religious 
beliefs or because they thought they would not be able to handle its psychological burden. 
 
“Well, at my age anyway, the chance is just a bit smaller [for Down syndrome]. 
Besides, I would not terminate my pregnancy if it [the unborn child] does have Down 
syndrome. They could also see it at the 20‐week scan, so I can still prepare myself for 
it.” (I9, age 20, no pre‐ natal screening) 
 
The pregnant women who opted for first trimester screening also gave various reasons. 
Some chose screening because they wanted information about the health of their child, 
because they wanted to have the possibility to end their pregnancy in case of an abnormal 
test result, or because they wanted to be able to prepare for the birth of a disabled child.  
 
“I just really wanted to know if it [the unborn child] was healthy. I really wanted that 
little piece of certainty, I really liked that.” (I7, age 27, combined test) 
 
The characteristics of the NIPT, such as its reliability and easiness compared to the ftCT, 
make testing more attractive to women. Ten women were interviewed before NIPT became 
available as a first‐tier test in the Netherlands. Most of these women indicated that they 
would have opted for NIPT if it was available for them during their pregnancy. The 
interviewed women expected an increase in uptake with the introduction of NIPT, although 
women also thought that when pregnant women do not want to participate in prenatal 
screening they still will not opt for it. 





“You are going to find out whether your chi ld is healthy or not [with the ftCT and 
NIPT], and many people do not want to know that. (…) There might be somewhat 
more [women who opt for NIPT than with the ftCT], because it is easier and more 
accessible (…). That could be the case, but I think that it [the uptake of ftCT vs. NIPT] 
would not differ very much.” (I17, age 39, combined test) 
 
A few participants made their choice concerning prenatal screening before they received 
pretest counseling, based on information on the internet, or flyers, or peers’ experiences. At 
the same time some women had a general concern that other pregnant women might not 
think through their choice for NIPT, that some accept the NIPT offer thoughtlessly, viewing it 
as part of standard procedure, without reading information leaflets or thinking about the 
information they received during counseling. As one woman indicated: 
 
“Because I think, they already take so much blood, why do you not add that [NIPT] to 
that [those tests]. (I3, age 32, no prenatal screening) 
 
Therefore, pretest counseling for FTS should emphasize choice awareness amon g pregnant 
women. According to the interviewed women, good counseling should further include 
medical information about the test, such as its process, the reliability and explanation about 
trisomies 21, 18, and 13, and the possible next steps. A few participants also mentioned that 
it is important to discuss the emotional impact of screening, including knowin g in advance 
what they want to do with the test result. However, other women indicated that they did 
not think about what to do with the test result before engaging in prenatal screening. They 
first wanted to wait and see what the test result would be. 
 
Experiences of pressure from social environment and society 
Women had different thoughts about and experiences with social and societal influence on 
their choice for first trimester prenatal screening. Most of the women indicated that their 
social environment did not influence their opinion about prenatal screening. However, some 
women indicated that their social environment did influence their choice. These pregnant 
women did not experience this influence as pressure: they stated that they could still make 
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their own individual choice. Most women, furthermore, stated that the counseling by the 
midwife did not change their opinion, but more so strengthened it. 
 
“Yes I told her [the midwife] in advance [that I did not want to opt for screening]. But 
she said she wanted to explain everything about the screening to me, so she did. But 
that did not make me change my mind. (I15, age 35, no prenatal screening) 
 
A few younger women (age range: 24–30) in our sample expected influence from family or 
friends on their choice when they would be older, because then they would be at higher risk 
and family and friends would stimulate them to opt for screening. Some of these women 
also indicated that friends and family asked them the question why they opted for screening 
while they were young. Two women mentioned a certain influence toward testing from 
healthcare professionals and got the idea that testing is more self‐evident to professionals. 
 
“Nobody said [during the counseling session]: you can also do nothing.” (I11, age 40,   
     NIPT) 
 
A few women believed that society participation in prenatal screening is portrayed as being 
self‐evident amongst others caused by media attention for the introduction of NIPT. It is 
presented as a very reliable test, and as an improvement of prenatal screening. It is expected 
that every woman would opt for it. Some women also had certain worries that being 
pregnant becomes medicalized, or that utilizing available tests becomes the social norm. 
Furthermore, concerning the termination of pregnancy, a few women had the opinion that 
there is certain societal pressure, in two directions: one woman's opinion was that 
terminating a pregnancy is more self‐evident than to carry an affected pregnancy to term. 
 
“You will be judged [by society] when you decide to keep a baby with a severe 
disorder while you had the possibilities to detect the disorder.” (I12, age 33, NIPT)  
 
Another woman had the opinion that it is less acceptable to choose termination of 
pregnancy and stressed the importance of complete in‐ formation in the counseling. 
 




“I think that people are opposed to it and look at you and ask if you are sure to do it 
[terminating the pregnancy]. I think that people do not easily opt for it and also do 
not easily accept from others that they choose it. (…) Because people do not really 
know the consequences of having such a child [with a disability].” (I17, age 33, 
combined test) 
 
Most of the participants did not experience pressure from the society to test or not test. 
Most women experienced that there is sufficient freedom to refrain from screening, and 
most women believed that you are free to either carry an affected pregnancy to term or to 
choose termination of the pregnancy. The pregnant women also believed that in society 
there is not one major opinion on the termination of pregnancy; there are different 
opinions, influenced by, amongst others, culture and religious beliefs. 
Thoughts and expectations about payment for prenatal screening 
Opinions on the role of payment for prenatal screening were quite diverse. Some women 
thought that having to pay for a test did not have any impact on their decision about 
prenatal screening. Others thought that asking a fee might have impact on their personal 
choice for screening. They expected to be influenced by the price of the test, and probably 
would not opt for it if it were expensive. Some thought that if the tests were free of charge 
they would certainly opt for screening, whereas they would not take part if they were asked 
to pay. 
 
“If I did not have to pay I would definitely do it [the combined test]. But the fact that I 
have to pay really makes me think it is a lot of money. I almost did not want to do it 
[the combined test].” (I2, age 29, combined test) 
 
A few women thought €175 is a lot of money for people with limited financial resources, 
while others thought that it is acceptable to ask that fee. Some women indicated that they 
think that a reimbursement of the test carries the message that it is a standard practice. 
 
“But if it is free of charge, then it is more as if it is included in the total package [of 
tests during pregnancy], like the ultrasounds. You do not feel obliged, but it seems 
that it is included.” (I8, age 26, combined test) 
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Moreover, women thought that more pregnant women would opt for screening if it was free 
of charge and the uptake would increase. Therefore several women suggested that asking a 
fee might function as a threshold and makes pregnant women aware that it is an import‐ ant 
choice they have to make. 
 
“I do not know, if it is completely reimbursed it is accessible for everybody [NIPT]. I 
think that people would take the test more often. But on the other hand you do have 
to think about it very well, about the con‐ sequences. Maybe if it is too accessible 
people do not think about it good enough. So maybe asking money [for NIPT] could 
help.” (I10, age 29, NIPT) 
 
A few women stated that it is your own choice to become pregnant and therefore you have 
to pay for a prenatal screening test yourself. Other women thought that prenatal screening 
should be free of charge in order to eliminate any threshold and make the test equally 
accessible for all women. 
 
“People differ in their incomes and then [by asking a fee] you get involved in the rich 
versus poor argument. I believe that in healthcare income should not matter, 
especially not in the case of an unborn child.” (I18, age 33, no prenatal screening)  
 
 Expansion of the scope of prenatal screening 
The discussion on the expanding scope of prenatal screening was often difficult to 
understand for women. When asked about their preferences, benefits, and disadvantages of 
an expanded scope, women found it difficult to formulate their opinions becaus e of lack of 
knowledge. 
 
“I do not dare to say something about that. I did not learn about what kind of 
abnormalities there could be, because I assume that it [the child] was just healthy. In 
case of an abnormal test result of course you are going to look at what it means.” (I7, 
age 27, combined test) 
 




Some women expressed reservations regarding the expansion of prenatal screening. One 
woman mentioned that pregnant women (and their partners) would not have worry‐free 
pregnancies anymore if abnormalities were detected. Others thought that it is a step too far 
or felt it would be like playing God. Furthermore, a few women thought that society wants 
to exclude all possible abnormalities and feared that society tends to select perfect children 
and would not accept people with a disability anymore. Moreover, they feared that abortion 
for less severe abnormalities might also become accepted. 
 
“Just in general, I am opposed to everything being placed in a medical framework. 
That you can already know so many things in advance [before the baby is born]. The 
question is of course where this [expansion] will stop. (…) So I think I am just against 
it [the expansion] going on and on.” (I18, age 30, no prenatal screening) 
  
Other women thought that an expansion of the scope of prenatal screening is positive, 
because it provides certainty, or they were in favor of an expansion because it might prevent 
a long search for a diagnosis when a child is born with unexplained symptoms. 
 
“I would appreciate it when the test becomes expanded. I think it is something good 
because it just provides more certainty. You know, you are giving birth to a whole 
new life.” (I7, age 27, combined test) 
 
Especially the question on the kind of fetal abnormalities pregnant women want to know 
was difficult for women to answer, because of unfamiliarity with such abnormali ties. In the 
interviews several categories of disorders were discussed such as early onset, late onset, and 
neurological disorders, based on categories as used in clinical genetics practice. Women who 
positively evaluate (a certain) expansion of the scope often indicated that disorders with 
limited or no life expectancy should be considered for inclusion in the test. Other 
considerations related to the question on which disorders should be included in the test, are 
the severity of the disorder, and the child's prospects of living an independent and happy 
life. 
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“It is difficult. My idea would be that it [NIPT] should concern severely disabled 
children. Children who could never live independently, who need a lot of medical 
care, where you ask yourself if they could be happy at all.” (I11, age 40, NIPT) 
 
However, women said that it is hard to say something regarding such a difficult and 
hypothetical situation of expecting a child with a severe disorder and regarding what they 
would do with such knowledge. They did not know what they would decide in the case of an 
abnormal test result. However, the different perceptions pregnant women have of, for 
example, Down syndrome suggest that women have different perceptions of severity and 
quality of life. Some women believed that Down syndrome is not sufficiently severe and they 
would not terminate the pregnancy for it. Others would terminate a pregnancy for Down 
syndrome because the child will always need care and might have many problems. 
Another important argument was life expectancy, which is often a reason not to include late 
onset disorders in a screening test. They believed that one can have a joyful life until your 
40s or 50s, without knowing about the disease, and maybe there will be new treatments 
discovered in the meantime. In contrast, a few women indicated that they probably would 
want to know late onset diseases because it enables you to prepare for your own future and 
the child's future. Some women believed that an expanded test might enforce str iving for a 
perfect child and also mild disorders might be included in pre‐ natal screening in the future. 
They were worried about where the expansion would stop. 
 
Discussion 
Pregnant women gave various reasons to accept or reject the first trimester prenatal 
screening. Women mainly chose for FTS to pre‐ pare for the birth of an affected child, or to 
terminate an affected pregnancy. Preferring a worry‐free pregnancy or not wanting to take 
action after an abnormal test result was the main reason for declining FTS. In concordance 
with other studies, NIPT was preferred over the ftCT by most women because of its 
reliability.(19, 20) Some participating women would terminate a pregnancy in case of an 
abnormality; others would never consider a termination. 
 
With regard to the influence of pretest prenatal counseling on the decision whether or not 
to participate in FTS, some pregnant women already made their choice about screening 




before visiting their obstetric caregiver, whereas others made this choice after counseling. 
Most women indicated that counseling for first trimester screening should both include 
information on the tests, the process, and the conditions screened for, as well as a 
discussion on the emotional impact of screening and the possibility of receiving an abnormal 
test result, which has been described before.(21) 
Pregnant women indicated that it is important that women think about what they would do 
with the results from prenatal screening beforehand, which is also underlined by healthcare 
professionals. 
 Deliberation, defined as the weighing and considering of what prospective parents consider 
to be a worthy life for their child and what a termination of pregnancy would mean to them, 
is seen as a key aspect of informed decision‐making.(22) However, a few interviewed women 
stated that they did not deliberate themselves, even not after pretest counseling, because 
they want to take the screening process step by step and would only start considering what 
they would do with an abnormal test result when they actually receive one. To our best 
knowledge this discrepancy is not found in previous studies, although one study did find that 
not wanting to think about what to do with a possible abnormal test result can be a reason 
for pregnant women to decline prenatal screening.(23) This discrepancy gives rise to the 
question what should be the focus of the prenatal screening counseling. Currently, the main 
focus of pretest counseling is pro‐ viding information  (21), but our results suggest that 
merely providing information is outdated: some women prioritize deliberation about their 
choice. Other studies also found that pregnant women want more than only information 
provision. They would like to have decision‐making support or even advice from their 
midwives, whether or not to test.(24) These results also show that women's personal 
information needs and preferences regarding deliberation differ. This requires personalized 
counseling in which the counselor addresses such personal needs. Previous research found 
that midwives feel more comfortable with providing in‐ formation than with inquiring about 
the feelings and thoughts of the pregnant couple.(21) Future research could focus on the 
best way to layout a pretest counseling session for first trimester prenatal screening, to 
balance information provision and deliberation support, and make midwives’ task a little less 
complex. Also, a deliberation‐focused approach to pretest counseling might need to be 
differentiated, as a subgroup of women want to take part in the first trimester prenatal 
screening without imagining what a detected abnormality might mean to them and 
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deliberating what reproductive decision they would make in response. To respect the 
autonomy of these women, they should be allowed to access screening without partaking in 
deliberation. 
 
Pregnant women feel like they are free to have their own opinion about the first trimester 
prenatal screening. They made different choices with regard to first trimester prenatal 
screening, but all felt that they could make these decisions independently, without pressure 
from others. Some of the women indicated that their surroundings influenced their choice, 
such as their partner, parents, friends, or family with (shared) beliefs or views of life, or their 
obstetric care‐ givers. These pregnant women did not experience this influence as pressure: 
they stated that they could still make their own individual choice. This phenomenon was 
described in the literature before, in a study in which it was examined whether prenatal 
screening programs allow pregnant women to make autonomous choices. The women in 
that study also stated that they were influenced by others during the decision‐making 
process, such as their partners, their midwives, and society, but they made their own choices 
without pressure by others.(25, 26) These results suggest that the concern that NIPT will 
lead to a societal pressure to take part in screening and/or to terminate an affected 
pregnancy (27), is contradicted in this study. This suggests that, for the women pretest 
counseling in the context of NIPT, emphasized freedom of choice. 
So, pregnant women do not personally experience any pressure to (not) engage in prenatal 
screening, however, some of them did express the concerns that in society there are certain 
expectations with regard to participation in screening and either termination of an affected 
pregnancy, or carrying this pregnancy to term. Earlier research has also shown that pregnant 
women are worried that NIPT may lead to pressure to engage in screening; however, none 
of these studies described pregnant women experiencing this pressure themselves.(8, 16) 
Pregnant women differed in their opinions regarding the re‐ imbursement of first trimester 
prenatal screening. These different views could be explained by differences in test choice, 
personal (financial) situation, and other aspects. Pregnant women did agree that a lack of 
reimbursement could result in unequal access to healthcare. 
Furthermore, pregnant women agreed that reimbursing a screening test carries the message 
that the test is standard practice, as can be seen with the second trimester sonography scan, 
of which the uptake is over 90% in the Netherlands.(28). Pregnant women believed that by 




reimbursing first trimester screening, the uptake will increase and women might venture 
into prenatal screening less thoughtfully. Some women indicated that asking a (small) fee 
made them think about their choice. They believed that it would also make other pregnant 
women aware that prenatal screening is a personal, important choice. However, they did 
feel that for some women even a small fee might be too much, therewith causing these 
women to forego participating in screening, even if they wanted to. In sum, women 
underlined the importance of informed choice, to which a small fee might be conducive, but 
that should not be at the expense of equal access. This again stresses the influence of how 
screening is organized on the women's choices, and demands that in the screening offer and 
pretest counseling the choice aspect is emphasized. 
 
These results show that both scenarios, a reimbursed screening offer and a non‐rei mbursed 
screening offer, might challenge the non-directiveness of the screening offer and the related 
counseling, whereby nondirective means ‘withholding any normative judgment regarding 
the obtaining and application of genetic information’.(29) Reimbursed first trimester 
prenatal screening might imply for pregnant women that the screening test is a good quality 
test, and participating in this test is self‐evident and part of routine antenatal care. By 
contrast, a non-reimbursed screening offer might imply that the test offered is not seen as 
an important or of good quality by the healthcare providers, and therefore pregnant women 
would not want to opt for it. The effect of either message should be minimized in the 
counseling by explaining that while the test is reimbursed, women are still free to not opt for 
the test, or that while the test is not reimbursed, it is a good test that might provide options 
to women. Adequate pretest counseling is the most important resource we have to 
counteract any negative effects of (not) reimbursing first trimester prenatal screening. 
Finally, a possible expanding scope of NIPT turned out to be a difficult discussion point for 
pregnant women. Pregnant women found it difficult to make statements about the 
expansion of NIPT because they were unfamiliar with other disorders than the common 
trisomies currently included in first trimester screening. In the discussion, various categori es 
were used, that is, early onset/late onset and actionable/non‐actionable. Pregnant women 
were also not al‐ ways familiar with these categories, in such cases examples to explain the 
categories were used, but the categories did make it easier for them to elaborate on the 
screening offer. 
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Some women were enthusiastic about an expansion because they thought that obtaining 
more information is something good. Others, however, were hesitant toward the expansion 
of NIPT and expressed the fear of a possible slippery slope. The interviewed pregnant 
women were made aware of the existence of a large number of serious conditions other 
than trisomies 21, 18, and 13 through this discussion, and some of them linked this to their 
own unborn child. Having this discussion could be burdensome for pregnant women, who 
could start questioning whether they are the ones having to decide on the screening offer.  
Analysis of the responses given by the pregnant women on the questions regarding the 
scope of NIPT showed that they consider three things to be important in deciding whether or 
not to screen for a certain condition: (a) severity, (b) life expectancy, and (c) the possibility of 
an independent and happy life. If a condition would have (one of) these characteristics most 
women agreed that it should be included in the screening. 
In the literature, to help women make individualized decisions about the scope of prenatal 
screening, it has been suggested that women should choose from a menu of options  (30), 
with different categories of conditions included in the screening offer. Also, in another 
interview study pregnant women favored ‘pure choice’ model for expanded NIPT, wherein 
reproductive autonomy and informed choice are used to justify any prenatal screening 
decision a women wants to make.(31) According to the findings of this study, such models 
would lead to practical problems: women had different interpretations of categories and 
found it hard to imagine what learning particular test results might mean to them and their 
child. Moreover, women had little knowledge of—or experience with—conditions that could 
potentially be included in the test, which raised the question whether women can make an 
informed, autonomous choice. From this the conclusion could be derived that the scope o f 
NIPT should mainly be determined by experts, not by women themselves. Which experts 
should decide on the scope of NIPT should be determined by future research. Based on 
earlier re‐ search an expert panel in the Netherlands could include midwives, gynecol ogists, 
clinical geneticists, laboratory specialists, policy makers, and ethicists.(30, 32) Nevertheless, 
opinions of women on the scope of prenatal screening, as found in this study, are important 
inputs for the determination of the scope. 
A second issue raised by the expanded scope and its related in‐ formed choice is that some 
interviewed women wanted to receive the test results first, and only after something of 
relevance has been found, they would wish to learn more detailed information on the 




condition detected. These findings suggest that in case of an expanded NIPT women might 
prefer a layered counseling wherein information in several stages can be provided to women 
in order to prevent information overload, as is proposed in a layered consent model for 
personal genetic tests.(33) Personal preferences regarding informational need and 
deliberation could therewith be taken into account. 
 
Strengths and limitations  
The strength of this study is that we included pregnant women from different regions in the  
Netherlands, aiming to include varying opinions within our sample. Furthermore, we 
included women with different test choices, to make sure that all choices (no prenatal 
screening, NIPT, and the ftCT) were well represented within our sample. Finally, we h eld 
these interviews right before and right after the introduction of NIPT as a first trimester 
screening test for all pregnant women in the Netherlands, making it a current and non‐
hypothetical matter for all interviewed pregnant women. 
For this study women signed up themselves, which may have caused a bias in our pregnant 
population. Women who are willing to participate in an interview about prenatal screening, 
might have different characteristics and opinions compared to pregnant women willing not 
to be interviewed. This might explain why in our pregnant group more than half (11 out of 
19) of the interviewed pregnant women opted for NIPT or the ftCT, whereas in the entire 
Dutch pregnant population less than half (45%) opts for first trimester screening. Therefore, 
the interpretation of these results must be performed with caution, as these might not be 
generalizable to the entire Dutch pregnant population. Furthermore, al‐ though we actively 
sought other target groups, mostly Dutch, highly educated, nonrel igious women 
participated, which may also cause problems in the generalizability of the results. Also, some 
of the interviews were conducted before the availability of NIPT to all pregnant women in 
the Netherlands, whereas other inter‐ views were conducted  after its implementation, which 
may have elicited different opinions. Finally, in our pregnant group most women were highly 
educated (12 out of 19) of which most (9 out of 12) chose for either the combined test or 
NIPT. In the lower educated group (7 women) only two women chose for first trimester 
prenatal screening. Because we conducted a qualitative interview study, we are not able to 
draw conclusions or elaborate on the fact that more highly educate women opted for first 
trimester prenatal screening than lower educated women. However, this finding is in line 
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Our study shows that there is a varying and broad range of opinions about first trimester 
prenatal screening, NIPT, pressure to test, the reimbursement of screening and the 
expanding scope among pregnant women in the Netherlands. Women feel that they have a 
free choice to opt for or decline prenatal screening, even though they sometimes receive 
advice from others for their decision. Adequate pretest counseling is important to maintain 
this experience of choice liberty now that NIPT has become part of the screening offer. 
However, counseling might need a shift in focus toward deliberation about wh at women 
want to know about the health of their child and what they want to do with the results, 
taking into account personal informational needs—which is already started in all Dutch 
training institutions and midwife practices. The significance of pretest  counseling for first 
trimester screening continues to be a factor of great attention. However, our study clearly 
shows two important social issues that should be addressed in counseling. First of all, 
freedom of choice should be emphasized and second, possible messages deriving from 
either reimbursed or non-reimbursed screening should be minimized. Most women felt that 
not fully reimbursing screening could prevent the routinization of NIPT, but that this may 
also cause unequal access to healthcare. Furthermore, women had difficulty making 
statements about expanding the scope of NIPT, but agreed that determining the scope 
should mainly be based on severe, life‐threatening disorders. Finally, our results suggest that 
the scope of NIPT should be determined by experts (in the Netherlands these could include 
midwives, gynecologists, clinical geneticists, laboratory specialists, policy makers, and 
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Chapter 4|  
What do parents of children with Down syndrome think about non-
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Abstract 
This study explores the attitudes of parents of children with Down syndrome towards non -
invasive prenatal testing (NIPT) and widening the scope of prenatal screening. Three focus 
groups (n=16) and eleven individual interviews with Dutch parents (and two relatives) of 
children with Down syndrome were conducted. Safety, accuracy and earlier testing were 
seen as the advantages of NIPT. Some participants were critical about the practice of 
screening for Down syndrome, but acknowledged that NIPT enables people to know 
whether the fetus is affected and to prepare without risking miscarriage. Many feared 
uncritical use of NIPT and more abortions for Down syndrome. Concerns included the 
consequences for the acceptance of and facilities for children with Down syndrome, 
resulting in more people deciding to screen. Participants stressed the importance of  good 
counseling and balanced, accurate information about Down syndrome. Testing for more 
disorders might divert the focus away from Down syndrome, but participants worried about 
“where to draw the line”. They also feared a loss of diversity in society. Findings show that, 
while parents acknowledge that NIPT offers a better and safer option to  know whether the 
fetus is affected, they also have concerns about NIPT’s impact on the acceptance and care of 













Non-invasive prenatal testing (NIPT) using cell-free placental DNA is increasingly being used 
to test for fetal aneuploidy. By using a maternal blood sample, NIPT can test for Down 
syndrome with a sensitivity of more than 99% and a false-positive rate of less than 0.1%.(1) 
For women with an elevated risk based on the first-trimester combined test (FCT), NIPT is a 
safe alternative to invasive testing, although invasive testing will be required to confirm a 
positive NIPT result. Due to its high accuracy, NIPT can also be used as a first-tier screening 
test for all pregnant women, thereby replacing the FCT (2), although the positive predictive 
value is significantly lower in lower-risk women as compared to high-risk women.(3) The 
introduction of this innovative test is having great impact on the prenatal landscape. 
Furthermore, it has been proven possible to scan the whole fetal genome with NIPT.(4) so 
future use is likely to expand to testing for a wider range of genetic disorders.   
Several studies have investigated the attitudes towards NIPT of important stakeholders such 
as health professionals and pregnant women. Overall, these studies show that  both 
pregnant women(5-7) and health professionals (8, 9) have great interest in NIPT due to its 
ability to test early in pregnancy with high accuracy and no miscarriage risk. However, 
concerns were expressed about potential “routinized” or uncritical use of NIPT, women 
feeling pressure to test, and the possible impact of NIPT on acceptance of people with a 
disability (6, 7). Alongside these concerns, the introduction of NIPT in routine prenatal care 
has been criticized (10), on the basis of the disability rights critique.(10, 11) It has been 
argued that prenatal screening for Down syndrome sends out a message that emphasizes 
the negative aspects of living with Down syndrome, and implementing NIPT runs counter to 
the hope of improving attitudes towards Down syndrome.(10)  
Very little is known about what parents of children with Down syndrome think about 
prenatal screening and, in particular, about NIPT. Using an online survey, Kellogg et al. (12) 
studied the attitudes of 73 US mothers of children with Down syndrome towards NIPT. They 
showed that the majority of mothers agreed that NIPT should be available to all pregnant 
women, and that NIPT was a good thing because it allows people to prepare themselves for 
a child with Down syndrome. However, most of the mothers also expected NIPT to cause an 
increase in pressure to test and in social stigma for having a child with Down syndrome. (12) 
When looking at the attitudes of parents of children with Down syndrome towards prenatal 
testing in general, it seems that most believe prospective parents should have autonomy 
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and reproductive freedom.(13, 14) However, studies have shown cultural and religious 
differences in attitudes towards prenatal testing and termination of pregnancy amongst 
parents of children with Down syndrome.(15, 16) A study of 78 women who had a sibling 
with Down syndrome showed that they overall had a positive experience of having a brother 
or sister with this condition, but around one-third would still consider prenatal testing and 
termination of pregnancy since they experienced a negative impact on themselves and their 
family.(17)  
Decisions in a national screening system need political support, thus taking account of many 
perspectives. Since the introduction of NIPT could have an impact on the way soci ety 
perceives Down syndrome and the lives of people living with this condition, it is important to 
further investigate what parents of children with Down syndrome think about introducing 
NIPT into a national prenatal screening system and which consequences they think this wi ll 
have. This information can be used to establish a responsible implementation of NIPT, taking 
account of all stakeholder perspectives. This study therefore addresses the following 
research questions: 1) What do parents of children of Down syndrome think are the 
advantages and disadvantages of using NIPT for prenatal screening?; 2) What are important 
requirements for a responsible NIPT offer according to them?; and 3) What do they think 
about widening the scope of prenatal testing with NIPT? 
This study was performed in the Netherlands, where the uptake of prenatal screening for 
Down syndrome (and trisomy 18 and 13) is relatively low (~27%) (18) compared to nearby 
countries like Denmark (90%) (19) or England (74%).(20)The low uptake of screening might 
be partially explained by the way screening is offered to women, with a clear emphasis on 
the “right not to know,” women having to pay for FCT (21), and the rather positive attitudes 
towards Down syndrome in the Netherlands.(22, 23)  
 
Methods 
A qualitative research design was used. Focus groups were formed to explore multiple 
perspectives and to stimulate discussion. Additional individual, semi-structured interviews 
were held to allow for a more private environment to explore the attitudes and (often 
emotional) experiences of parents of children with Down syndrome. Ethical approval for this 
study was obtained from the Medical Ethical Committee of the VU University Medical Center 




Amsterdam (VUMC). Informed consent was obtained from all individual  participants 
included in the study. 
 
Participants 
Participants were recruited with help of the Dutch Genetic Alliance (VSOP). An invitation for 
participation was placed on the website of the Dutch Down Syndrome Foundation (SDS, 
parent organization). As this produced no responses, another invitation was placed on a 
closed Facebook group consisting of about 900 members sharing experiences of having a 
child with Down syndrome. In total, 58 parents responded to the invitation, and two parents 
were recruited through the researchers’ network. A total of 27 people took part in the study; 
16 participated in the three focus groups (each consisting of 5 to 6 participants) and 11 in an 
individual interview. The parents who participated in the focus groups were not related. Two 
of the focus group participants were not parents but relatives of a child with Down 
syndrome (sister and aunt). Participant characteristics are summarized in Table 1. After 
three focus groups and 11 interviews no new information was obtained, and therefore data 
saturation was reached.   
 
Instrumentation and procedures 
In April 2014 NIPT became available in the Netherlands in public healthcare as a second -tier 
screening test. The first two focus groups were conducted prior to this period, in September 
2013, in a community center in the middle of the Netherlands (Utrecht). The last focus group 
was in April 2015 at the VUMC in Amsterdam. The individual interviews were conducted by 
A.K.K. between March and April 2015, and took place at participants’ home, workplace or by 
telephone. The focus group sessions were conducted using a semi-structured interview 
guide based on the one used in our previous study of pregnant women and their partners.(7) 
The guide included the following topics: participants’ perceptions of the current Down 
syndrome screening using the FCT and invasive tests; perceptions of the advantages and 
disadvantages of NIPT, especially when NIPT would become available as a first-tier screening 
test; and opinions about testing for a wider range of disorders using NIPT. Via a PowerPoint 
presentation, participants were given a brief explanation of the characteristics of the current 
screening program and characteristics of NIPT, including testing for more genetic disorders. 
The focus groups were managed by an experienced moderator, together with an assistant  
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Table 1: Characteristics of participants in the three focus groups and individual interviews 
Characteristic Focus groups (n = 16) Individual interviews (n= 
11) 
Sex 
  Female 







Mean age, years (range) 39.7 (29-50) 41.1 (31-48) 
Level of educationa 
  Low 
  Medium 










  None 







Mean number of children (range) 2 (0-3) 2 (1-4) 
Number of children with DS  
   0 
  1 









Mean age of child with DS, years (range) 6 (1-17) 6 (1-16) 
Prenatal screening during pregnancy of child 
with DS 
  Yes: 
  Low-risk FCT result 
  Low-risk FCT result, invasive test after  
  ultrasound abnormality 
  High-risk FCT result, no invasive test 
  High-risk FCT result, invasive test 
  FCT (result unknown) 
  No: 
  Not interested 
  Not offered 
  Declined screening because of the costs  





























aLow: elementary school, lower level of secondary school, lower vocational training; Medium: higher 
level of secondary school, intermediate vocational training; High: higher vocational training, 
university. 
bTwo relatives of children with DS, a sister and an aunt. 
 
taking notes and observing group interactions. For the individual interviews, the same semi -
structured interview protocol, with some minor changes, was used. During the individual 
interviews, information about the current screening program and NIPT was provided 
verbally, supported by illustrations. 




Data analysis  
Focus groups and interviews were audiotaped and transcribed verbatim. After transcription, 
a thematic content analysis was performed using the qualitative software program ATLAS.ti 
5.2. Responses in the text were coded independently by R.v.S. and A.K.K., and ranked and 
clustered into main topics and subtopics in order to identify important themes. Themes and 
codes were discussed with a third researcher (L.H.), and discrepancies were discussed until 
consensus was reached. Representative quotes from the focus groups (FG) and interviews (I) 
were translated from Dutch and are presented to illustrate the themes. 
 
Results 
Participants’ own experiences with prenatal testing for Down syndrome varied widely as did 
their attitudes towards prenatal screening and NIPT. Participants discussed four main 
themes: NIPT test characteristics; consequences of a lower barrier for prenatal screening; 
requirements for a responsible NIPT offer; and widening the scope of prenatal screening. 
The findings are summarized below. 
 
Theme 1: NIPT test characteristics: accuracy, safety, earlier testing 
Although not all participants necessarily agreed with prenatal screening, their first 
impressions of NIPT were positive. Different advantages of NIPT related to its test 
characteristics were discussed.  
 
Accuracy and safety 
The high accuracy of NIPT was seen as an advantage, as participants felt that the test 
currently used for prenatal screening, the FCT, had limited accuracy, causing unnecessary 
invasive tests and a false sense of security in women with a low-risk estimation. 
 
“I had a chance of 1 in 800 [after FCT], well, I had some friends who had a chance of 1 
in 20. They did not have a child with Down syndrome, and I did. I was totally not 
prepared for it, because I actually thought that my child would not have Down 
syndrome, because I had excluded that with the test [FCT].” (I11) 
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Participants stated that NIPT’s ability to reduce the number of invasive procedures, and thus 
miscarriages, is a great advantage since these tests are risky and stressful, both for pregnant 
women and obstetricians.  
 
“Lower risk of miscarriages, and that is of course, the big advantage I think […] I have 
had chorionic villus sampling, but that’s just not nice. It was a very bad experience 
[…] it was painful but also emotionally a bad experience.” (FG1) 
 
Most participants argued that because NIPT is accurate and safe, it is easier for women to 
test whether the fetus has Down syndrome. In the case of a positive test result, this allows 
women to prepare themselves emotionally for the birth of a child with special needs, 
arrange adapted perinatal care, or terminate the pregnancy if they feel they are not able to 
cope with a child with Down syndrome.  
 
“For me that is the biggest advantage, that without the risk of a miscarriage you 
know what the situation is and from there on can think: What do I choose?” (FG2)  
 
“If NIPT had been available back then, I would have liked to have had it, because then 
at least I would have known [that the fetus had Down syndrome]. Our child had a 




The fact that NIPT can test earlier in pregnancy than the FCT was seen as an advantage 
because participants expected less maternal-fetal bonding during the early phase of 
pregnancy. Should the fetus have an abnormality, and prospective parents wish to 
terminate, it was thought that this would be easier to deal with because they are less 
attached to the child.  
 
“Yeah I think the earlier you know, the less difficult an abortion will be probably, for 
me I think, because a child develops so quickly […] I think I would be able to live with 
it [termination of pregnancy] better if it‘s done as early as possible.” (FG2)  




Participants also mentioned that testing early in pregnancy is better because fewer people 
are aware of the pregnancy, which means that a potential termination of pregnancy would 
be easier for the parents socially as they would not have to explain it to others. While most 
agreed that earlier testing is an advantage of NIPT, some argued that this could also be a 
disadvantage. They thought that women (and their partner) would terminate the pregnancy 
less thoughtfully since they are less involved in the pregnancy at this stage, feel less of a 
bond with the child, or do not have enough time to think carefully about what they want. 
They expected this could even lead to regret afterwards. 
 
“You are maybe less involved with your pregnancy. […] you have thought less well 
about the consequences of aborting it, while later on you may feel sorry about it.” 
(FG1) 
 
Theme 2: Consequences of a lower barrier for prenatal screening 
Most participants felt that because of the better test characteristics, N IPT would lower the 
barrier for participation in prenatal screening. Some saw this as an advantage since prenatal 
screening will become easier as only a blood sample is required, and there is no risk of 
miscarriage.  
 
“It is just more accessible because of the fact that there is less risk of a miscarriage 
[…] you can just give blood, so in that sense it is more accessible […] it lowers the 
barrier.” (FG1) 
 
Most participants, however, saw this lessened barrier as a disadvantage. Since NIPT is such 
an easy and risk-free test, it might become more “normalized” to screen for Down 
syndrome, and Down syndrome would become less accepted.  
 
“It will become more normal to test for Down syndrome with the consequence that 
Down syndrome becomes even more undesirable, because the fact that you screen 
for something means it is undesirable, otherwise you wouldn’t screen for it.” (FG1)  
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Moreover, participants thought that pregnant women and their partner might feel pressured 
by society to have NIPT. Participants stated that already with the FCT some parents of 
children with Down had the experience of being judged on their choice not to screen. Since 
NIPT is a better test, women who decline NIPT might feel the need to explain their decision. 
Having a child with Down syndrome might be regarded as their own responsibility for which 
society would then be justified to hold them (financially) accountable. 
 
“Your freedom of choice will be limited in such a way that you have to explain the 
fact that you don’t want to screen.” (FG3) 
 
“Like, you consciously decided not to test, so it’s kind of your own fault…so then you 
also will carry the burden of it. So everything it [having a child with Down syndrome] 
costs, yeah: Sorry madam, you should been tested then.” (FG3) 
 
Participants thought that the uptake of prenatal screening would increase with NIPT, and 
more people would terminate their pregnancy. This would cause a decline of the population 
with Down syndrome, leading to a potential loss of acceptance and facilities for affected 
individuals. They also were concerned that because of the decreasing number of people with 
Down syndrome there would be less research on Down syndrome-related complications, 
thereby eroding the knowledge concerning treatments and care for people with Down 
syndrome. In this scenario women would not really have a choice anymore to turn down 
prenatal screening, which would lead to an even higher uptake. This supposed self -
reinforcing process is illustrated in Figure 1.  
 
“The moment you make screening more accessible and lower the barriers [...] more 
people will do it […], and as a consequence of that, the population [of people with 
Down syndrome] will decline. I am sure of that.” (FG1) 
 
“What has been fought for, for so long, that those people finally, yeah, are more 
accepted in society, […] that will all go, well, it might deteriorate.” (FG2) 
















Figure 1. Self-reinforcing process of impact of NIPT, based on expectations of Dutch parents of children with 
Down syndrome (DS) 
 
Participants hypothesized that the advantages of NIPT are mostly applicable to the individual 
woman. In contrast, the disadvantages of NIPT are more likely to affect society as a whole. 
For example, they feared it would lead to a loss of diversity in society. They thought that 
people with Down syndrome were valuable to society, and that people could learn from 
them.  
 
“The way he [son] has contact with other people, everybody can take it as an 
example. […] he gives a lot of joy, and it sometimes brings you back to reality.” (I3) 
 
Participants indicated that having a disability could become less acceptable by society.  
 
“[Screening] affects people with a disability.[…] There is a negative attitude towards 
people with a disability, and this is stimulated [by the introduction of NIPT].”(I2) 
 
In addition, participants thought that people may get the idea that life can be controlled by 
using NIPT, and that this might lead to unrealistic expectations about having children. 
 
“It’s not like: Okay, I did the test and I am done now, and everything will be fine. 
Having a child is not easy, and a lot of things can be wrong with the child, and there 
are external factors that influence child development. Now [with NIPT] it seems like, 
well you can exclude everything […]. That’s just not true.”(I7) 
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Lastly, participants felt that prenatal screening puts a lot of focus on Down syndrome, while 
trisomy 13 and 18 can also be identified. They felt that with NIPT, the focus is even more on 
Down syndrome. They stated that in the (Dutch) media NIPT is being called “the Down -test” 
(24), which in their opinion suggests that Down syndrome is the worst thing that can happen 
to your child.  
“It [prenatal screening] makes it seem as if the most important thing is to avoid 
having Down syndrome […] like, when it [the child] has Down syndrome then your 
world will fall apart, there is nothing worse than that […]. I am not saying it is not a 
handicap. But it is not the worst in the world, no.” (FG2) 
 
“Actually it’s already becoming standard: NIPT equals Down syndrome, which equals 
terminating the pregnancy.” (FG3) 
 
Some participants wondered why Down syndrome is still screened for at all. They felt that 
people with Down syndrome can have a valuable life, and that there has been significant 
medical progress, giving children with Down syndrome much fewer medical problems 
nowadays.  
 
“I support screening if there is something one can do, and if suffering can be avoided. 
We therefore did the FCT because trisomy 13 or 18…we wouldn’t wish that on a 
child. But a child with Down syndrome […] overall can have a valuable life in society.” 
(FG3) 
 
“I often wonder for what medical reason they screen for Down syndrome [..] the 
reason why those children did not survive was primarily because of their heart 
disorder, and there has been so much medical progress on that.” (FG1) 
 
Theme 3: Requirements for a responsible NIPT offer  
NIPT in public healthcare 
Although not all participants agreed with screening for Down syndrome, most did think it is 
unrealistic to stop offering prenatal screening. Therefore, when prenatal screening is being 
offered anyway, they felt that it would be better to screen with a safe and accurate test like 




NIPT and to embed this in public healthcare with proper counseling, instead of women going 
to a commercial setting where they might receive poor counseling and information.  
 
“You’re better off starting to offer it [NIPT] within public healthcare and making sure 
there is proper counseling than having it offered anyway in some kind of commercial 
setting.” (FG1) 
 
Reimbursement of NIPT 
Participants had trouble deciding whether NIPT should be reimbursed. They felt that by 
doing so, you send out a certain message that would encourage all people to do this test 
without thoroughly thinking about it. However, the present cost of NIPT could create double 
stigmatization, where children with Down syndrome are only born in lower social economic 
classes, because those people cannot afford NIPT.  
“People with a low income, yeah, they cannot do it [NIPT]. Yeah, it will be like when 
you could recognize someone’s poverty by the state of his teeth.” (FG3) 
 
Information and counseling 
Almost all participants mentioned that improving information provision during the 
implementation of NIPT is important to support informed decision-making and avoid 
routinization. Participants felt improvement to be necessary because they thought there was 
a lack of good counseling and up-to-date, balanced information about Down syndrome. They 
also felt that in society Down syndrome is portrayed as being either too negative or too  
optimistic.  
 
“We are programmed to think it is terrible to have a child with Down syndrome. But 
if you see how normal a child with Down syndrome can be, if you, in some way, can 
incorporate that [in counseling], then you get more balanced information than there 
is now.” (FG1) 
 
“There is a group that portrays it [Down syndrome] as very positive, but they want to 
counterbalance all those negative stories […] I would like to see a midway, the reality 
[…] just show how it really is, and that is very diverse.” (FG1) 
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Several participants mentioned that the government contributes to the negative image of 
Down syndrome by providing the possibility to test for Down syndrome. 
 
“Down syndrome really gets labelled as a disorder that should not exist. At least, 
that’s how many parents [of children with Down syndrome] perceive it, and for that 
we blame the government.” (I9) 
 
They indicated that the government therefore has the responsibility to correct the negative 
image of Down syndrome by, for example, information campaigns, and that the governmen t 
should not spend money on the implementation of a new test without improving the 
information provision. 
To achieve balanced and complete counseling for NIPT, many parents stated that, in 
addition to medical information, more information about living with Down syndrome should 
be given.  
 
“Yes, also the counseling, […] I think that obstetricians and midwives can still learn a 
lesson about that when NIPT gets implemented. […] I think counseling is very 
important. To portray a realistic picture (of) what it’s like to live with a child that has 
a disorder.” (I10) 
 
“I think you should highlight all sides (of Down syndrome). The current counseling for 
Down syndrome is like ‘high risk of heart disease,’ ‘higher risk for  this’ […] you are 
just getting a list of symptoms. […] When you offer it [NIPT] to people, you should 
also offer all information […], all sides of it. Make sure that people really get an 
honest picture.” (I6) 
 
Several participants mentioned that parents of children with Down syndrome could have a 
role as an information source. They could share their experiences of having a child with 
Down syndrome and make people understand what it is like. 
 
“Not to convince them [prospective parents], but to tell the truth, to show the   
  reality.” (I8) 




Some participants also thought there was unfamiliarity with Down syndrome amongst 
healthcare professionals. They were concerned because professionals play a major role 
during counseling and can have a significant impact on parents’ decisions, as parents might 
feel uncertain and anxious after receiving test results. Some participants also mentioned 
that for some obstetricians, a termination of pregnancy is the obvious next step after a 
Down syndrome diagnosis. Participants therefore stressed the importance of a non-directive 
attitude of the health professional. 
 
“That people hear like ‘Well you had amniocentesis, you carry a child with Down 
syndrome, so when are we going to set the appointment to terminate the 
pregnancy?’” (FG1) 
 
 “I can imagine that, when you are pregnant and have a lot of hormones and 
emotions and whatever, and then you hear that your child has Down syndrome and 
you know nothing about it, then you get the opinion of a doctor. The question is 
whether all doctors will have the same opinion. I think not.” (I1) 
 
Theme 4: Widening the scope of prenatal screening with NIPT 
Participants had conflicting thoughts about testing for more disorders with NIPT. They 
agreed it had a number of advantages, like being able to prevent suffering, to arrange 
adapted perinatal care, or starting soon after birth with a certain diet to lessen the 
pathology of the disorder.  
 
“If people indeed happen to have a disorder that you can, for example, partly prevent 
with a lifestyle or diet […] yeah that of course has its advantages.” (FG1) 
 
Some participants mentioned that it would give parents the option to decide whether they 
would be capable of caring for a child with a disorder.  
 
“I find the freedom of choice of parents very important. Like, can I handle this? Will 
we be able to deal with this in my family?” (FG2) 
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Some participants also felt that testing for more disorders could lessen the focus on Down 
syndrome, which they saw as a benefit. 
 
Moderator: “Expanding the offer [of NIPT] to other disorders, what do you think 
about that?” 
Respondent: “Well, I think, that as long as it [a broader NIPT test] goes along with 
good information provision...look, what I find wrong at this moment is that the focus 
is so much on Down syndrome […] and if there will be more [disorders], […] as long as 
the information provision is right, everyone should be able to decide for themselves.” 
(FG1) 
 
Participants expected it to be difficult to decide where to draw the line when testing for a 
broader range of disorders, and to avoid that this line getting crossed over time.  
“Yeah, what would worry me a lot is how to guard that line […] what we can all test 
for. We are curious by nature you know, there will always be people that will want to 
cross that line.” (FG1) 
 
Some participants noted that it is not up to prospective parents to decide about everything 
since we cannot control everything in life. Some also mentioned that society would not 
benefit from eliminating everything that differs from the “normal standard.”  
 
“I find it very dangerous that as a society we more and more make value judgments 
on everyone who doesn’t fit the strict definition of normality.” (FG3)  
 
Other participants mentioned that people would be faced with even more difficult decisions 
to deal with during pregnancy. Moreover, they worried what kind of impact it would have on 
eligibility for healthcare insurance or housing mortgages.  
 
Discussion 
Parents of children with Down syndrome considered the accuracy, safety and possibility to 
test earlier as advantages of using NIPT in prenatal screening. However, they thought that 
prenatal screening in general, and the use of NIPT in particular, put too much focus on Down 




syndrome, making it seem like Down syndrome is the worst thing that can happen to one’s  
child. They expected that NIPT would lower the barrier for participation in screening, which 
has both advantages and disadvantages. Participants argued that NIPT gives people a more 
accurate option to test for Down syndrome without having to risk a miscarriage; but because 
of that, testing for Down syndrome and terminating the pregnancy could also become more 
normal. They feared the latter could erode the acceptance, facilities and research for Down 
syndrome, which in turn leaves women with little room to decline testing (self-reinforcing 
process illustrated in Figure 1). Participants stated that, when implementing NIPT, the 
counseling should be improved by giving more balanced, accurate information, including 
more information about living with Down syndrome. Although participants assumed that 
testing for more disorders with NIPT diverts the focus away from Down syndrome and allows 
for early medical intervention, they worried about where to draw the line. They also feared a  
loss of diversity in society. 
This study describes the views of a sample of parents and relatives of children with Down 
syndrome in the Netherlands, a country with relatively low uptake of prenatal screening. 
When compared with the attitudes of pregnant women in the Netherlands as well as 
pregnant women in other countries (5-7), it seems that parents of children with Down 
syndrome often perceive similar advantages and disadvantages of NIPT. Like pregnant 
women, they believe NIPT lessens the barrier for participation in screening because it is a 
simple and safe test that can be done early in pregnancy. Similar to the study by Kellogg et 
al.(12) of mothers of children with Down, participants agreed the lower barrier is beneficial 
because it allows people to test without risk and decide whether or not to continue the 
pregnancy based on that information.   
The notion that it could also lead to an increase in termination of pregnancies  also 
corresponds to findings of Kellogg et al.(12), where the majority believed NIPT would lead to 
the termination of more pregnancies. A study by Natoli et al.(25) on termination rates after a 
Down syndrome diagnosis showed that higher termination rates were associated with 
earlier gestational age. This finding supports the assumption that NIPT’s ability to test earlier 
could lead to more termination of pregnancies, although others have suggested that with 
NIPT the percentage of women who opt for termination of pregnancy in the case of an 
affected pregnancy may decrease.(26)  
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The fear expressed by participants that fewer children with Down syndrome being born 
could lead to stigmatization and fewer facilities, is a concern that was also observed in 
several other studies.(6, 7, 27, 28) Due to the lower barrier for NIPT, participants indicated 
that good quality counseling and informed decision-making are of great importance. This 
awareness also exists amongst health professionals, for example, genetic counselors from 
the UK, who stated that because NIPT has the potential to become routinized, it is the 
professional’s role to make sure that women understand what they are consenting to.(29)
  
To help healthcare professionals facilitate meaningful discussions between themselves and 
prospective parents, Sachs et al.(30) have developed a framework for pre-test counseling 
about NIPT, especially focusing on its capabilities and limitations. Participants in our study, 
however, felt that already in current screening practice, information and counseling were 
not up to standard. They were especially critical of the quality of the information about 
Down syndrome given at different stages of the screening trajectory. Studies in other 
countries suggest that knowledge of Down syndrome among healthcare professionals could 
be improved (31), and that some parents perceive the information about what it may mean 
to live with this condition, both for the individual and for the parents, as insufficient (32, 33) 
or overly negative.(12) It was also noted that the information leaflets for thos e considering 
screening for Down syndrome should provide more accurate information about this.(34) 
Participants in our study thought that parents of children with Down syndrome could play a 
valuable role in this respect as well. 
Similar to pregnant women (7), parents of children with Down syndrome think that testing 
for more disorders with NIPT can have some advantages. Interestingly, one of the 
advantages mentioned was that it would shift the focus away from Down syndrome, thus 
avoiding the impression of Down syndrome as a disorder for which screening would 
somehow be more justified than for other (including more serious) conditions, something 
that many of these parents find unjust and hurtful. Participants, however, feared testing for 
more disorders would confront prospective parents with even more difficult decisions. This 
fear was also expressed in our previous questionnaire study of Dutch pregnant women, who 
stated that “testing for a broad range of disorders may complicate the decision -making 
process beyond what most couples are able to comprehend”.(35) Although it was not 
explicitly mentioned in this study, widening the scope of testing will also make it increasingly 




difficult to meaningfully discuss prior to testing what it is like to have a child with any of the 
conditions screened for. Participants in our study also feared a loss of diversity in society, 
which is in line with findings from a previous study in the UK that highlighted public fears of 
fueling a problematic quest for perfection if NIPT were to be used to screen for an ever 
wider range of disorders.(36)  
 
Study limitations and research recommendations 
A strength of this study is the qualitative approach, which allows for exploring in -depth 
views about NIPT. Using both focus groups and individual interviews allowed us to explore 
opinions in both a group context and more private environments, which strengthened the 
credibility of the results. As far as we know, this is the first qualitative study of the attitudes 
of parents of Down syndrome children towards NIPT. A limitation of the study is that almost 
all participants were recruited from one source, a Facebook group which consisted of people 
with relatively young children. Moreover, participants were Caucasian and highly educated. 
This might have led to biased responses. Additionally, previous discussions on this Facebook 
page might have influenced participants’ opinions. Moreover, attitudes of parents might 
have been influenced by the strongly articulated opinions in the Dutch media. I n the focus 
group and individual interviews held in 2015, participants seemed more negative about NIPT  
than in the focus groups in 2013. However, the sample size is too small to draw conclusions 
on this point. The study was conducted in the Netherlands, where prenatal testing is offered 
in a nationally organized prenatal screening system, the uptake of which is relatively low. 
Attitudes of participants in this study may thus vary from those living in countries where 
NIPT is offered by individual (commercial) healthcare providers, or in countries with other 
cultures and religions. Finally, qualitative data are not intended to be generalized to the 
population of interest. Future studies might include larger samples of males and females. 
Moreover, should NIPT be introduced as a first-tier screening test, it would be interesting to 
see whether and how it affects parents’ opinions. 
 
 
Conclusion and practice implications 
The findings from this study provide insight into the expectations and concerns that parents 
of children with Down syndrome have about introducing NIPT into a national prenatal 
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screening system. It can be concluded that parents of children with Down syndrome may 
have ambivalent attitudes towards NIPT. While they do not necessarily all agree with 
prenatal screening, they do acknowledge that NIPT offers a better option than the combined 
test to know whether the fetus has Down syndrome. However, they also expressed concerns 
for the future of children with Down syndrome and emphasized the need for good 
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Abstract 
Informed consent is a key condition for prenatal screening programs to reach their aim of 
promoting reproductive autonomy. Reaching this aim is currently being challenged with the 
introduction of non-invasive prenatal testing (NIPT) in first-trimester prenatal screening 
programs: amongst others its procedural ease –it only requires a blood draw and reaches 
high levels of reliability– might hinder women’s understanding that they should make a 
personal, informed decision about screening. We offer arguments for a renewed recognition 
and use of informed consent compared to informed choice, and for a focus on value-
consistent choices and personalized informational preferences. We argue for a three-step 
counselling model in which three decision moments are distinguished and differently 
addressed. 1) Professionals explore women’s values concerning whether and why they wish 
to know whether their baby has a genetic disorder. 2) Women receive layered medical -
technical information and are asked to make a decision about screening. 3) During post-test 
counselling, women are supported in decision-making about the continuation or termination 
of their pregnancy. This model might also be applicable in other fields of genetic (pre-test) 
counselling, where techniques for expanding genome analysis and burdensome test-
















In many countries, when a pregnant woman first visits an obstetric care provider, she will be 
offered information about several prenatal screening tests. Some tests are offered to 
promote the health of mother or child, for example screening for Rhesus factor. Other 
prenatal screening tests, however, are aimed at the detection of foetal abnormalities for 
which no therapeutic or preventive interventions are possible or available.(1) Rather, testing 
for these foetal abnormalities provides reproductive options to pregnant women or couples, 
with the aim of promoting reproductive autonomy.(2) These tests enable future parents 1) 
to obtain information about their future child, and 2) decide about whether to continue or 
terminate a pregnancy in case of a genetic disorder.  
Non-invasive prenatal testing (NIPT) is being introduced widely as a screening test for t hree 
common foetal aneuploidies: trisomy 21, 18 and 13, leading to Down’s, Edwards’ and 
Patau’s syndrome, respectively. NIPT is an alternative for and an improvement of the first -
trimester combined biochemical test for these trisomies.(3) It is based on the assessment of 
cell-free DNA in the blood of the mother and has better test characteristics compared to the 
first-trimester combined test, being more accurate and reliable. However, these advantages 
of NIPT have raised several ethical questions and concerns.(4) For instance, an increase in 
uptake of NIPT is feared to lead to an increased abortion rate and to social exclusion of 
people with a disability. Moreover, next-generation sequencing technologies allow for a 
future expansion of the scope of NIPT. Some people are concerned that NIPT may come to 
include trivial conditions or findings that are difficult to interpret.(5) Prenatal clinics today 
are already confronted with - sometimes difficult to interpret - incidental findings resulting 
from the use of next-generation technologies in NIPT.(4)  
Another frequently mentioned problem is that NIPT may lead to problems for informed 
decision-making: NIPT might be considered by pregnant women as ‘just another blood 
test’(6) easy to conduct and very reliable. Women might routinely accept NIPT as a screening 
test for trisomy 21, 18 and 13 and may not be prepared for abnormal test results.(7) Besides, 
it is feared that women would step into what is called a ‘screening trap’.(8) This means that 
NIPT might put women on a pathway to invasive follow-up diagnostic testing and potentially 
termination of the pregnancy, while they not have fully assessed the consequences 
beforehand.   
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These problems are considered to challenge the ‘informedness’ of NIPT-related decisions 
and consequently to undermine the aim of reproductive autonomy.(2) Counselling is the 
generally preferred instrument to promote informed decisions and includes providing 
information and decision-making support.(9) How can counselling be used to counter some 
of the ethical and practical problems for informed consent raised by the introductio n of 
NIPT? What should be the focus of counselling, and how can women best be supported in 
decision-making for or against first-trimester prenatal screening?  
We first discuss the aim of prenatal screening (reproductive autonomy), the definition of 
informed consent and its operationalization in counselling. We offer arguments for a 
renewed recognition and use of the term informed consent – rather than informed choice – 
in ethical discussions of prenatal screening, and a different understanding of what it me ans 
to give or ask for informed consent for first-trimester screening.  
The aim of prenatal screening: promoting reproductive autonomy  
The aim of prenatal screening programs is formulated as promoting reproductive 
autonomy.(10) By explicitly stating this aim, health care systems try to make clear that 
prenatal screening is different from other forms of screening in the public health context, 
such as breast or cervical cancer screening, the aims of which are the (secondary) prevention 
of disease or the promotion of health.(1) It would be problematic for prenatal screening 
programs to be aimed at prevention, for this implies that the birth of affected children ought 
to be avoided. If that were so, states or healthcare systems might appear to be promoting or 
encouraging abortion in case of genetic disorders. Abortion would turn into a (eugenic) 
public health instrument.(2) Also, it would carry the discriminatory message that children 
with the conditions screened for should not be born and their lives are worth less than those 
of citizens without genetic conditions. Thirdly, it might put pressure on women to terminate 
the pregnancy of an affected foetus.(2, 7) Pressure is precisely what should ideally be 
avoided in decision-making with regard to NIPT: women must be free to decide whether or 
not to take part in screening, and whether or not to terminate a pregnancy because of 
detected abnormalities. To distance prenatal screening from these problems, its aim is 
formulated as the provision of health-related information about the foetus in order to offer 
courses of action to pregnant women and couples in case of a foetal abnormality, or the 
promotion of reproductive autonomy.(7) This means that the decision to reject prenatal 




screening, too, is and should be part of reproductive autonomy, in recognition of “patients’ 
individual right(s) to decide whether or not they wish to receive testing and then to make 
reproductive choices based on test results”.(11)  
Informed consent in the context of NIPT  
The aim of prenatal screening is operationalized through informed consent. Through the 
instrument of informed consent, healthcare professionals seek to ensure that women make 
autonomous decisions for or against a screening offer.(12, 13) According to the seminal 
theory of informed consent by Faden and Beauchamp, an “informed consent is given if a 
patient or a subject with (1) substantial understanding and (2) in substantial absence of 
control by other (3) intentionally (4) authorizes a professional.”(14) Firstly, a decision 
whether or not to take part in screening should be based on ‘substantial understanding’. 
This implies that women should be informed about characteristics of the tested condition, 
potential risks and benefits of the test and implications of possible test outcomes.(15) 
Secondly, women should be free to make a voluntary decision about screening and not be 
coerced or pressurized by others. Thirdly, women should have the capacity to consent. Most 
women do, and healthcare professionals are expected to presume that all patients are 
decisionally competent to decide unless they have reason for doubt. Traditionally, someone 
is believed to have the capacity to consent when she demonstrates the following four 
competencies: understanding of relevant information, reasoning based on this information, 
appreciating her situation and the consequences of her choice, and communicating a 
choice.(16) Fourthly and finally, the woman must in fact make a choice. It is noteworthy that 
in the field of prenatal screening the term ‘informed choice’ is frequently used instead of 
informed consent, which is ubiquitous in medical ethics and medical practice generally. (17) 
In one dominant model, ‘informed choice’ is defined as “one that is based on relevant 
knowledge, consistent with decision-maker’s values and behaviourally implemented.”(18) In 
the context of NIPT, informed choice is achieved when a woman has sufficient knowledge 
and either a positive attitude towards undergoing a test while opting for screening, or a 
negative attitude while refusing screening.  
One of the rationales offered for preference of the term informed choice is that it distances 
prenatal screening programmes from unwanted eugenic associations.(17) Another rationale 
is that informed choice suggests that decision-making is less active than in informed consent, 
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and that informed consent requires a more elaborate discussion with a health 
professional.(19) Also, it is claimed that “informed consent is not explicitly concerned with 
the understanding of those not consenting.”(20) Informed consent would suggest that 
patients should accept the option that is proposed or preferred by the healthcare 
professional. The withholding of consent to this preferred option might be considered ill-
advised or irrational. By using the term informed choice in lieu of informed consent, it is 
emphasized that accepting and rejecting of prenatal screening are evaluated as equally 
valuable options. Both the choice to accept and the choice to reject prenatal screening are 
an expression of reproductive autonomy.(21) Finally, it has been suggested that informed 
consent “is not explicitly concerned with the consenting individual’s values” while informed 
choice includes someone’s values reflected in attitudes.(20) Also, in the literature on 
prenatal screening, the term ‘informed decision-making’ is being used. Informed decision-
making often refers to the pre-decisional process, “the process of arriving at a decision”(22) 
and includes a process of deliberation and of weighing of pros and cons (23), while informed 
choice refers to the decision itself for or against a screening offer.  
We contend that there is no ethical need for the use of the terms informed choice or 
informed decision-making in the context of prenatal screening. Traditional notions of 
informed consent encompass the criterion of voluntariness, and thus forestall concerns 
related to a lack of opportunity to withhold consent or related to state -enforced eugenics. 
They imply that patients (or pregnant women) understand relevant information about the 
proposed (or offered) screening test, and that this may require elaborate discussion with a 
healthcare professional. Also, when a woman is reasoning based on relevant informatio n or 
appreciating her situation and the consequences of her choice, she is deliberating and 
evaluating. As a complement to their ‘autonomous authorisation’ model, Faden and 
Beauchamp propose a condition of authenticity: “An authenticity condition would req uire 
actions to be consistent with a person's reflectively accepted values and behaviour in order 
to be autonomous. Authenticity in this usage requires that actions faithfully represent the 
values, attitudes, motivations, and life plans that the individual  personally accepts upon due 
consideration of the way he or she wishes to live.”(14) With this condition, the traditional 
model of informed consent incorporates the consenting individual’s values and attitudes. 
Ultimately, in this ‘autonomous authorisation  plus authenticity’ model, informed consent in 




the context of prenatal screening would require women’s choices to be deliberate  and 
consistent with their values as reflected in their attitudes. Thus, the rationales offered in the 
literature for preferring the term informed choice (or decision-making) over the term 
informed consent, do not hold.  
Besides, a rehabilitation of the notion of informed consent in the context of prenatal 
screening may offer the added benefit of embedding it in the broader basis of existing 
ethical literature concerning the principle of respect for autonomy, which plays an especially 
important role in ethical discussions of NIPT as its main aim. 
Limitations of current models for ‘informed consent’   
Given the aim of prenatal screening, to evaluate the success of screening programs for 
aneuploidies including pre-test counselling, the informedness of women’s decisions for or 
against screening must be assessed, rather than uptake or detection rates.(2) Various 
measures of informed consent and informed choice have been developed in the past to 
measure the ‘informedness’ of women’s choices with regard to screening offers.(18, 24, 25) 
  
The knowledge component of these models, however, is problematic for NIPT. Firstly, the 
necessity of knowledge might get too little attention amongst women because, as said, the 
procedural ease of NIPT could hinder women’s understanding that they have to provide 
informed consent for first-trimester prenatal screening, leading to routine acceptance of the 
test.(26) Furthermore the next-generation sequencing technologies used for the test and its 
possible outcomes – trisomy 21, 13 and 18, and incidental findings – are increasingly 
complex. There are concerns that women may lack understanding of relevant information 
about its aim, procedures, possible outcomes and consequences. Also, it may not be possible 
to redress these concerns by having healthcare professionals provide more and more – 
written and verbal – information to pregnant women. In fact, the provision of a lot of 
medical-technical information during pre-test counselling may overwhelm women and cause 
‘information overload’, which may hinder them in becoming aware of what prenatal 
screening might mean for them.(27) When measurement scales focused on information and 
knowledge are being used to assess the quality of informed consent, such assessments are 
likely to result in high percentages of ‘uninformed’ decisions. But is that to say that women 
have not given valid informed consent for screening, or that their decisions were not 
118 | Chapter 5 
 
autonomous?  
Providing or ‘disclosing’ information may not be a primary requirement for informed consent 
in the context of prenatal screening. Manson and O’Neill have pointed out the complexities 
of the disclosure or what they call the ‘conduit’ of information in the context of consent. 
Information, for instance, is ‘inferentially fertile’(28): when a pregnant woman receives a bit 
of information about a test, she may consciously or unconsciously go on to make a range of 
inferences about the test, which may or may not overlap with the counsellor’s 
understanding of the test and may or may not be correct or relevant. Moreover, when she 
enters the counselling session, she may have already made her decision about participation 
in screening.(29) She may have gathered her information from various types of sources (e.g. 
magazines, acquaintances, social media). Thus, when she consents, she may consent to 
something (slightly) different than that which is envisioned and disclosed to her by the 
counsellor.  
Pre-test counselling should therefore not focus on the knowledge component of informed 
consent, but on supporting pregnant women and their partners in making personal, value -
consistent decisions about prenatal screening. This is how reproductive autonomy is best 
served. Offering decision-making support can at the same time be used to counter the 
problem of routine acceptance of prenatal screening: although NIPT is not a diagnostic test, 
and any abnormal results must be confirmed through invasive follow-up testing, it is much 
more sensitive and specific than previous technologies. It further requires only a single blood 
draw. As women may thus have fewer reasons to refuse screening, they may accept it 
automatically, without full consideration. Focussing on personal decision-making might help 
women to make a personal decision about prenatal screening. 
Screening is offered to help women to plan their lives according to their values – if they want 
to, with use of prenatal screening. Women therefore should make considered decisions for 
or against first-trimester screening, for it may have great impact on their lives. The decision 
to take part or not to take part in screening should be informed but above all authentic. To  
respect women’s autonomy and enable them to decide about prenatal screening according 
to their personal values they should be enabled to think about the question why they would 
want to know whether their baby has a genetic disorder. Women should be prompted to 
think about whether they want to have the options (termination or preparation in case of a 




genetic disorder) which prenatal screening provides them in order to plan their lives. This is 
in line with the notion that informed consent includes a more active decision-making than 
informed choice.(19) Reproductive autonomy not only involves sufficient knowledge as 
argued by previous authors but also “involves (…) encouraging self-reflection to act in 
accordance with broader life goals”(30) which emphasizes autonomous decision-making. 
This aim is more in line with the definition of informed consent including the authenticity 
requirement, as it focuses on self-determination and the broader ideal of planning one’s life 
according to one’s values.  
A three-step counselling model  
To reach an authentic choice according to someone’s life plan requires a restructuring of the 
current approach to counselling, and requires primarily a dialogue about the pregnant 
woman’s or couple’s values, instead of providing ‘value free’(31) medical technical 
information as is suggested by several professional committees.(32, 33)   
We propose a re-focusing of pre- and post-test counselling and a re-envisioning of the 
decision-making process, consisting of three central decision moments for women and their 
partners (Figure 1). These three decision moments are derived from the current counselling 
practice in the Netherlands, in which pregnant women are already presented with three 
decision moments. In the Netherlands pregnant women first receive an ‘information offer’. 
With this offer, a woman is asked whether she would want to receive information about 
prenatal screening at all. When a woman declines, the counsellor will explore her motivation 
and will not inform her any further about first-trimester prenatal screening options.(34) The 
information offer is meant to promote the moral right not to know about the options of 
prenatal screening for foetal aneuploidies, in order to stress the fact that this screening is 
not mandatory.(35)   
Critics of the information offer suggest that it is not possible to make an informed choice to 
decline screening when one does not know about the options for prenatal screening. This 
criticism touches upon a realistic problem, but we think that the so lution is not to provide 
complete information in this first step. Instead, the health professional first should explore 
women’s motivations and related values to determine whether the declination is either the 
result of an autonomous decision or on misunderstanding of prenatal screening.   
Step 1: Exploration. The first decision moment of our proposed counselling model focus on 
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women’s personal attitudes towards prenatal screening and its meaning to their life 
planning, instead of providing medical-technical information. The main goal of this first  step 
is that health professionals will explore women’s values, discussing with them why they do 
or do not want to know about genetic disorders at this stage of pregnancy. This might enable 
women to make their values explicit in context of this decision. We acknowledge that in this 
step women might want some information about prenatal screening, for example to imagine 
what possible results might mean to them. But foremost, in this first step it must become 
clear to women that opting for - or against - prenatal screening is a free and personal choice: 
it should focus on promoting choice awareness. More than the information offer, this first 
step might infringe upon the presumed right not to know about screening options. This first 
step does not replace the information offer, because in this step it is about accepting or 
declining the screening offer, not an information offer. An information offer could take place 
beforehand, but might entail the same exploration questions to find out whether women or 
couples have deliberated about their decision.  
Step 2: Information. The second step in the counselling is that, when women would like to 
have prenatal screening, they will receive information about the test , its procedures, its 
possible outcomes and the consequences thereof, and risks and benefits. At this stage 
medical-technical information becomes more important and provides women the option to 
compare this information with their values. Information provision can be done through 
multiple modalities, including written materials, video materials, individual and/or group-
based face-to-face discussions with healthcare professionals, according to women’s personal 
needs, to ensure that key information on the (increasingly) complex test is conveyed. In this 
step it should again be stressed that women are free to withdraw from taking part in 
screening.   
In the current Dutch practice of offering NIPT, wherein women can choose to learn about 
incidental findings, the question raises whether women need to know everything abou t the 
abnormalities included in the test, before they opt for screening, or whether they could wait 
to receive a full explanation of the implications of detected abnormalities when it turns out 
that one has been detected. We suggest that in order to make an informed choice, in the 
second decision moment women do not necessarily need to know medical -technical 
information about the test, such as the percentage of women that has a low risk based on 
first-trimester screening or which follow-up test are available beforehand. They primarily 




should understand that first-trimester prenatal screening may yield information about 
serious diseases for which often no treatment is available. They should know that t his may 
be a reason for women or couples to consider termination of an affected pregnancy, and 
should consider whether or not they wish to make use of the possibility of obtaining such 
information about their foetus. However, women’s preferences, concerning which 
information is provided, how much and in what way, might differ. To design the second step, 
a tiered-layered-staged model for informed consent, which has been proposed in the 
context of genomic testing, might provide direction, proposing a choice between specified 
categories of diseases.(36) In the context of prenatal screening and pre-test counselling, 
categories of incidental findings can be based on characteristics of abnormalities, e.g. 
pathogenic for the foetus, variants of unknown clinical significance, benign findings and 
incidental findings, as proposed for diagnostic genetic tests.(37) Based on these categories 
women and couples can be informed about possible outcomes according to their needs, to 
make a personal informed decision about prenatal screening. Furthermore, in the second 
step, information about the prenatal test and its outcomes could be presented in a layered 
fashion, offering more detailed information (written materials, websites, group information 
meetings) to women on request, in order to keep the first layer of information (offered 
during the face-to-face counselling discussion with the healthcare professional) limited and 
focused on key messages, preventing information overload. Besides, information provision 
could be spread over time to promote elaboration about the information and reflection on it 
(36), although in the context of prenatal screening counsellors should take account of the 
fact that during a pregnancy, the time of having courses of action, including the possibil ity to 
terminate the pregnancy, is limited and thus the time to reflect on information is limited. 
  
Ultimately, in step two, women should again be encouraged to reflect on the information 
provided based on their personal values. Therefore, the information given in step two should 
foremost support value-consistency, and not be aimed of providing as much objective 
technical-medical information as possible.  
Step 3: Follow-up and support. The third step takes place when women receive an abnormal 
test result. This step does not differ from the current practice after receiving an abnormal 
result from prenatal screening. Women will receive post-test genetic counselling from one or 
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more relevant professionals, in most cases a clinical geneticist, about the detected 
abnormality, its prognosis and possible courses of action. After considering this information 
women and their partners should obtain information about follow-up tests including 
amniocentesis or chorionic villus sampling, the consequences of carrying the pregnancy to 
term or terminating the pregnancy. They should be free to decide whether or not to opt for 
follow-up tests and termination or continuation of the pregnancy and receive professional 
support during their decision-making.  
This three-stage choice process covers the problem which NIPT might cause for informed 
consent. It moves towards resolving the problems of routine uptake of prenatal screening by 
emphasizing the personal-choice aspect, focusing on women’s or couples’ personal values. 
This stepwise counselling model, including the layered information provision might also be 
applicable to other types of prenatal screening like the 20-week ultrasound scan, and also to 
other types of genetic testing as for example parents with a known family history of a 
genetic history. Furthermore, this restructuring of pre-test counselling could address the 
concern that reproductive autonomy could be hindered by future expansions in conditions 
screened for prenatal screening test. It is feared that therewith NIPT will involve too much 
information about many abnormalities, which might cause an information overload for 
women during pre-test counselling. Women might not understand what a broad NIPT might 
disclose, hindering them to give informed consent about whether or not to participate in 
screening.(2)  
But for the first of three decisions moments, the width of the scope and the technicalities of 
the test are of less importance. The most important question is whether women want the 
options prenatal screening might provide to them, including preparation and termination of 
pregnancy in case of a genetic disorder.   
 
The three-step model in practice  
Our proposal to change the focus of pre-test counselling from information provision towards 
elaborating women’s values is not fully new. Studies amongst pregnant women found that 
not only information about a test but also personal circumstances(6) and ethical beliefs 
influence their decision. Furthermore women want to have time to deliberate (38), and 
prefer a form of advice besides non-directive health education.(39) Professionals indicated 




that they should “trigger women to think”(40) and midwives thought that it is important to 
ask exploring questions that make women think.(41) However, they indicated that they 
experience a lack of time to ask them. The lack of time could be solved with decision-aids, 
which can help women to prepare the counselling and already obtain information about 
prenatal screening, or to resume what is discussed in the counselling, facilitating a staged 
process. Although some women might wish to receive information about prenatal screening 
in a separate visit, step one and two of the counselling model could take place in a single 
visit. Nevertheless, two separate counselling moments do not necessarily demand very many 
additional resources because it often can take place in visits wherein other topics are 
discussed and measurements are done. But, as professionals already underlined, to provide 
women with time to consider, the prenatal test should not take place at the same visit as the 
pre-test counselling.(42) 
The three-step counselling model might fulfil women’s needs of support in making a decision 
according to their beliefs and help counsellors to facilitate reflection on women’s choices for 
or against prenatal screening. Furthermore, it might protect those women who are less able 
to understand information and formulate their personal values and promote their 
reproductive autonomy, corresponding to what is stated by O’Neill: “Informed consent 
procedures protect choices that are timid, conventional and lacking in individual autonomy 
(variously conceived) just as much as the protect choices that are self-assertive”.(43) In the 
Dutch context, it may help to avoid the moral discomfort experienced by professionals when 
they do not provide any information at all to those who decline the information offer. The 
present article shows that there are also ethical arguments for a revised approach of pre-
test counselling for prenatal screening, which should focus on personal decision-making.  
Finally, as reproductive autonomy also includes relational aspects(30), enabling women to 
give informed consent and reaching the aim of prenatal screening program is successfully, is 
not only the responsibility of counsellors. As argued elsewhere, also the context in which a 
decision is made matters.(44) Women or couples should have the feeling that accepting or 
rejecting prenatal screening are equally valuable options. This is not only established by 
counselling but also by the broader societal context, in which provision of care and sup port 
should be in place for those who choose to continue a pregnancy when it is known that the 
child born will have a disability, as well as for those who choose to terminate the pregnancy. 
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Conclusion 
The introduction of NIPT is associated with several ethical problems including negative 
consequences for informed consent. Because of its procedurally ease, NIPT is believed to 
hinder women’s understanding that they have to personally decide about a first -trimester 
prenatal screening offer. Furthermore, the potential for future expansion of NIPT might pose 
challenges for sufficient information provision. The current way of counselling focuses on 
the non-directive provision of practical and medical-technical information about the test, 
and may not be equipped to counter these problems. Informed consent in prenatal 
screening should be characterized as the decision to participate or not participate in 
screening, based on an understanding that screening may yield information about serious 
disorders in the foetus, which may be a reason for women and their partners to consider 
termination of the pregnancy. In our view, having knowledge about the test itself, its 
possible outcomes and the consequences thereof may be conducive to the informed 
consent process for some women, but it is not of central importance to all women.  
We have proposed a three-step counselling model, in which three decision moments are 
distinguished and recognized as different types of decisions, for which different types of 
counselling should be offered to women and their partners. The primary decision should 
focus on the values concerning obtaining knowledge about whether the baby has a genetic 
disorder and the courses of option this knowledge provide. The second step involves layered 
information provision about the test and the final decision to test or not test, adapted to 
women’s personal informational need. In case of an abnormal test result, in a third step, 
women will need to decide about follow-up tests and the continuation of their pregnancy.  
We have argued that reaching the aim of prenatal screening not necessarily lies in having 
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The ethics of routine: A critical analysis of the concept of ‘routinization’ 
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Abstract 
In the debate surrounding the introduction of non-invasive prenatal testing (NIPT) in 
prenatal screening programmes, the concept of routinization is often used to refer to 
concerns and potential negative consequences of the test. A literature analysis show s that 
routinization has many different meanings, which can be distinguished in three major 
versions of the concept. Each of these versions comprises several interrelated fears and 
concerns regarding prenatal screening and particularly regarding NIPT, in three areas: 1) 
informed choice, 2) freedom to choose and 3) consequences for people with a disabili ty. 
Three of the strongest arguments raised under the flag of routinization are assessed for their 
validity: the threat that NIPT poses to informed choice, the potential increase in uptake of 
first-trimester prenatal screening and its consequences for social pressure to participate in 
screening or terminate affected pregnancies, and the negative consequences for disabled 
people. These routinization arguments lack empirical or normative ground. However, the 
results of this analysis do not imply that no attention should be paid to possible problems 
surrounding the introduction of NIPT. At least two problems remain and should be 
addressed: there should be an ongoing debate about the requirements of informed choice, 
particularly related to an expanded scope of prenatal screening. Also, reproductive 
autonomy can only be achieved when expecting parents’ options are variegated, real and 
valuable, so that they can continue to choose whether or not to screen or to terminate a 
pregnancy. 





For several years, first-trimester prenatal screening for chromosomal abnormalities has been 
available for pregnant women and their partners. With the first-trimester combined test 
(FCT), which includes a blood test and an ultrasound scan, the foetus can be assessed for i ts 
risk of trisomy 21, 18 or 13, or Down's, Edwards' or Patau's syndrome, respectively. The 
introduction of non-invasive prenatal testing (NIPT) now changes the field of first-trimester 
prenatal screening. NIPT is based on the possibility to analyse cell -free foetal DNA in the 
blood of the mother for chromosomal abnormalities in the foetus. With a simple maternal 
blood draw, the foetus can be assessed for trisomy 21, 18 and 13.(1) NIPT can be performed 
throughout the pregnancy, from ten weeks onwards, and provides more reliable test results 
for these trisomies than the FCT.(2) Further, as genome-wide sequencing techniques and the 
bioinformatics analyses of the data are improving, more abnormalities other than trisomy 
21, 18 and 13 can be detected through NIPT.(1) In theory, this allows for the expansion of 
the number of disorders that can be included in the test. 
The favourable test characteristics of NIPT - early, reliable and safe - make the test attractive 
to pregnant women.(3) But pregnant women and professionals have also indicated that 
these improved test characteristics might raise ethical concerns.(4, 5) It is feared that the 
test is ‘too easy’ and influences the way the test is perceived and presented, namely as a 
routine offer, which a pregnant woman will accept as a matter of course.(6-9) This might 
impede the informed choice of women (7-9), or lead to pressure to test.(10, 11) In the 
literature this concern is often referred to as routinization of prenatal testing.(7, 9, 12) 
Routinization is thought to affect the generally acknowledged single justified aim of prenatal 
screening: to promote reproductive autonomy.(13) Reproductive autonomy in the context of 
prenatal screening presupposes that women make informed choices (13), and also that they 
are free to choose from a range of options (14), which should be varied, realistic and 
valuable.(15) This implies that women or couples should have the freedom to choose 
between screening and not-screening, and, more importantly, between termination and 
continuation of the affected pregnancy. Routinization of prenatal screening is not only 
thought to negatively affect the precondition of autonomous choice, but can also indicate 
other concerns, such as adverse consequences for people with Down’s syndrome, including  
discrimination and stigmatization.(11, 16) Routinization is presented either as a 
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disadvantage of first-trimester prenatal screening in general, or as an argument against a 
widespread implementation of NIPT.(13, 17) The literature about prenatal screening 
encompasses a large number of interpretations of the concept of routinization. Routinization 
refers to concerns that having a prenatal test might be self-evident to pregnant women or 
couples or that their choices for prenatal screening are uninformed and not well-considered, 
but it may also refer to the trivialization of abortion or to the conseq uences of prenatal 
screening for people with Down’s syndrome or other disabilities. Routinization serves as an 
umbrella term for many kinds of concerns and consequences of prenatal screening. 
Moreover, using an umbrella term as an argument in an ethical discussion is usually not 
productive, as it may be unclear what concern or problem exactly, is being referred to. Also, 
when a problem is not clearly defined, it is difficult to devise or assess possible solutions.  
This paper explores the various meanings of the concept of routinization as it is used in the 
ethical and psychosocial literature on prenatal screening. It further examines the validity of 
three prominent versions of routinization as arguments in the debate about a responsible 
implementation of NIPT, both normatively and empirically. It contributes to the current 
debate not only by clarifying the routinization argument and dispelling some of the public 
fears for routinization in the current prenatal screening landscape, but also by pointing out 
possible solutions to some of the more serious concerns that routinization may refer to.  
Different interpretations of routinization in the literature  
In order to find different interpretations of the concept of routinization we conducted a 
literature search. We collected publications that include ‘routinization’/‘routinisation’ or 
‘routinize’ and ‘prenatal screening’ in the full text from the following databases: Emb ase, 
PsycINFO OvidsSP, Google Scholar and Pubmed. Search strings included ‘prenatal screening’, 
‘antenatal screening’, ‘prenatal test*’ and routini*. Results included empirical studies, ethical 
analysis and governmental documents. Interpretations of routinization were listed, coded 
and clustered in several themes.  
Table 1 provides an overview of the various meanings of routinization. Three clusters of 
interpretations of routinization were identified: informed choice, freedom to choose and 
consequences for people with a disability. 
 




Table 1: Interpretations of routinization in the literature 
Version Definition Articles 
1. Informed choice   
Unconsidered choice 
Pregnant women do not deliberate their choice 
and they are not aware of the consequences of 
testing.  
(7-9, 12, 18-20) 
Presentation by healthcare 
professional 
Professionals present a prenatal test, especially 
NIPT, as routine. 
(4, 18, 21) 
2. Freedom to choose   
Self-evidence of testing and 
increase in uptake 
Prenatal screening becomes self-evident. With 
the introduction of NIPT more pregnant women 
opt for prenatal screening. 
(11, 22) 
Pressure to test 
Pregnant women feel a (social) pressure to take 
part in prenatal screening, 
(2, 9-11) 
Normalization of termination of 
pregnancy 
Termination of pregnancy after a positive test 
result becomes a matter of course.  
(17, 23) 
3. Consequences for people with 
a disability 
  
Decrease in number of people 
with disabilities  
Prenatal screening decreases the birth of 
children with disabilities. 
(11, 24, 25) 
Consequences for people with a 
disability and their family 
Acceptance of children with disabilities decreases 
and they become discriminated and stigmatized. 
(26, 27) 
 
Informed choice  
Firstly, routinization refers to the potential negative consequences of a routine offer of 
prenatal screening for the informed choice of pregnant women. Routinization means that 
giving consent is an ‘act of routine’ or ‘habitual’.(19) According to authors first-trimester 
prenatal screening has already become routinized (9, 12) or the introduction of the NIPT 
might lead to routinization of prenatal screening.(7, 18, 28) Routinization of the decision 
about prenatal screening means that women or couples do not deliberate their choice for 
prenatal screening.(9, 20) In contrast to FCT, NIPT is perceived by many women as a one-
step process rather than a multi-step process: in FCT, women are offered risk estimates for 
trisomies 12, 18 and 13, while NIPT is seen as providing yes-or-no answers.(7) A one-step 
process, it is feared, might shorten the time for deliberation about the choice for or against 
prenatal screening and its implications.   
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Women’s informed choice also depends on the way prenatal screening is offered and 
discussed by healthcare professionals.(22) Routinization is thought to negatively influence 
counselling and decision making: professionals may offer less or incomplete informatio n, 
present prenatal screening as a standard procedure that is offered to all pregnant women as 
part of standard antenatal care (29), or might even counsel women directively and 
encourage them to undergo screening.(22) It is thought that the easier and more risk-free 
the test is, the less importance healthcare professionals will attribute to offering adequate 
pre-test information which is thought of as routinization of pre-test counselling.(21)  
Freedom to choose  
A second cluster of meanings of routinization includes the obviousness of testing and the 
consequences of routine testing for a pressure to test and a normalization of abortion. When 
prenatal screening becomes routinized, the social norm might become that women should 
use prenatal screening and that it is responsible to do so, which might generate a social 
pressure to test.(9) Routinization also refers to normalisation of the termination of af fected 
pregnancies.(11, 17) When prenatal screening becomes unquestioned, it is suggested, more 
people will opt for termination of affected pregnancies, not as a result of well -considered 
choices, but, likewise, as a matter of course, or because of social pressure.(11)   
It is feared that when NIPT becomes widely available and is less invasive and free from risks 
these consequences will be enforced.(10, 11) NIPT might become part of routine procedure 
in antenatal screening as “just another blood test” (6) and might be accompanied with an 
increase in uptake, social pressure to test and an increase in terminations of affected 
pregnancies.(25) 
Consequences for people with a disability   
Thirdly, some authors have used routinization to refer to the consequences of the offer of 
first-trimester prenatal screening for people with a chromosomal abnormality or other 
disability. The total number of people with a disability might decrease over time, and this 
might provoke discrimination and stigmatization of people with a disability.(26, 27)  
The three clusters of versions of routinization are not separated but relate to and reinforce 
each other:(16) an increase in uptake of first-trimester prenatal screening might lead to an 
increase in abortions, which might lead to fewer children with Down’s syndrome. This might 
have consequences for the existing group of people with Down’s syndrome, including 




discrimination or less or lower-quality healthcare. These consequences might also have 
implications for women’s freedom to choose or decline prenatal screening. The existence of 
only limited (health) care for people with Down’s syndrome or of a negative public image of 
Down’s syndrome could pressure women into choosing prenatal screening and into 
abortions of affected pregnancies.(16) Routinization as used in the literature can thus also 
refer to more than one version at the same time and these versions can be interrelated or 
affect one another.  
Analysis of three leading routinization arguments  
We have seen that routinization can refer to a variety of ethical concerns related to prenatal 
screening. Some of these concerns are introduced as arguments in the ethical and societal 
debate about the introduction of NIPT as a first-trimester prenatal screening test. We will 
now critically assess three of the most prominent routinization arguments in relation to the 
introduction of NIPT: the threat that NIPT poses to informed choice, the potential increase in 
uptake of first-trimester prenatal screening and its consequences for a pressure to test and 
abortion rates, and the negative consequences for disabled people. We will examine the 
validity of these arguments, and see if there is any empirical or normative support for them. 
1. Informed choice: The challenges of NIPT for informed choice   
The first identified routinization-argument is that NIPT could threaten the informed choice of 
pregnant women for prenatal screening because of the favourable test characteristics of 
NIPT. Besides, women might be less aware of potential consequences of prenatal screening, 
such as unwanted and difficult choices regarding invasive diagnostic testing and the 
termination of pregnancy.(18) Uninformed choices about prenatal screening are normatively 
problematic because the aim of prenatal screening is to promote reproductive autonomy, 
for which informed choice is an important requirement.(13) Moreover, a high level of 
knowledge about a test and its implications is associated with an improved psychological 
management of decisions and a better personal well-being.(30)  
Informed choice for prenatal screening has been studied empirically, with varying results. 
Research groups have measured the ‘informedness’ of pregnant women’s or couples’ 
choices regarding first trimester prenatal screening, and reported varying outcomes: 51%, 
59%, 77,9% and 89% of women or couples, respectively, were found to have made informed 
choices with regard to first-trimester prenatal screening.(20, 31-33) Part of the differences in 
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outcomes may be explained by the different methods for measurements employed: some 
studies measured knowledge, attitude and actual choice(31-33) and others also studied the 
decision-making process and included deliberation in the measurements.(20, 33) Besides, 
these studies mentioned limitations related to the feasibility of measuring informed choice. 
Authors questioned which elements determine informed choice and whether elements of 
knowledge, value-consistency and deliberation should be weighed equally.(20, 31) This 
should be taken into account when considering these results in the context of NIPT. The 
empirical studies on informed choice for NIPT suggest that NIPT does not lead to uninformed 
choices, showing that a majority of women, 77, 9% and 89%, were capable of making 
informed choices regarding NIPT.(32, 33) However, a comparative study suggest that 
informed choice rates may be lower in routine prenatal care than in a study setting; 89.0% 
versus 75.6%.(34) This difference emphasizes the importance of continuous improvement of 
informed choice in practice. Efforts are underway to train midwives in counselling for 
NIPT(35) and to develop decision aids for pregnant women.(36)  
In conclusion, recent studies of informed choice do not offer convincing reasons to expect a 
critical effect on informed choice for prenatal screening. Attention to counselling and 
information provision may further relieve some of the concerns related. The introduction of 
NIPT could be an opportunity to continue work on the methodological difficulties of 
measuring informed choice and the content and quality of counselling.  
2. Uptake screening & freedom to choose: NIPT and an increase in the uptake of prenatal 
screening 
A second prominent routinization argument is that the introduction of NIPT could lead to an 
increase in the uptake of first-trimester prenatal screening.(11)  
Empirical studies that investigated women’s motivations for opting for first -trimester 
screening do support the expectation that the uptake of screening will increase significantly 
with the widespread availability of NIPT.(37-39) Foremost, women take part in screening 
because they wish to be reassured about the health of their baby (40), and NIPT can 
facilitate that, free from risk and on the basis of a reliable test result. Women also indicated 
that they would choose NIPT even if they would not choose FCT, because of the favourable 
test characteristics of NIPT.(5, 39) On the other hand, women do not seem to 
overwhelmingly opt for prenatal screening in all countries. Studies showed that for instance 




in the Netherlands and in the US women or couples decline prenatal screening, because they 
are against abortion or wish to accept a child with Down’s syndrome.(37-40) The uptake of 
screening will not become 100% as long as women are free to decline prenatal screening for 
these reasons.   
Furthermore, an increase in uptake is not normatively problematic in itself, but becomes 
problematic when it is caused by a lack of freedom for pregnant women to act according to 
their own motivations or the existence of (perceived) pressure to opt for prenatal screening. 
Pressure could arise in the communication with the healthcare professional, the set -up of 
the screening offer itself and in the social context.(9, 41) Pressure to test undermines 
reproductive autonomy and jeopardizes the freedom not to participate in screening.(13) 
Reproductive decisions should be the result of autonomous choice, without coercion  or 
control by others.(19) Pressure to take part in screening should therefore be counteracted.
  
Empirical evidence for the existence of pressure to test is limited. Studies report that some 
women feared social reactions (41) or experienced pressure to accept the test.(22) Some 
women who declined a prenatal test had the feeling that they had to explain or justify their 
decision to others.(42) On the other hand, this does not apply to all women: many women 
do not experience pressure to test, not by the screening offer itself nor by others.(41, 42) 
Probably the experience of pressure is highly personal and its causes are complex. Because 
of the importance of reproductive autonomy further research should be directed at 
women’s experiences of pressure, the causes thereof and ways to mitigate these.  
An increase in the uptake of prenatal tests is also thought to be problematic because it 
might result in an increase in the abortion rate, which is a major concern to several groups of 
people: some believe that abortion is morally unacceptable because of the sanctity of early 
human life and argue that prenatal screening is questionable by association, as it  may lead to 
abortion.(2) Others argue that particularly the selective abortion, of children with certain 
disabilities, is a problematic consequence of prenatal screening.(27) The concern that NIPT 
will lead to an increase in abortions is probably premature as research and clinical practice 
show that there are also women or couples who choose not to terminate affected 
pregnancies. Instead, they use the information about the health of their foetus to prepare 
for the birth of an affected child.(6) This emphasizes the importance of sensitive 
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communication about screening and a responsible set-up of screening programmes, 
highlighting individual, autonomous reproductive choice as the central measure of success in 
screening programmes.  
The absence of pressure is also important for another group of people, who may have less 
principled objections against prenatal screening but may still feel a reaction of disgust (moral 
intuition or emotion) towards prenatal screening and believe that ‘nature should run its 
course’.(5) They also should be free and autonomous in their choices regarding prenatal 
screening and abortion. In the Netherlands, for instance, the uptake of fi rst-trimester 
prenatal screening, therefore, is relatively low (38), under 30%.  
To conclude, the expectation that the introduction of NIPT might increase the uptake of 
prenatal screening because of its benefits can be empirically supported. An increase in  the 
uptake of first-trimester screening in itself is not necessarily problematic, when women and 
couples make informed, autonomous choices regarding prenatal screening and follow-up 
reproductive options. There is little supporting empirical evidence for an increase in social 
pressure to take part in screening or to terminate affected pregnancies. Further research is 
needed of public attitudes towards prenatal screening and people with disabilities, and the 
influence of these attitudes on women’s and couples’ decisions-making.  
It is important to note that women’s and couple’s decision -making may be affected by 
funding arrangements, as well. It is sometimes suggested that reimbursement of prenatal 
screening by the health care system may ‘legitimize’ the screening offer and gives women 
the (false) impression that screening is important and/or necessary, and thus that all 
pregnant women should or must participate in screening.(43) Letting women pay out of 
pocket could help to underline that participation in screening is voluntary and elective. The 
meaning of this financial barrier merits further discussion, including its ethical implications 
e.g. for women with limited financial resources, for whom this barrier may not promote but 
rather restrict freedom to choose with regard to screening.  
3. Social aspects: Consequences for people with a disability  
The third routinization argument relates to societal consequences of the introduction of 
NIPT for people with a relevant abnormality. A routine offer of NIPT and a related routine 
choice for testing and abortion might lead to a reduction in the number of peop le with 
Down’s syndrome.(3, 5, 16, 24) Parents and pregnant women suggested that a decrease in 




the number of people with a disability might result in an impoverished care and support 
system for people with disabilities.(3, 16) Besides, routinization of testing might negatively 
influence public perception of Down’s syndrome.(27)  
Whether these effects will occur will partly depend on the effect of NIPT on the number of 
children born with Down’s syndrome. To our best knowledge these results are not available 
yet for NIPT. Previous studies on first-trimester screening showed that in Europe between 
1990-2009 47% of the pregnancies affected with Down’s syndrome were terminated, but 
due to an increase in incidence of Down’s syndrome because of an increase in maternal age, 
the overall prevalence stayed the same.(44) Other studies showed a decrease in life born of 
Down’s syndrome of 28-50% in the Netherlands and 18%-59% in Western Australia.(25, 45) 
The fear of an increase of the abortion rate is also supported with referring to high numbers 
of abortion as for example in Denmark, but due to cultural differences between countries it 
might be hasty to suggest that in the Netherlands the uptake and abortion rate will increase 
until same numbers.(46) This remains to be seen in practice. 
Another aspect that will influence social consequences of NIPT is the public’s perception of 
Down’s syndrome. Studies have shown that parents of children with Down’s syndrome 
experienced negative consequences in their social environment, such as being judged for not 
having done a test, receiving negative reactions after deciding to continue an affected 
pregnancy or failing to find help from organisations.(16, 47, 48) More widespread availability 
of NIPT - and more positive attitudes towards NIPT - may exacerbate such consequences: 
positive attitudes towards screening have been found to correspond with negative attitudes 
towards individuals with Down’s syndrome.(49) NIPT might thus exacerbate discrimination 
of individuals with Down’s syndrome. Wider education and information provision about 
chromosomal abnormalities will be indispensable to build and maintain nuanced public 
attitudes towards these conditions, and thus help to counter discrimination and 
stigmatization. Patient, parents and patient organisations have an important role to play in 
public education about the implications of chromosomal abnormalities for patients and their 
families. While it is unclear whether and to what extent public attitudes towards Down’s 
syndrome and other chromosomal abnormalities will deteriorate with the implementation 
of NIPT, this is something that can – and should – be monitored over the next couple of 
years.  
142 | Chapter 6 
 
In conclusion, we have discussed three prevalent versions of the routinization argument in 
the context of NIPT, for which support is limited. Current studies showed high percentages 
of informed choice and the improvement of counselling, information provision and decision 
aids might counter potential negative effects of NIPT. Furthermore, the uptake of first-
trimester screening may increase with the wide availability of NIPT, which however does not 
contradict the aim of prenatal screening. It is not yet clear whether NIPT will spur any rising 
social pressure to participate in screening, and whether this affects women’s freedom to 
choose to decline prenatal screening. This is an area of concern that will need to be 
addressed over the next couple of years. The rate of selective abortions might increase as a 
result of an increased uptake of first-trimester screening, which is considered undesirable by 
individuals or groups who believe that the intentional termination of a pregnancy is morally 
unacceptable. This dilemma, however, is not new. Nor is it significantly affected by the 
introduction of NIPT as compared to existing first-trimester screening programmes, such as 
the FCT or the 20-week ultrasound.   
Finally, as many arguments under the denominator of routinization are either not valid or 
not fully convincing as arguments against the implementation of NIPT, the term routinization 
is losing some of its force in ethical discussions. Although the umbrella term routinization 
has been exposed as largely ineffectual, its usage does reveal the existence of concerns or 
fears among stakeholders. Some of these concerns need to be addressed or can be 
overcome.  
 
NIPT and the problems that remain: informed choice and an expanded NIPT, and freedom 
to choose   
We now have seen that routinization is an umbrella term that is frequently used within the 
ethical debate surrounding the introduction of NIPT and that it can refer to a variety of 
concerns. Some of these concerns have an empirical component that can largely or partly be 
refuted. Other concerns are based on ethical principles or values, such as the sanctity of 
early human life, and are not new or specific to NIPT nor in any significant way affected by 
NIPT, which is, in the light of this discussion, simply a more reliable and safe alternative to 
FCT within existing first-trimester prenatal screening programmes.   
However, our analysis does not provide grounds to discard all concerns related to the 




introduction of NIPT. From the analysis it follows that at least two ethical issues should be 
taken seriously when implementing NIPT.  
Firstly, the effects of NIPT on society are an area of concern. For its ease, safety and 
accuracy, pregnant women may feel pressured to take part in prenatal screening or forced 
to account for their choice to decline. The feeling of no longer ‘having a good reason not to’ 
participate in screening may negatively affect women’s freedom to make (autonomous) 
choices or their experience of this freedom. If women are blamed for bringing child ren with 
chromosomal abnormalities into this world or if children are discriminated against or lacking 
in appropriate healthcare and social support, it will no longer be an (equally) valuable or 
realistic option to continue a pregnancy following the detection of an abnormality. The 
precondition of equally valuable options is not met. It should be (and feel) feasible – socially, 
financially, practically for women and couples to choose not to participate in screening and 
to carry a child with a chromosomal abnormality to term. Otherwise, participation in 
prenatal screening is no longer the result of an (autonomous) choice, and the screening 
programme will not meet its aim: that of promoting reproductive autonomy. NIPT can be 
seen as an improvement of existing programmes as long as valuable options are created and 
maintained for children with disabilities and their families.  
Secondly, informed choice is not only thought to be affected by the easiness of NIPT but also 
by the potential expansion of its scope, which comes closer with NIPT.(13) Genomic 
sequencing techniques will allow for the detection of other chromosomal abnormalities 
including microdeletion syndromes like DiGeorge and Prader Willi/Angelman.(13) Moreover, 
women are interested in additional information on microdeletion syndromes and sex 
chromosome aneuploidies.(50) Several studies suggested however that an expand ed scope 
undermines an informed choice because of the quantity and complexity of pre-test 
information, including information test results with unknown clinical significance.(6, 13, 50) 
Especially sufficient knowledge levels may be difficult to reach in the context of a broad 
range of abnormalities of varying clinical significance. There the question is whether 
knowledge should be equally valued as value-consistency or deliberation in order to reach 
informed choice. The weighing of these elements should change and deliberation should get 
more attention, in order to counter routine uptake as well as an uninformed uptake for an 
expanded NIPT. 
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Conclusion 
In the ethical debate on the introduction of NIPT, routinization is used as an umbrella term 
that is used to refer to various potential negative consequences of the test. When the 
meaning of the term is unclear, it is difficult to devise or discuss ways to counteract specific 
negative consequences of NIPT. Unqualified usage of the term routinization does not serv e 
the debate: rather, the underlying concerns should be specified and made explicit.   
On further consideration, many specifications or versions of the routinization argument are 
not valid because they lack empirical or normative foundations. Empirical stud ies have 
shown, for instance, that there may be no need to fear an increase in the uptake of 
screening or a significant threat to informed decision-making among pregnant women or 
couples. Furthermore, an increase in uptake is not normatively problematic in  itself. This 
paper directs attention to two areas of serious concern related to the wider availability of 
NIPT and its potential expanded scope, and suggests ways of mitigating these concerns. 
High-quality pre-test counselling focusing on attitude-consistency could help safeguard 
informed, autonomous choice. Also, reproductive autonomy can only be achieved as long as 
declining participation in screening and carrying an affected pregnancy to term remain 
realistic options for pregnant women and their partners. This means that support and care 
systems for disabled people should be in place and that social pressure to test or to 
terminate an affected pregnancy and stigmatization should be actively counteracted through 
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Abstract 
The introduction of the accurate and procedurally easy non-invasive prenatal test (NIPT) 
raises ethical concerns that public attitudes towards prenatal screening may change, leading 
to societal pressure to participate in aneuploidy screening. This study examined Dutch 
citizens’ attitudes towards a pregnant woman’s decision to 1) decline NIPT in the context of 
two different funding policies and 2) to terminate or continue a pregnancy affected by 
different disorders. The attitudes of 1096 respondents were assessed with the contrastive 
vignette method, using two pairs of vignettes about declining NIPT and termination of 
pregnancy. Most respondents either agreed with a woman’s decision to decline NIPT or 
were neutral about it, stating that this decision should be made independently by women, 
and does not warrant judgment by others. Interestingly, funding policies did influence 
respondents’ attitudes: significantly more respondents disagreed with declining NIPT when it 
was fully reimbursed. Respondents had similar attitudes to the vignettes on termination and 
continuation of pregnancy in case of Down’s syndrome. In case of Edwards’ or Patau’s 
syndrome, however, significantly more respondents disagreed with continuation, citing the 
severity of the disorder and the child’s best interests. This study demonstrates broad 
acknowledgment of women’s freedom of choice in Dutch society; a finding that may help to 
rebut existing concerns about societal pressure for pregnant women to participate in 
prenatal screening. As the reimbursement policy and the scope of NIPT may influence 
people’s attitudes and elicit moral judgements, however, maintaining freedom of choice 













The aim of offering prenatal screening for aneuploidies is promoting women’s and couples’ 
reproductive autonomy.(1) This implies that women and couples make their personal 
decision about prenatal screening according to their life plan and values, and it precludes 
any form of pressure to accept or decline prenatal screening. However, women’s freedom of 
choice is subject of concern with the introduction of non-invasive prenatal testing (NIPT).(2) 
The current study explores whether there are public attitudes towards NIPT in the 
Netherlands which might give rise to societal pressure to participate in screening. 
NIPT is offered as an alternative to – or in lieu of – the first-trimester combined test for 
trisomy 21, 18 and 13, or Down’s, Edwards’ and Patau’s syndrome respectively. NI PT allows 
for the analysis of cell-free foetal DNA in maternal blood using genome-wide sequencing 
techniques. It only requires a blood draw from the mother, while the first -trimester 
combined test also includes an ultrasound scan. Furthermore, NIPT is more reliable than the 
first-trimester combined test which provides a risk estimation for these three trisomies.(3) 
With both testing modalities, abnormal test results must be confirmed by an invasive follow -
up diagnostic test. Because of its higher specificity, NIPT leads to fewer follow-up tests than 
the combined test. These favourable characteristics of NIPT however raise ethical and social 
concerns and are amongst others believed to change the informed decision-making process 
and lead to self-evident acceptance of NIPT – a concern often referred to as 
‘routinisation’.(4) It is feared that NIPT takes away reasons for women to deliberate or reject 
the screening offer (5) or provokes the feeling that women have to justify themselves when 
they decline an easy and reliable prenatal test.(6, 7) These consequences are thought to lead 
to societal pressure to test. Such societal pressure poses a threat to a reproductive 
autonomy and thus to the aim of prenatal screening.(4)  
Testing this hypothesis is a challenge, because it is difficult to assess whether societal 
pressure to participate in screening exists at all – or what exactly societal pressure is. We 
interpret societal pressure not as pressure exerted by the state (e.g. mandatory screening 
programs) or by health professionals (e.g. directive counselling). In the countries in which 
NIPT is currently being introduced, screening is offered on a voluntary basis and women are 
not forced or coerced by their health professionals to take part.  
Instead, we take societal pressure to be associated with explicit positive societal attitudes 
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towards prenatal screening,(8) negative explicit or implicit societal attitudes towards people 
with a disability,(9) holding parents (financially) accountable for the birth of a disabled ch ild 
or with suggesting that raising a disabled child is one’s own (financial) responsibility.(10) 
Moreover, societal pressure can be associated with pressure to abort an affected pregnancy, 
e.g. fearing that people may perceive giving birth to a disabled child as irresponsible.(5, 10) 
Dutch parents of children with Down’s syndrome, for example, have collected their 
experiences with societal critique on having a child with Down’s syndrome in a book titled 
‘Blackbook Down’s syndrome, all people are unequal and similar’.(11)This book for example 
includes judgements that parents ‘could have known that their child has Down’s syndrome 
with prenatal screening’ and that ‘it is not necessary to have such a child because they could 
have terminated the pregnancy’. The experienced or feared societal pressure to test and to 
terminate a pregnancy of a child with Down’s syndrome was also mentioned in qualitative 
studies amongst parents of children with Down’s syndrome.(10, 12, 13)   
Besides, in the Netherlands, women must make a co-payment of €175,- for NIPT. Funding 
policies are thought to influence the routine practice of prenatal screening(14) and possibly 
therewith societal pressure to test: a prenatal screening offer which is paid with government 
subsidies might strengthen the message to the public that it is important to have that test. 
And vice versa, a test that is not reimbursed might send a message that it is an unnecessary 
test. Additionally, it is evident that women decide about NIPT in a social context, and may 
take the perspectives of partners, family members and friends into account, but that does 
not inevitably amount to societal pressure.   
To our knowledge little is known about the influence of public attitudes on women’s 
decision-making concerning prenatal screening. In the field of social psychology, research is 
done on the effects of group pressure on people’s opinions. Several experimental studies 
found that when people face a majority’s or an expert’s opinion different from their own 
opinion, they adopt this opinion, even when it includes a wrong judgment.(15, 16) 
Translating this to the context of decision-making in prenatal screening, pregnant women 
and couples might (unreflectively) adopt a dominant societal attitude towards NIPT, also 
when it would not fit their personal attitude towards this test. To assess whether this 
pressure from societal attitudes might arise it is firstly important to investigate public moral 
attitudes towards prenatal screening. This might provide insight into the possible prese nce 




of predominant attitudes that might lead to pressure to test or to abort an affected 
pregnancy. The objective of this study was therefore to examine the attitudes of Dutch 
citizens towards the decision to decline NIPT and to study the possible impact o f funding 
policies on citizens’ attitudes. Furthermore, this study investigated the assumption that 
women and couples are expected by society to terminate the pregnancy when they learn 
about the presence of a disorder. It additionally explored respondents’  underlying reasons 
for their attitudes.  
Secondly for the assessment of societal pressure and its impact on women’s decision making 
it is also important to assess pregnant women’s experiences of pressure. Studying women’s 
experiences falls outside the aim of this study but is already done elsewhere.(17, 18) 
Method  
In this study we used the contrastive vignette technique (CVT) in order to prevent soliciting 
socially desirable responses.(19) With this technique, respondents are presented with one of 
two contrastive vignettes, while unaware of the contrastive condition and the hypothesis of 
the study. The vignettes are contrastive in one condition while other variables are kept 
constant, enabling the identification of factors that affect people’s attitudes to wards moral 
issues.(19) The outcome measure of the CVT is the difference in group means between 
contrastive situations. In this study the decision to decline a state-funded NIPT was 
contrasted with the decision to decline a non-reimbursed NIPT and termination of an 
affected pregnancy was contrasted with continuation of an affected pregnancy. 
Sample population and survey  
We searched for a sample population representative of the Dutch population. Respondents 
were recruited via an external Dutch market research agency, Motivaction. Motivaction has 
an online research panel consisting of 65.000 Dutch members (reference date: April 2018), 
who participate in (market) research.(20) With filling in online questionnaires on the website 
www.stempunt.nu panel members earn credits which can be exchanged for gift cards. For 
this study Motivaction randomly invited members from their panel until 1096 panel 
members filled in the questionnaire: for their surveys Motivaction always use groups of 
approximately 1000 participants whereby they strive for a representative sample. The 
response rate for this survey was 36%. The panel members did not know the topics of the 
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survey beforehand.. The study was conducted in September 2017, shortly after the 
introduction of NIPT as a first-trimester prenatal screening test in the Netherlands.  
Design of the vignettes 
In a multidisciplinary team we designed two pairs of contrastive vignettes (appendix A). In 
the vignettes we introduced a third person, a fellow citizen in the person of Hanna, w ho is 
pregnant for the first time and has to decide whether or not to take part in NIPT, and, when 
an abnormality is detected, whether to continue or to terminate the pregnancy. We 
introduced a third person and not for example ‘your sister’ or ‘your friend’ in order to 
prevent the influence of relationships.   
The first pair of vignettes involved the decision to decline NIPT including varying funding 
conditions (i.e. the test is fully reimbursed contrasted with a test offered at a price of     
€175,-). In the second set of vignettes the decision to terminate the pregnancy was 
contrasted with the decision to continue, primarily in case of Down’s syndrome and 
subsequently in case of Edwards’ or Patau’s syndrome. The vignettes were pilot tested 
among acquaintances of the researchers and 23 students following a university minor 
programme in genetics, and were optimized after this pilot. 
Procedure 
Respondents first read a short introduction about NIPT and about Down’s, Edwards’ and 
Patau’s syndrome. Then every respondent received one vignette of the first pair about 
declining a reimbursed or non-reimbursed NIPT or of the second pair about termination or 
continuation of pregnancy. Respondents were randomly assigned to the vignettes. They 
were asked to indicate on a 7-point Likert scale to what extent they agree with Hanna’s 
decision (‘completely disagree’ = 1, ‘disagree’= 2, ‘disagree a little’ = 3, ‘do not disagree/do 
not agree’= 4, ‘agree a little’ = 5, ‘agree’= 6 and ‘completely agree’ = 7). Responden ts were 
asked to explain their answers in a follow-up free-response question. Subsequently, we 
investigated whether people’s attitudes changed when confronted with the contrastive 
condition, as an additional investigation of the effect of varying reimbursement or disorder-
severity conditions. In question 1c and 2c respondents were asked what their attitude would 
be when the situation was the opposite, thus declining a fully reimbursed NIPT instead of co -




payment, or vice versa. In question 3c and 4c respondents were asked what their attitude 
would be when it concerned a pregnancy affected with Edwards’ or Patau’s syndrome 
(appendix A). It should be noted that the answers on these follow-up questions might be 
influenced by the preceding questions. When respondents answered a question and clicked 
through, they could not go back to previous questions. The vignettes were part of a survey 
from Motivaction consisted of 20-23 questions about several other topics including cheese, 
internet domains and elevators. 
Statistical analysis 
Differences in demographic characteristics were tested between groups for each vignette 
pair: independent sample t-tests were used to test mean age differences and the Chi-square 
statistic was used to test differences with respect to the remaining variables. We tested for 
each vignette the possible impact of sex, education and income on mean agreement, with a 
one way ANOVA and correlation between age and agreement. To investigate differences in 
agreement between groups within each pair of vignettes, independent sample t-tests were 
conducted. Differences in agreement within groups, between questions a and c, were tested 
with paired sample t-tests. 
We were specifically interested in ‘disagreement’ with the choice presented in the vignette 
because when people disagree with each other, particularly when a majority holds a 
different attitude, this might affect the individual’s attitude, not because of a change in this 
person’s own values but because of the values of others.(15) To compare the group  who 
disagreed with those who did not agree or disagree and those who agreed, in a second step 
we transformed the 7-point Likert scale into three distinctive subcategories: “Disagree” (1-
3), “Do not disagree/do not agree” (4), and “Agree” (5-7), to see how many people agreed, 
did not disagree/did not agree and disagreed with the decisions. 
For comparing the between sample difference in proportions choosing the ‘Disagree’ 
subcategory we used the 2-sample z-test available in Epitools at 
http://epitools.ausvet.com.au. Data were analysed with IBM SPSS Statistics 25. The effect 
size for between and within groups mean differences, was expressed as Cohen's d for 
respectively independent and paired means(21) and interpreted according to Cohen’s 
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standard rules of thumb: 0.20 = "small", 0.50 "medium", 0.80 = "large". The level of 
significance was defined as p < 0.05.  
All free-response answers were exported from the data set. X and X coded the answers 
independently. Afterwards the codes and discrepancies were discussed until consensus was 
reach. Then the dataset was recoded which result in a list of 14 different explanations of 
participants concerning their attitudes towards NIPT or termination of pregnancy. The codes 
and therewith the different explanations were quantified in order to obtain numbers and 




In total 1096 panel members participated in the study. The mean age of this group was 50.6 
years, 49.4% was man and 50.6% woman (Table 1). This is representative for the Dutch 
population. No significant differences were found in demographic variables between the two 
groups of each pair of vignettes. Some demographic variables were significantly related to 
attitudes: in vignette 1 and 2 significantly more women agreed with the decision to decline 
NIPT than men. And in the vignettes 1c, 2a and 2c in the northern and eastern regions of the 
Netherlands respondents agreed significantly more with the decision to decline NIPT than in 
the western and southern regions. In vignette 3c people from the south agreed significantly 
more with termination for Edwards’ or Patau’s syndrome than people in the north.  
 
The results provide insight firstly in differences in participants’ attitudes towards declining a 
reimbursed or a non-reimbursed test and towards the decision to continue or terminate a 
pregnancy of a child with Down’s syndrome. They furthermore reveal that respondents 
frequently mentioned four important explanations for their stated attitudes including 
freedom of choice, necessity of testing, valuing life, and quality of life. 
Attitudes towards declining NIPT and the impact of reimbursement 
Respondents’ attitudes in vignette 1 and 2 revealed that the mean agreement with Hanna’s 
choice to decline NIPT in vignette 1, in which NIPT was fully reimbursed, was significantly 




lower than in vignette 2, where NIPT required an out of pocket co-payment of €175,- (p = 
.006, Table 2). In line with this finding, the subgroup percentages showed that significantly 
more people disagreed with declining a reimbursed NIPT (p = .002, Table 2). The first of the 
four most indicated explanations in the total sample for agreeing or being neutral (not 
agreeing and not disagreeing) was that this decision to decline is someone’s personal choice 
(Appendix B, Table B1): 
 “It is her decision, I should not have an opinion about that.” 
Furthermore, most of the respondents who disagreed with the decision to decline a fully 
reimbursed as well as a non-reimbursed NIPT did so because they thought that availability of 
a test offers courses of action, creates a responsibility to test, or costs society too much 
money (Appendix B, Table B1): 
 “It is not necessary anymore to bring a handicapped child into the world. Firstly from  
  a moral point of view, secondly because of the costs (healthcare is already  
  unaffordable).” 
The second of four most offered explanations for agreeing or being neutral was a perceived 
lack of necessity. Some respondents expected a low chance of having a disabled child or a 
low risk because of the younger age of Hanna – Hanna’s age was not mentioned in the 
vignette, but people thought that she was young, because she was pregnant for the first 
time. They therefore thought that it was not necessary to test and consequently agreed with 
declining NIPT.  
When both groups of respondents were confronted with the contrastive condition in 
question 1c and 2c no significant changes occurred within vignette 1, in which then NIPT cost 
€175,-. But within vignette 2, in which then the NIPT was fully reimbursed the mean of the 
Likert-scale answer in 2c was significantly lower than in 2a (t(265) = 4.74, p < .001, d  = 0.22). 
As a result, the difference between vignette 1 and 2 was not significant (p = .791, Table 2). 
Apparently, when respondents first read about a NIPT costing €175,- and then about a 
reimbursed NIPT, they tended to agree less with declining a reimbursed test. A X2 test 
showed that there were no significant differences between vignette groups with respect to  
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different income groups (X2(9) = 2.98, p = .965) Most of those respondents indicated that 
availability creates a certain responsibility (Appendix B2, Table B1):  
“Then [when NIPT is reimbursed] it belongs to standard prenatal screening and there  
  will be good reasons to offer it to every pregnant woman. A waste of opportunity to  
  reject it.”  
Besides, fewer respondents agreed with declining a reimbursed NIPT than with declining a 
non-reimbursed NIPT because of a perceived lack of necessity of the test (2c: 12.8 % resp. 
2a: 22.7%, Appendix B, table B1). This suggests that perception of necessity is influenced by 
reimbursement policy. It is noteworthy that fewer respondents disagreed with declining 
NIPT because ‘testing provides courses of action’ in 1c compared to 1a (10.4% resp. 31.3%, 
Appendix B, table B1) which also suggests that reimbursement policy affects respondents’ 
attitudes:  
“When it costs money, I understand it better. Maybe Hanna cannot pay €175, -. That   
            is a lot of money.” 
Exploratory additional analysis showed that the difference between “state-funding vs. non-
reimbursement” was not significantly associated with income. 
In sum, the most important explanation respondents gave for agreeing with or being neutral 
about declining NIPT is that it is someone’s personal decision. Secondly, the perceived lack of 
necessity of testing was a frequently indicated reason to agree with declining NIPT. But 
reimbursement affected respondents’ attitudes: when NIPT was fully reimbursed 
respondents were less likely to agree with declining NIPT.  
 
Attitudes towards termination or continuation of pregnancy and the impact of severity  
Respondents’ agreement with the decision to terminate a pregnancy in case of Down’s 
syndrome (vignette 3a) did not differ significantly from agreement with the decision to 
continue a pregnancy in case of Down’s syndrome (vignette 4a), p = .080 (Table 3). Neither 
did the subgroup percentages show any difference in agreement. This suggests that the 
public does not prefer one course of action above the other: the decision to terminate or 
continue a pregnancy after a prenatal diagnosis of Down’s syndrome would meet the sa me 




public attitude. As with the previous pair of vignettes, respondents indicated that the 
decision to terminate or continue an affected pregnancy is someone’s own choice to make. 
The most frequently indicated reason to disagree with termination was that someone has to 
accept life as it comes and should accept every child (Appendix B, Table B2). This was also 
the third of the top four explanations in general. Within this group most respondents 
thought that every child should be accepted because they were against abortion. 
In the group that agreed with termination of the pregnancy or disagreed with continuation 
the most frequently indicated reason was that it is in the child’s or parents’ best interest to 
end the pregnancy, respectively 33.3% and 37.2%, which is the fourth most frequently 
indicated explanation in the total sample. Respondents thought that it takes too much from 
parents to raise a disabled child or that the child is awaiting a low quality of life, being always 
dependent on the parents and the community. 
We further wanted to know in question 3c and 4c whether respondents’ attitudes would 
change when the decision to terminate or continue concerns more severe disorders, i.e. 
Edwards’ or Patau’s syndrome. Most children with these aneuploidies are no t viable. The 
severity of a disorder affected respondents’ attitude: respondents were more likely to 
disagree with continuation of a pregnancy in case of trisomy 13 or 18, or agree more with 
termination of a pregnancy in case of such severe chromosomal aberrations (p < .001, Table 
3).   
The mean attitudes towards the decision to terminate or continue the pregnancy also 
changed significantly within both groups: respondents changed their mind in case of more 
severe disorders. Respondents in vignette 3 agreed more with termination of pregnancy in 
case of trisomy 13 or 18 compared to trisomy 21 (t(303) = -5.04, p < .001, d = .15). Likewise, 
in vignette 4, more people disagreed with continuation of pregnancy in case of trisomy 13 or 
18 compared to trisomy 21 (t(257) = 9.45, p < .001, d =.47). Most respondents stated that a 
reason for them to agree with termination or disagree with continuation of pregnancy in 
case of trisomy 13 or 18 was that termination is in the best interest of the child, sometimes 
indicating that Edwards’ or Patau’s syndrome is more severe: 
 “A child with Down’s syndrome can still be happy but with this handicap you cannot.  
  There is no life expectancy [for children with Edwards' or Patau’s syndrome].” 
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In sum, the detected attitudes towards the decision to decline NIPT and the decision to 
terminate or continue an affected pregnancy revealed not one but at least four major 
societal attitudes towards NIPT: “It is someone’s own choice”, “It is not necessary to test”, 
“One must accept every child” and “Testing is in the best interest of parents and child”. 
Besides, 13.1% gave no explanation and 13.8% gave somewhat generic or just personal 
explanations, like ‘I would make the same decision’, ‘I would never have a handicapped 
child’, and ‘I do not have enough information about Hanna’s personal situation’, which were 
classified as ‘other’.  
 
Discussion 
This contrastive vignettes study provided valuable insights into public attitudes in the 
Netherlands towards the decision of a pregnant fellow citizen to decline NIPT and towards 
termination or continuation of pregnancy. Also, it sheds light on the impact of 
reimbursement policies and of the severity of disorders included in NIPT on these attitudes. 
The most remarkable finding was that a majority of the respondents either agreed with or 
did not have an outspoken opinion about the decision of a pregnant woma n to decline 
either a fully state-funded NIPT or a NIPT requiring a co-payment of €175,- because these 
decisions are considered to be personal in nature. This suggests that Dutch citizens 
acknowledge the importance of free choice, and that society leaves room for personal 
decision-making concerning prenatal screening, which is a prerequisite for autonomous 
reproductive choices. The results of this study may help to rebut the ethical concern that 
NIPT leads women to be pressured into accepting the prenatal screening offer. Furthermore 
many respondents did not have a dominant preference for either termination or 
continuation of pregnancy in case of a diagnosis of Down’s syndrome – which also supports 
this. Moreover, respondents’ explanations revealed some degree of diversity in public 
attitudes towards NIPT and termination of pregnancy. The existence of a range of public 
attitudes – we have identified four major attitudes and many (minor) others – regarding 
NIPT theoretically provides pregnant women and couples with room to conceive personal 
attitudes.  
This study also showed that funding policies affect public attitudes towards NIPT. 
Respondents agreed less with declining a fully funded NIPT and agreed more with declining a 




NIPT for which a co-payment was required. This suggests that state funding of NIPT might 
influence public attitudes towards declining prenatal screening. Offering a fully reimbursed 
test seemed to provoke amongst a small group the idea that NIPT becomes an offer one 
cannot refuse, suggesting a legitimizing effect for accepting prenatal testing. This finding 
might fuel the fear which was previously indicated in the literature by pregnant wome n and 
parents of children with Down’s syndrome namely for self-evident acceptance of NIPT 
among pregnant women, and societal moral judgements on those who decline screening.(5, 
6, 10) But whether pregnant women will be influenced by a funding policy and th e possible 
related public attitudes should be asked to women themselves. In one interview study 
women suggested that state-funding might carry the message that prenatal screening is 
standard practice but this is still hypothetical, further study of women’s  personal decision-
making is necessary.(18) On the other hand, requiring a co-payment might contribute to the 
misunderstanding that reimbursed tests are important and non-reimbursed tests are 
unnecessary or not applicable to certain (younger) women. Further research should address 
the influence of funding policies on public attitudes and societal pressure to  test.  
Attitudes towards termination or continuation of a pregnancy in case of Down’s syndrome 
or Edwards’ or Patau’s syndrome seemed to be shaped in first instance by attitudes towards 
abortion. Secondly, they were shaped by how respondents perceived living with these 
syndromes. This study’s findings about the impact of the severity of the disorder and its 
expected burden for children and their parents are relevant in light of recent discussions on 
the technical possibilities for expanding the scope of NIPT, allowing for the assessment of 
many more genetic disorders. Societal support for inclusion of more disorders in a prenatal 
screening program will vary with the severity of the disorders. This might be relevant when 
thinking about the possible expansion of the scope of prenatal screening. 
Furthermore, the current study showed that a small subgroup within the Dutch population 
has a negative attitude towards declining NIPT or giving birth to a disabled child, pointing at 
parental responsibility or social costs. The finding that this is a small group might fend off 
existing fears of future societal pressure as expressed by pregnant women, professionals and  
parents of children with trisomy 21, 13 or 18.(5, 10, 22, 23) Nevertheless, since these 
attitudes exist, during counselling, professionals could investigate whether women 
experience pressure from societal attitudes and pay extra attention to women’s free and 
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personal decision-making. The current study does not provide insight in the extent to which 
women recognize or feel influenced by these kinds of expressed attitudes. Whether these 
experiences are present amongst women should be asked to women themselves as already 
done in previous studies: In these studies women reported that they felt free to decide 
about prenatal screening independently.(8, 17, 24). But the question is whether women will 
always be aware of societal pressure if it exists. Therefore, the interaction between women’s 
and public attitudes merits further scrutiny to understand the effects of societal pressure 
and ways to counter it. 
The strengths of this study are the large representative sample population, the 
heterogeneity within groups and comparability between groups. However, demographic 
information on respondents' views on life or religious convictions was not asked. Religious 
convictions are known to influence attitudes towards prenatal screening and termination of 
pregnancy.(25) This might explain that in the current study, respondents from the eastern 
region agreed significantly more with the decision to decline NIPT, as the population in the 
eastern region of the Netherlands is more conservatively religious than in the western 
region. Previous research found a low uptake of the first-trimester combined test in this 
region.(25) Furthermore, we found that termination and continuation met the same public 
attitudes, but the distribution of those who agreed with termination actually differed 
between the vignettes: in vignette 3 more people were pro termination and in vignette 4 
more people were pro continuation. In vignette 4a we used the phrase ‘continuing the 
pregnancy and keeping the baby’. Possibly the word ‘baby’ made the vignette feel  more 
personal to respondents and elicited moral intuitions about the life of the future child. Fo r 
the formulation of the vignettes we had to deal with on the one hand the comparability of 
the vignettes and on the other hand natural language. Although ‘continuation’ and 
‘termination’ are more neutral opposite terms, the phrase ‘to continue the pregnancy’ is not 
often used in Dutch natural language to describe a decision to ‘keep the baby’. This dilemma 
shows that terminology in vignettes may be value-laden and steering. It is outside the scope 
of this paper, but it would be interesting to study if and how framing and terminology used 
by counsellors influence pregnant women’s decision-making. 
To conclude, this study showed that within a representative sample of Dutch citizens, 
personal choice is broadly acknowledged. Also, Dutch society appears to allow for a wide 




range of attitudes regarding NIPT, which could help to nuance the concern that in the 
Netherlands, one moral attitude may become predominant and lead to societal pressure to 
take part in screening and to terminate pregnancies affected by chromosomal abnormalities. 
However, opinions are partly influenced by the funding policy and by the severity of the 
disorder. Thus, continued focus on personal decision-making in pre-test counselling and 
responsible screening-policy decisions will be required to serve reproductive autonomy. 
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Appendix A: Vignettes  
Vignettes as presented to the respondents, including the introduction about non-invasive 
prenatal testing (NIPT) and Down’s syndrome, Edwards’ syndrome and Patau’s syndrome.  
Introduction 
What is NIPT? 
The non-invasive prenatal test (NIPT) is a screening test in the pregnancy. Since April 1st, 
2017 NIPT is offered to all pregnant women within a study. Every pregnant woman has the 
choice to opt for this test. To conduct NIPT a blood sample is taken from the pregnant 
woman which is used to find out whether the unborn child has Down’s syndrome (trisomy 
21), Edwards’ syndrome (trisomy 18) or Patau’s syndrome (trisomy 13). In case of an 
abnormal test result there are strong indicators that the unborn child has Down’s  syndrome, 
Edwards’ syndrome or Patau’s syndrome. However, the test does not provide a 100% 
reliable test result. Therefore in case of an abnormal test result a chorionic villus sampling or 
an amniotic fluid test is necessary, to confirm the test result. Reference: 
www.meerovernipt.nl 
What are Down’s syndrome, Edwards’ syndrome and Patau’s syndrome? 
Down’s syndrome is a congenital anomaly. People with Down’s syndrome have learning 
disabilities. Therefore a child with Down’s syndrome may learn skills more slowly than their 
peers. These children often also have physical handicaps and health problems. The severity 
of these problems varies from one child to another. Also Edwards’ syndrome and Patau’s 
syndrome are congenital anomalies. Children with Edwards’ syndrome and Patau’s 
syndrome have a very fragile health and severe intellectual disability. Most children also will 
have a serious congenital heart defect. Besides, in many cases, other organs are also 
affected such as the kidneys (in case of Edwards’ syndrome) and the brain (in case of Patau’s 
syndrome). Most children with Edwards’ or Patau’s’ syndrome die during the pregnancy or 
shortly after birth or in the first year. Reference: www.rivm.nl 
What we would ask you 
You are going to read a short story. After this story three questions will be asked. We would  
want to ask you to answer each question. When you have answered a question and go to 
the next question, you cannot go back to the previous question. 




Vignette 1 Vignette 2 
Hanna is expecting a baby for the first time and 
is 11 weeks pregnant. The midwife has told her 
that she can opt for NIPT, to find out whether 
her child has Down’s syndrome, Edwards’ 
syndrome or Patau’s syndrome, and that this 
test is reimbursed. Hanna chooses to not have a 
NIPT. 
 
Hanna is expecting a baby for the first time and 
is 11 weeks pregnant. The midwife has told her 
that she can opt for NIPT, to find out whether 
her child has Down’s  syndrome, Edwards’ 
syndrome or Patau’s syndrome, and that this 
test costs €175,-. Hanna chooses to not have a 
NIPT. 
 
a. What is your opinion about Hanna’s 
choice? 
I… really disagree – disagree - disagree 
a little – do not disagree/do not agree - 
agree a little – agree - really agree.  
b. Explain your answer. 
 
a. What is your opinion about Hanna’s 
choice? 
I… really disagree – disagree - disagree 
a little – do not disagree/do not agree - 
agree a little – agree - really agree.  
b. Explain your answer. 
 
c. What would you think about Hanna’s 
choice when she had to pay €175,- for 
the test? 
I… really disagree – disagree - disagree 
a little – do not disagree/do not agree - 
agree a little – agree - really agree. 
d. Explain your answer. 
 
c. What would you think about Hanna’s 
choice when she had to pay nothing for 
the test? 
I… really disagree – disagree - disagree 
a little – do not disagree/do not agree - 
agree a little – agree - really agree. 
d. Explain your answer. 
  
Vignette 3 Vignette 4 
Hanna is expecting a baby for the first time and 
is 11 weeks pregnant. She had a NIPT to find out 
whether her child has Down’s syndrome, 
Edwards’ syndrome or Patau’s syndrome. From 
the test result it turns out that her child possibly 
has Down’s syndrome. This result is confirmed 
with a chorionic villus sampling. Hanna and her 
partner choose to terminate the pregnancy. 
 
Hanna is expecting a baby for the first time and 
is 11 weeks pregnant. She had a NIPT to find out 
whether her child has Down’s syndrome, 
Edwards’ syndrome or Patau’s syndrome. From 
the test result it turns out that her child possibly 
has Down’s syndrome. This result is confirmed 
with a chorionic villus sampling. Hanna and her 
partner choose to continue the pregnancy. 
 
a. What is your opinion about Hanna’s 
choice? 
I… really disagree – disagree - disagree 
a little – do not disagree/do not agree - 
agree a little – agree - really agree.  
b. Explain your answer. 
 
 
a. What is your opinion about Hanna’s 
choice? 
I… really disagree – disagree - disagree 
a little – do not disagree/do not agree - 
agree a little – agree - really agree.  
b. Explain your answer. 
 
c. What would you think about Hanna’s 
choice when it concerns Edwards’ or 
Patau’s syndrome? 
I… really disagree – disagree - disagree 
a little – do not disagree/do not agree - 
agree a little – agree - really agree. 
d. Explain your answer. 
c. What would you think about Hanna’s 
choice when it concerns Edwards’ or 
Patau’s syndrome? 
I… really disagree – disagree - disagree 
a little – do not disagree/do not agree - 
agree a little – agree - really agree. 
d. Explain your answer. 
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Abstract  
The introduction of non-invasive prenatal testing (NIPT) in health care systems around the 
world offers an opportunity to reconsider funding policies for prenatal screening. In some 
countries with universal access health care systems, pregnant women and their partners are 
asked to (co-)pay for NIPT. In this paper, we discuss two important rationales for charging 
women for NIPT: 1) to prevent increased uptake of NIPT, and 2) to promote informed choice. 
Firstly, given the aim of prenatal screening (reproductive autonomy), high or low uptake 
rates are not intrinsically desirable or undesirable. Using funding policies to negatively affect 
uptake, however, is at odds with the aim of screening. Furthermore, co-payment 
disproportionally affects those of lower socio-economic status, which conflicts with justice 
requirements and impedes equal access to prenatal screening. Secondly, we argue that 
although payment models may influence pregnant women’s choice behaviours and 
perceptions of the relevance of NIPT, the co-payment requirement does not necessarily lead 
to better-informed choices. On the contrary, external (i.e. financial) influences on women’s 
personal choices for or against prenatal screening should ideally be avoided. To improve 
informed decision-making, health care systems should instead invest in adequate non-
directive, value-focused pre-test counselling. This paper concludes that requiring 
(substantial) co-payments for NIPT in universal access health care systems fails to promote 
reproductive autonomy and is unfair. 





A new first-trimester prenatal screening test commonly referred to as non-invasive prenatal 
testing (NIPT) is in the process of being implemented in countries around the world. With 
NIPT, chromosomal abnormalities can be detected in cell-free DNA circulating in maternal 
blood, giving pregnant women the opportunity to consider reproductive options – either 
prepare for the birth of a child with a disability or terminate the pregnancy. In some 
countries, including the United Kingdom, France, Canada and the Netherlands, NIPT is 
available in implementation research settings.(1, 2) In the United States of America, Israel 
and Australia, NIPT is available primarily through commercial providers.(3) In other 
countries, such as Belgium, Denmark and Singapore, it is either already part of routine 
antenatal care (4) or offered through publicly funded screening programs.(5) NIPT is 
procedurally safe and simple, and its test performance for trisomy 21 (Down syndrome), 18 
(Edwards syndrome) and 13 (Patau syndrome) is better than that of the conventional 
combined test based on nuchal translucency ultrasound, blood tests and maternal age. Even 
in low-risk pregnancies, NIPT is characterized by high sensitivity and specificity.(6) It requires 
only a blood draw from the pregnant woman at 9-11 weeks of gestation. NIPT is not a 
diagnostic test; as cell-free DNA is derived not from the foetus but from the placenta, an 
abnormal NIPT result requires confirmation through invasive follow-up diagnostic testing 
(i.e. chorionic villus sampling or amniocentesis). Because of its better test performance for 
trisomies 21, 18 and 13, however, NIPT requires fewer invasive follow-up tests than does the 
combined test, and thus leads to fewer iatrogenic miscarriages.  
First-trimester prenatal screening has traditionally been offered free of charge in many 
countries. A survey conducted in 2015 across 28 countries around the world shows that 
conventional first-trimester screening was generally covered in full or in part by public health 
programs, with the exception of Argentina, Ireland, India, the Netherlands, Mexico, Qatar 
and the United States.(4) Funding policies for screening are likely to affect its uptake; in 
countries where first-trimester prenatal screening is fully publicly funded, the uptake is 
usually high, such as in Denmark (90%) and Belgium (80%) (7), whereas in countries like the 
Netherlands, where women paid out of pocket for the combined test, the uptake has 
traditionally been lower, at around 30%.(8) NIPT costs approximately 400 US dollars (9) and 
insurance coverage for NIPT is variable.(3) In a recent study, US obstetricians indicated tha t 
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the cost of NIPT is currently hampering its utilization.(10) Health care professionals in 
Canada, too, observe that financial cost is “an important barrier” to accessing NIPT. (11) 
The introduction of NIPT raises ethical quandaries. Notably, there are discussions with 
regard to the appropriate scope of NIPT.(12-14) Dutch laboratories are licensed to screen for 
trisomies 13, 18 and 21 only, although pregnant women can choose to have incidental 
findings reported as well. These findings pertain mostly to other chromosomal 
abnormalities, which may be rarer, but can be equally or more severe, and of sufficiently 
understood clinical significance. In some countries, the scope of NIPT has expanded to 
include sex-chromosomal abnormalities and microdeletion syndromes. In this paper, when 
we write about NIPT, we consider the use of NIPT primarily as a first-tier (‘universal’) or 
second-tier (‘contingent’) screening test for trisomies 13, 18 and 21. The argument may be 
extended to other chromosomal abnormalities that are “markedly severe”(15), or “serious 
congenital conditions and childhood disorders”.(13) We do not consider the use of NIPT for 
the detection of other medical or non-medical conditions (including sex determination), for 
which there has thus far been less public support.(16) Also, we proceed from the notion that 
prenatal screening programs are acceptable, and that allowing women to terminate a 
pregnancy in case of a serious foetal health condition, is acceptable.  
The ongoing introduction of NIPT around the world requires a reconsideration of funding 
policies for first-trimester prenatal screening. Should pregnant women and their partners be 
charged for NIPT, and on what grounds? There are practical as well as principled reasons to 
charge women for NIPT. In resource-constrained settings, societies may not have sufficient 
funds to offer NIPT free of charge. Universal NIPT is both more effective than the first-
trimester combined test in detecting trisomies and more costly.(17) In most ‘cost-
effectiveness’ studies, however, the costs of the care and support required for children with 
chromosomal abnormalities are not taken into account. Furthermore, although the costs of 
NIPT may currently be among the main reasons for states to charge women, these costs will 
likely decrease in the future as the technology develops. 
This paper, therefore, focuses on principled reasons for charging – assuming that the 
practical reasons for doing so (i.e. lack of resources, organizational challenges) need not be 
decisive. We critically discuss two principled rationales for asking pregnant women and their 
partners to (co-)pay for NIPT: to prevent increased uptake of screening and to improve 




informed decision-making. First, a financial contribution can function as a hurdle, making 
prenatal screening more difficult to obtain, and discouraging women from taking part. Some 
of those who oppose widespread uptake of prenatal screening and/or abortion may not only 
wish to refrain from screening themselves, but may also prefer others to forego screening. 
Asking a significant sum may help in maintaining or decreasing the number of w omen who 
participate in screening. A second moral justification for charging women is to promote 
informed and well-considered choices for or against the prenatal screening offer. Charging is 
believed to help women understand that first-trimester screening is not part of routine 
antenatal care, but something different. Co-payment is believed to help create ‘choice 
awareness’ and to ensure well-considered participation in screening. Both rationales merit 
further scrutiny, as it is not self-evident that charging for NIPT is justifiable from a justice 
perspective or contributes to well-considered choices.  
 
Rationale 1: Charging women to prevent increased uptake of screening   
One reason for charging pregnant women for NIPT is to prevent an increase in uptake of  
prenatal screening, and thus to prevent an increase in the number of abortions. Although 
commentators do not usually explicitly mention this rationale, it follows from the reverse 
concern that public funding of NIPT may encourage women to take part in prenatal 
screening. If the state offers prenatal screening free of charge, it gives the impression that it 
condones screening as a form of routine care among other antenatal care services. An offer 
of NIPT would lead to a higher uptake of screening, and – following this rationale – a higher 
uptake is perceived to be problematic.  
With the start of the NIPT implementation study in April 2017, for instance, it was feared 
that pregnant women would ‘rush’ to Dutch academic medical centres to obtain NIPT. (18) 
The notion that all Dutch women would engage in screening was seen as intrinsically 
undesirable. Pregnant women and mothers of children with Down syndrome were 
concerned that abortion rates would rise, and that Down syndrome might disappear from 
society.(19-21)  
This is not likely. In the Netherlands, the majority of women decline first-trimester screening 
altogether, even today, now NIPT is widely available. Moreover, not all prenatal screening 
results in abortion. In the period 2000-2013, around 85% of pregnancies with a confirmed 
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diagnosis of Down syndrome resulted in termination, (22) which means that a substantial 
minority chose to continue the pregnancy. Certain groups in Dutch society hold a relatively 
high acceptance and positive image of Down syndrome; some Dutch women do not consider 
Down syndrome ‘severe enough to justify termination of pregnancy’.(23) The number is 
consistent with termination rates found in other countries, such as the US (24), the UK (25), 
and other European countries (26), but lower than the rates reported elsewhere, such as 
93% in Australia (27) and 98% in Denmark.(28) Overall, the prevalence of Down syndrome 
has been relatively stable around the world since the early 1990s.(29) This is not likely to 
change with the introduction of NIPT, as in countries like the UK and the Netherlands, some 
women continue to opt for first-trimester prenatal screening ‘for information only’  (1), and 
refrain from abortion. A recent review of studies from the US, Asia and Europe suggested 
that termination rates following the introduction of NIPT were unchanged or even 
decreased.(30) 
Even if Down syndrome would disappear from society, this may be considered a loss in 
terms of social diversity, but it may not be a soluble problem or a moral wrong as long as 
terminations resulted from pregnant women’s autonomous decisions. A related – and 
possibly valid – concern is that if fewer children are born with Down syndrome, the 
acceptation of persons with Down syndrome and the quality of their medical care and 
support might decrease(20, 21) and discrimination and stigmatization of affected persons 
and families might increase. Pregnant women and their partners may indeed feel less free to 
carry an affected pregnancy to term if good-quality medical care and support were not 
available for disabled children. Reproductive autonomy, the stated aim of first-trimester 
prenatal screening (12), presupposes that disabled children receive the support they need. 
Therefore, the existence of “decent, fair, inclusive and supportive policies with regard to the 
abilities and conditions of all people”(15) is a precondition for a responsible prenatal 
screening program. 
Charging money can be thought of as a political compromise to those who oppose 
widespread use of prenatal screening and/or abortion and believe that first -trimester 
screening may (need to) be available to women who actively and purposively request it, but 
should not be too readily available. (Co-)payment thus serves as a barrier to access, aimed at 
discouraging women from taking part. However, this is not consistent with the aim of 




prenatal screening. Women should not be withheld from screening, just as  those who 
oppose screening should not be put under pressure to take part. In Dutch counselling 
practices, women are presented with an ‘information offer’ about screening first, which they 
are free to refuse, to safeguard their ‘right not to know’. Also, the ethical requirement of 
non-directiveness in counselling is meant to safeguard the voluntariness of participation. 
Such measures should be in place in screening programs around the world to avoid any 
pressure on women to participate in screening just because it is ‘the norm’.(31)  
In countries where screening and/or abortion are morally controversial, so it is argued, it is 
not obvious that society should bear the costs.(32) Other health care priorities may be more 
important than sustaining screening programs aimed at promoting reproductive “liberty and 
autonomy”.(15) In response, we would like to stress that prenatal screening does not aim at 
promoting unrestricted reproductive liberty and autonomy, but at offering information 
about severe health conditions in the foetus that could be a reason for pregnant women to 
consider terminating the pregnancy, so as to prevent the birth of an affected child. Children 
born with trisomy 13 or 18 are severely ill, and most children die before birth or within days, 
weeks or months after birth. There is less consensus on Down syndrome as a justified reason 
to terminate an affected pregnancy; some children born with trisomy 21 may lead relatively 
contented lives, while others develop severe cognitive delays and somatic conditions. A life 
with Down syndrome, “even if it does not involve major medical problems, is fraught with 
intellectual disabilities and (…) it is, in most cases, a life that is shorter than other human 
lives.”(33) Some prospective parents may wish to prevent this in their families. Empirically, 
there is broad societal support for public funding of NIPT for trisomies. A Canadian study 
found that the majority of women (66,9%) thought that all pregnant women should have 
access to NIPT free of charge.(11) Also women in Australia (93% of respondents) have been 
found to support public funding of NIPT.(34) 
Finally, by putting up a barrier that is higher for less affluent women than for more affluent 
women, the (co-)payment requirement raises intractable justice concerns and hinders equity 
of access to first-trimester prenatal screening. Charging for NIPT affects disproportionally 
those who are least well off financially, which challenges the principle of equal access to 
first-trimester prenatal screening. The (co-)payment requirement may in part explain the 
especially low uptake among groups of lower socio-economic status and minority ethnic 
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groups vis-à-vis groups of higher socio-economic status, which have been found to be 
unrelated to attitudes towards screening.(35) Rather, socio-economically disadvantaged 
women are less likely to act upon their (positive) attitudes towards screening than socio-
economically advantaged women when confronted with financial and physical barriers, such 
as requiring extra visits to the midwifery clinic. Women from minority ethnic groups may 
also be less aware of Down syndrome (36), and other chromosomal abnormalities. Putting 
up a financial barrier may exacerbate these differences in uptake (37), and therewith, it may 
exacerbate choice disparities among groups of higher and lower socio-economic status. 
Offering NIPT free of charge is likely to reduce these disparities. Alternatively, differenti ated 
funding policies could be considered, in which women who can afford (co-)paying for NIPT 
would be asked to do so, while those who cannot would be offered NIPT free of cha rge, or 
would be partly reimbursed afterwards. Although other ways to promote equal access to 
prenatal screening can thus be imagined, practical and logistical issues are likely to limit the 
feasibility of, for instance, differentiated pricing schemes.  
Finally, in countries such as the Netherlands, where all pregnant women are offered a free 
ultrasound scan for structural anomalies at 20 weeks of gestation, charging for NIPT seems 
strikingly inconsistent. Despite morally relevant differences between the two screening tests 
(notably, although the 20-week ultrasound is aimed primarily at reproductive autonomy, it 
also aims to improve maternal health and pregnancy outcomes), we find it remarkable  that 
NIPT tends to elicit ethical discussions, whereas the 20-week ultrasound does not.  
In sum, funding policies should support prenatal screening programmes in achieving their 
aim of promoting reproductive autonomy. They should not be used to negatively affect 
uptake rates. 
 
Rationale 2: Charging women to improve informed decision-making  
A second argument brought forward in public discussions for charging money for NIPT is that 
it will improve decision-making.(38) A financial contribution to NIPT is thought to have the 
benefit of signalling to pregnant women and their partners that screening is optional: 
screening is an offer that may have far-reaching implications that should be considered 
beforehand.(39) Because NIPT requires only a simple blood draw, just like other routine 
screening tests offered during the pregnancy, such tests for HIV, hepatitis B, syphilis, blood 




type, Rhesus factor or antibodies, observers are concerned that women will thoughtlessly 
accept NIPT.(12) Also, they may feel less justified in forsaking screening, as NIPT “removes 
the risk to pregnancy as a reason for declining testing” (40), and may experience societal 
pressure to take part in screening. Meeting the aim of reproductive autonomy is generally 
considered to require ‘informed choice’ for or against a screening offer. Participation in 
screening should be the result of such adequately informed, voluntary and value-consistent 
decisions (41), not of passive acceptance or acquiescence to societal pressure.  
It is feared that because of the non-invasive character of NIPT, health professionals may 
treat the informed choice process differently – less stringently – than they would in the 
context of invasive testing, requiring less time to consider, or not asking for written informed 
consent.(42) NIPT would be presented by counsellors as a routine procedure and would 
consequently be perceived as such by pregnant women and their partners; a concern 
referred to as ‘routinisation’.(43) If women may not appreciate the significance of the test, it 
would “become more difficult to achieve the aim of enabling autonomous reproductive 
choices.”(12) In sum, in the absence of accepted reasons not to take part in first-trimester 
prenatal screening, such as safety or financial considerations, pregnant women may consider 
less thoroughly whether or not to take part. Also, state funding is believed to send a 
‘legitimizing’ message about the importance of NIPT, implying that the government 
encourages screening (38), making pregnant women more likely to participate without 
deliberation. 
Putting up a (small) barrier by charging women, on the other hand, so it is argued, may help 
reinstall well-considered decision-making.(39) If women must pay 175 euro, the fee required 
in the Netherlands, or the small sum of 8,68 euro, the fee required in Belgium, for NIPT, they 
will deliberate the benefits, risks and implications of screening. Especially in countries like 
the Netherlands, where all ‘medically necessary’ health care services are offered free of 
charge, including the 20-week ultrasound scan, the co-payment requirement may signal to 
women that NIPT is a different test, and help them understand that NIPT “is an offer that can 
be declined.”(44) At the same time, however, it may signal that first-trimester screening is 
less relevant and lead women to (mistakenly) believe that screening is “not necessary”(23) 
because of an assumed low risk of foetal abnormalities.  
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Thus, reimbursement policies are not neutral and may influence women’s choice behaviours. 
But is charging a substantial or a ‘symbolic’ sum an effective way to promote informed 
choices? Does it not have adverse moral implications? Are there no subsidiary and better 
ways to prompt women to make informed choices? 
Although many women are willing to co-pay for NIPT (45), for some women, the costs of 
first-trimester screening withhold them from taking part.(23, 46) Personally incurred costs 
significantly influence pregnant women’s choices whether or not to undergo screening. (47, 
48) For a majority of Canadian women (66.4%), costs have ‘a lot of impact’ (5 on the 1-5 
scale) on their decision use screening.(11)When a prenatal screening offer is declined on the 
basis of financial constraints, in fact quite the opposite from the ideal of informed choice is 
being realized: women are not choosing for or against NIPT based on their values, but 
because of financial constraints.  
To illustrate the caveat, imagine that an opposite policy would be proposed: women who do 
not take part in prenatal screening are asked to pay a fee of 175 euro. Policy makers would 
claim that this fee was introduced to prompt women to more thoroughly consider their 
decision. The fee, however, will likely be perceived by pregnant women as a discouragement 
or a punishment for the decision not to take part. This policy would signal that participation 
in screening is the preferred option and may limit women’s freedom to decline screening, 
thus failing to promote informed choice. Strictly speaking, if a fee is considered instrumental 
in promoting informed choice, it should apply to both options (screening and not screening). 
For if reproductive autonomy is the justified aim of prenatal screening programs, both 
options should be considered equally valuable and equally acceptable. A fee should be asked 
for both options or none.   
In sum, it is unclear how funding policies best serve reproductive autonomy. We have seen 
that there is no reason to assume that either a financial barrier or a fully reimbursed test will 
promote informed choice. To help women make choices regarding screening that are well -
informed, voluntary and consistent with their values, other solutions must be sought. 
To make informed choices, women need time to become informed about screenin g, to talk 
to health care professionals and others, to imagine futures with children with disabilities, 
and to deliberate their options. Repeat discussions with health care professionals, over time, 
may be preferable to “only one point of contact.”(3) Another requirement may be good 




information about the implications of screening, offered individually and/or collectively, and 
through multiple modalities, including written information material and audio -visual 
material, and – if requested – balanced narratives from parents of children with disabilities 
to illustrate the range of experiences of living with and caring for children with 
disabilities.(49) Further, women may need to be assisted in explicating their values and in 
making decisions in accordance with these values. In the Netherlands, obstetricians and 
midwives are specifically trained to focus on deliberation in pre-test counselling. Counsellors 
are expected to conduct 30-minute dedicated face-to-face discussions with pregnant women 
to facilitate informed choice for or against the NIPT offer.(50)  
To help increase choice awareness regarding first-trimester prenatal screening, pre-test 
counselling may therefore need to focus on conveying key information about the aim and 
utility of prenatal screening, and foremost on the question whether women and their 
partners wish to start on the trajectory of reproductive decision-making (at all). The decision 
(not) to take part in screening should be based on women’s values, not on their financial 
resources – although pregnant couples may reasonably ask themselves whether they have 
the social, practical and financial means to care for a child with a disability. Health 
professionals should discuss with pregnant women and their partners the reasons why they  
would wish to use screening, and what they would do in case of abnormalities.(50) Not 
making people pay, but offering adequate pre-test counselling should thus be (part of) a 
solution to safeguard informed choice. The offering of value-based pre-test counselling will 
likely be more effective in promoting reproductive autonomy than the asking of a co -
payment for NIPT.  
 
Conclusion 
We have argued that the (co-)payment requirement for NIPT is not a necessary nor a 
subsidiary approach to the promotion of informed choice among pregnant women and their 
partners, and does not serve reproductive autonomy. While informed choice remains of 
paramount importance in all prenatal screening programs, there are no indications that 
charging women for NIPT will prove effective in accomplishing this. In fact, it may lead to the 
opposite of reproductive autonomy, when women forego screening not based on well-
considered choice, but simply because of financial constraints. Although reimbursement 
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policies will likely affect pregnant women’s and their partners’ choice behaviour, neither full 
reimbursement nor the asking of a co-payment is fully neutral, and neither will in and of 
itself improve informed choice. Rather, informed choice should be accomplished through 
adequate information provision and value-based pre-test counselling focused on the 
promotion of choice awareness and deliberation.  
Funding policies should not be used to prevent increased uptake of first-trimester prenatal 
screening. Financial barriers will disproportionately affect those of lower socio-economic 
status, which is not in line with general justice requirements nor with the aim of prenat al 
screening. Instead, full reimbursement of NIPT for trisomies 13, 18 and 21 – and in future, 
possibly for other serious childhood disorders – will help to guarantee equal access to 
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In both the scientific and social debate about the implementation of non-invasive prenatal 
testing (NIPT), scientists, health professionals, pregnant women, parents of children with 
Down’s syndrome and the general public extensively discuss the pros and cons of this 
relatively new and promising prenatal screening test for Down’s, Edwards’ and Patau’s 
syndrome. Both debates address the ethical and social aspects of implementing NIPT in a 
national prenatal screening programme, including the possible negative consequences of 
NIPT for individuals and society. These negative consequences include the negative effects of 
NIPT on informed choice, routinization of prenatal screening, societal pressure to test and 
reimbursement of prenatal screening. These concerns are often referred to by those who 
have reservations regarding the implementation of NIPT and are used as arguments in both 
debates. However, empirical or ethical support for them is limited. In this thesis these 
arguments are analysed and provided with supporting or refuting ethical and empirical 
argumentation. The aim of these analyses is to advance and nuance the scientific and social 
debate about prenatal screening, especially about NIPT and the expansion of its scope: in the 
future, whole genome sequencing technologies may be used to screen the foetus for 
conditions other than trisomies 21, 18 and 13, based on NIPT.  
Main findings of this thesis 
Reconsidering pre-test counselling  
Firstly it is argued in several analyses of the ethical and social aspects of introducing NIPT 
that its procedural easiness and strong validity might lead to routine acceptance of NIPT: 
compared to the first trimester combined test which combines a blood test and an 
ultrasound to provide a risk estimate NIPT provides a more clear and easy understandable 
test result. Women might therefore accept NIPT routinely without making an informed 
choice, or professionals might present NIPT as a routine test.(1-3) An uninformed decision 
about prenatal screening is seen as problematic for reaching the aim of prenatal screening 
which is formulated as promoting reproductive autonomy. Pre-test counselling is the 
preferred instrument to reach informed decision-making and therewith reproductive 
autonomy and to counter these negative consequences of NIPT. But several studies 
suggested that the introduction of NIPT might pose challenges for pre-test counselling as 
counsellors sometimes had difficulties with having or taking enough time to for pre-test 
counselling (4), underestimated the importance of pre-test counselling about NIPT 




compared to invasive tests(5) or framed information when discussing different test 
options.(6) Furthermore, professionals, women and parents of children with Down’s 
syndrome interviewed for this thesis (chapter 2, 3 and 4) indicated that informed consent 
should be improved for the implementation of NIPT.(7-9) Interviewed professionals in the 
‘framework study’ (chapter 2) for example questioned the focus on information provision in 
pre-test counselling and suggested that the focus of pre-test counselling should shift to 
deliberation on personal values. Besides, the current focus on objective or ‘value-free’ 
information provision in pre-test counselling (10-12) might complicate counselling especially 
in the context of the expansion of the scope of prenatal screening. The next generation 
sequencing technologies and related possible test outcomes are increasingly complex and 
women might feel overwhelmed and unable to understand the relevant information 
necessary for the decision. In that case, an expansion of the scope might hinder the aim of 
prenatal screening because information overload impedes rather than fosters informed 
decision-making and autonomous reproductive choices.(13) To be able to deal with these 
current and future aspects of prenatal screening we proposed a three step counselling 
model the priory of which is exploring women’s personal values towards prenatal screening 
and related follow-up, including termination of pregnancy or caring for a child with a 
disability (chapter 5). In the first step of the counselling counsellors will exp lore women’s 
values and discuss them in order to enable women to make their values explicit and find out 
what is important to them. Medical technical information provided in the second step might 
support these considerations or maybe change it. In this second step women could weigh 
the information in the context of their values. With this counselling model women w ould be 
supported to provide informed consent for prenatal screening, also in case of an expanded 
scope. 
An analysis of routinisation   
A second argument introduced in the debate about possible consequences of NIPT is that 
this test might induce routinisation of prenatal screening. In chapter 6 we showed that this 
concept has several meanings when used in the context of prenatal screening, which 
consequently makes it unclear to what kind of problems the concept refers and how these 
can be counteracted.(14) Three versions of the concept were distinguished which comprise 
several inter-related fears or negative consequences of NIPT: 1) a reduced informe d choice, 
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2) a lack of freedom to choose and 3) negative consequences for people with a disability. We 
found that empirical studies limitedly support the first version because in general women 
did make informed choices and experienced freedom to choose not to accept prenatal 
screening, although the found percentages leave room for improvement. We also argued 
that to guarantee freedom of choice, actions should be taken to continue to evaluate 
(societal) pressure to test amongst pregnant women, and when it arises, to counteract it. 
Furthermore, we argued that when using the concept of routinisation it is necessary to  
specify to which kind of consequence it refers in order to devise strategies to counteract this 
consequence. 
Studying public attitudes with contrastive vignettes  
A third argument is that the test characteristics of NIPT could lead to societal pressure to  
accept prenatal testing: prospective parents might have the feeling that they cannot decline 
prenatal testing anymore, because its easiness and reliability compared to the first trimester 
combined test take away good reasons for declining it.(14) Furthermore, in contrast to 
invasive diagnostic tests (chorionic villus sampling and amniocentesis) NIPT holds no risks of 
miscarriage. This might contribute to positive public attitudes towards NIPT, which, it is 
feared, could lead to societal pressure to accept prenatal screening. But little is known about 
what the public attitudes towards prenatal screening are. It is furthermore difficult to study 
attitudes of the public without eliciting socially desirable responses. Therefore, to study 
public attitudes towards prenatal screening and termination of pregnancy, we made use of 
the contrastive vignette method which is designed to prevent socially desirable responses 
from participants (chapter 7). This vignette study revealed that a majority of participants  
thought that a decision about prenatal screening is a personal one that should not warrant 
judgment by other people. This result could help to reduce existing fears that current public 
attitudes lead to social pressure. Furthermore, this finding is, I think, strong result because 
the question we asked participants, about what they think about the decision of another 
person, precisely provokes a normative judgment about someone’s decision. Therefore, this 
finding reflects a normative public attitude towards how someone should relate to these 
personal decisions.  
Reimbursement of prenatal screening does not promote informed choice   
The fourth argument in the debate about NIPT concerns co-payment of prenatal screening. It 




is argued or assumed by amongst others healthcare professionals (7), pregnant women (8) 
and parents of children with Down’s syndrome (9) that asking a co-payment could make 
women aware of the importance of the decision and improve informed decision-making. 
However, as shown in the ethical analysis in chapter 8 this assumption lacks ethical support: 
given the aim of prenatal screening (promoting reproductive autonomy) we argue that 
although payment models may influence pregnant women’s choice behaviours and 
perceptions of the relevance of NIPT, the co-payment requirement does not necessarily lead 
to better informed choices and thus does not promote the aim of prenatal screening 
(Chapter 8).(15) 
Reflection on the framework of prenatal screening and the expansion of the scope  
Based on existing reports and statements about the ethical and social aspects of prenatal 
screening a framework was distilled consisting of four pillars: 1) the aim of prenata l 
screening for congenital disorders, 2) the proportionality of the test, 3) justice and 4) social 
aspects (chapter 2).(7) The main findings in this thesis provide specification or 
reconsideration of these pillars in the ethical framework of prenatal screening, especially in 
the context of the possibility to expand its scope.   
1. The aim of prenatal screening for congenital disorders  
Firstly the aim of prenatal screening, the first pillar of the framework, is formulated as 
offering reproductive choices or promoting reproductive autonomy.(13) In the practice of 
prenatal screening this aim should be reached by enabling parents to make an informed 
decision. The fear related to the expansion of the scope of prenatal screening is that an 
increase in the number of disorders included in the test affects informed decision-
making.(13) An information-overload might make it difficult for women to make an informed 
choice, particularly when the focus of pre-test counselling is the provision of objective or 
‘value-neutral’ information.(11) But, when the aim of pre-test counselling primarily is to 
elicit pregnant women’s values and norms towards prenatal screening and its follow -up, as 
proposed and argued in chapter 5, the amount of technical and medical information might 
have less impact on decision-making. This approach of pre-test counselling and obtaining 
informed consent complements the first pillar of the framework and contributes to the 
promotion of reproductive autonomy. It provides direction in how this aim still can be 
reached when the scope of prenatal will expand and might counter the objection of 
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information-overload when more disorders will be included in the test. In sum, within the 
first pillar we specified that the aim of reproductive autonomy is not reached  primarily by 
providing objective information during pre-test counselling but by exploring women’s values. 
  
Furthermore, in practice the process of informed decision-making may start before pre-test 
counselling. Women gather information on the internet and in their social environment. 
Some women already made a decision concerning prenatal screening before they visited the 
midwife.(8) The impact of the news media and social media on this decision should not be 
underestimated I think. Therefore I would suggest that the public debate about prenatal 
screening could be used to provide women with different kinds of values and information 
concerning prenatal screening and its possible follow-up decisions. In the introduction of this 
thesis I mentioned two newspaper articles which for example might be helpful to pregnant 
women who are thinking about prenatal screening. To enhance informed decision -making 
health professionals and scientists as well as women and parents of children with a disability 
could contribute to this debate with sharing their information and values in order to create a 
social context wherein all values are mentioned. This might help women to reflect on their 
personal considerations. This possibly also might contribute to the freedom to accept or  
decline prenatal screening and to terminate or continue a pregnancy in case of a diagnosis of 
a congenital disorder. 
2. The proportionality of the test   
The second pillar of the prenatal screening framework concerns proportionality of the test 
and includes the balance between benefits and harms of prenatal screening. The question 
how this balance should be found is particularly relevant when thinking about the expansion 
of the scope of prenatal screening. The possibility to include more disorders not only  
increases women’s courses of action but might also have disadvantages. In our interview 
studies, health professionals and pregnant women mentioned the possible limited clinical 
validity of some test results and the related unnecessary anxiety, an increase in unnecessary 
invasive testing (which would undo the positive effects that NIPT limited to trisomies 13, 18 
and 21 currently has on the number of invasive follow-up tests), and the difficulty to define 
which disorders are ‘serious’ enough to include (chapter 2 and 3). Related to the question 
which disorders should be seen as serious enough, in the WHO framework document it was 




argued for example that parents should personally decide which disorders should be 
included.(16) Also some of the interviewed professionals in our study thought that pregnant 
women should decide themselves whether a disorder is serious enough to test for, taking 
into account their personal situation and personal views.(7) We therefore asked pregnant 
women in interviews which kind of disorders they would include in prenatal screening 
(chapter 3). We discussed several categories of disorders with them, including early onset, 
late onset, and neurological disorders, based on categories as used in clinical genetics 
practice.(17) These interviews showed that for every woman the balance between benefits 
and disadvantages of prenatal screening as well as the personal considerations differ. 
Women furthermore indicated negative psychosocial aspects of an expanded scope: women 
might not have ‘worry-free’ pregnancies anymore, the children with all kinds of 
abnormalities might be excluded from societies and abortion might be asked for less severe 
abnormalities. Besides, they found it difficult to assess the impact of prenatal screening for 
the several categories of disorders that could be included in prenatal screening and they had 
difficulties to demarcate the scope (chapter 3). However, another study on preferences of 
women concerning NIPT and its scope showed that 78% chose to learn about incidental 
findings including other trisomies or microdeletions which might have variable clinical 
implications.(18) And previous studies on women’s preferences for prenatal diagnosis 
indicated that most women opted for the option which provides a maximum of 
information.(19, 20) If pregnant women prefer a maximum of information, how should that 
be combined with the qualitative studies which found that women feared a slippery slope or 
questioned where to draw a line?(21, 22) Additionally, other studies showed that p otential 
users of prenatal screening had doubts about having the choice between a smaller or 
broader test because it might be a burden to decide.(23, 24) The question will be whether 
women are able to make informed decisions for themselves about which disorders they 
would wish to have included in their prenatal test.  
In sum, besides the clinical test requirements for performance and validity of the offered 
test, which are necessary for a responsible implementation of a prenatal test, in the pillar of 
proportionality another balance must be sought: the balance between on the one hand the 
benefit of having reproductive options in order to make informed autonomous reproductive 
decisions and on the other hand the burden of having too many options which does not  help 
women to make autonomous reproductive decisions. And the related difficulty is that this 
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balance might be personal for every woman. Those who offer prenatal screening have to 
decide between promoting autonomous decisions on one hand and doing no harm with 
providing too many difficult decisions on the other hand, without being paternalistic.  
3. Justice  
The third pillar justice addresses the specific issue of access to prenatal screening, including 
reimbursement of the tests. We argued in chapter 8 that asking a co-payment is not a 
measure to improve informed decision-making. On the contrary it hinders autonomous 
decision-making for those for whom the co-payment is too high to pay.(15) We also stated 
that the role of money in decision-making will not be neutral but could carry a message both 
in case of a fully reimbursed test as well in case of a co-paid test: a fully reimbursed test 
might carry the message that the government stimulates screening and that women should 
accept the test. A co-paid test might carry the message that the government does not 
endorse screening and does not consider it important or necessary to offer the test.  
The findings from the vignette study on public attitudes towards prenatal screening (chapter 
7) also suggested an impact of asking a co-payment: more people agreed with declining NIPT 
when the test was not reimbursed. This possible impact of reimbursement policy should be 
addressed in the framework and at least be considered when deciding about a 
reimbursement policy because, although asking a co-payment will not promote well-
informed choices, it could influence women’s decision-making and also public attitudes 
towards prenatal screening.(15)  
Another issue of justice is the equality in people’s ability to understand the necessary 
information, according to the UNESCO international bioethics report about human genome 
and human rights.(25) It is feared that an increase in pre-test information for an expanded 
prenatal test might enlarge the difference between those who are able to understand the 
information and to make an informed decision and those who are not. The counselling 
model as proposed in chapter 5 might render the concerns regarding inequality of 
information less important, because it focusses on women’s values (not on technical or 
medical information about the screening test) as a key component of informed consent. In 
combination with a layered approach to information provision women might be helped with 
understanding the information necessary to make  




4. Social aspects  
In this thesis routinisation of prenatal screening and societal pressure to test, two of the 
social aspects of prenatal screening from the fourth framework pillar, are ethically and 
empirically addressed. The analyses of routinisation showed the importance of specifying 
the concept in order to make clear to which problem it refers. One of these problems which 
are referred to as routinisation is a lack of freedom to choose or the presence of societal 
pressure (chapter 6). In the vignette study we empirically examined this concern by studying 
public attitudes towards prenatal screening in the Netherlands (chapter 7).  
Societal pressure to test is a recurring theme in the discussion about societal aspects of 
prenatal screening (7, 14), but also in the discussion about the aim of promoting 
reproductive choices(14) and reimbursement policy for prenatal screening.(8)  
However, the vignette study on public attitudes towards NIPT and termination of pregnancy 
(chapter 7) and also the interview studies amongst professionals, pregnant women and 
parents about prenatal screening and NIPT (chapter 2, 3 and 4) raise the question  how 
societal pressure actually should be defined. In for example the interview study amongst 
pregnant women most participants declared that they did not experience pressure 
themselves. They explained that there is freedom to choose in the Dutch society, that there 
are different public opinions present about prenatal screening and termination of pregnancy 
and there is not one major opinion that steers pregnant women into accepting or declining 
prenatal screening. This is in line with previous studies which assessed reasons for prenatal 
screening. These studies revealed that the opinion of others was one of the least mentioned 
reasons to accept or decline a prenatal test.(26, 27)   
But, in the context of societal pressure we also discussed with pregnant women the possible 
influence of opinions of others on decisions about prenatal screening and then they referred 
to several societal attitudes that might influence women’s decision. Firstly, some women 
mentioned the possibility that opting for a test and termination of pregnancy is taken as self-
evident in society which might steer decision-making. Others related societal pressure to a 
perceived pressure not to terminate the pregnancy after receiving an abnormal diagnostic 
test result. Women also mentioned critical questions from friends and relatives as sources of 
pressure or the influence or pressure from a healthcare professional who offered the 
prenatal test (chapter 3).   
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Societal pressure could thus refer to different kinds of pressure including firstly outs poken 
positive or negative judgments concerning prenatal screening from other people in society 
or from family and friends or the ‘trusted’ health professional, sources which were also 
mentioned in the literature.(21, 28, 29) Secondly, societal pressure could refer to explicit 
public opinions that disabled children should not be born, because for example they are too 
expensive for society. Some of the parents of children with Down’s syndrome for example 
referred to being held responsible for raising a child with a disability and a few parents 
feared that in the future this might also include the financial costs.(9) In another qualitative 
study this is defined as a ‘social reaction of intolerance’(28): participants who declined 
prenatal screening feared that they will be held accountable for negative consequences of 
their decision. Related to that feelings of pressure could be fed by the suggestion that 
accepting a test belongs to responsible parenthood and not accepting a test might be seen 
as ‘irresponsible’.(21, 30)  
A third interpretation of societal pressure indicated in several empirical studies is that 
women may have the feeling that they cannot decline prenatal screening because it is simply 
available or, in case of NIPT, because it is ‘just another blood test’.(21, 31) Furthermore, 
women might feel the need to justify their decision to not accept NIPT because it is expected 
that they participate in prenatal screening.(32) These kinds of pressure are linked to 
routinisation of prenatal screening and are not new or specific for NIPT but were previously 
associated with prenatal screening and reproductive choices.(28, 33, 34)   
This short overview of several meanings of societal pressure has similarities with the 
outcomes of the analysis of the container concept of routinisation (chapter 6). In the analysis 
of the concept of routinisation we have already argued that using such a container concept 
does not provide enough information to analyse the specific possible problems of prenatal 
screening or to find possibilities to counteract these problems. Our analysis showed that the 
distinct problems that routinisation may refer to may require different solutions. We 
therefore argued for a specified use of the concept routinisation. The same conclusion might 
follow from a comparable analysis of the concept of societal pressure. Also for the 
arguments concerning societal pressure it would be an important first step to clarify what 
people’s fears exactly are.  




The second step in the analysis of societal pressure is to examine whether these fears can be 
supported with empirical evidence. People assume that the societal attitudes are mainly 
positive towards prenatal screening and therefore could pressure women to accept prenatal 
testing. But it was not studied yet what the attitudes of the Dutch public are towards 
prenatal screening. Therefore we conducted a contrastive vignette study on the Dutch public 
attitudes towards prenatal screening and termination of pregnancy (chapter 7). This 
quantitative study revealed that the vast majority of participants had a neutral attitude 
towards someone else’s decision about prenatal screening, explaining t hat it is someone’s 
own choice that should not be influenced by other people’s opinion. Nevertheless, some 
participants had outspoken normative judgements concerning accepting or declining 
prenatal screening including that when prenatal screening is available there is no reason to 
not accept it, especially when it is fully reimbursed. Other participants thought that prenatal 
screening is in the interest of the child and might prevent severe suffering for the child and 
close family. A few participants thought that it is ‘not necessary’ to have a child with a 
disability and that it costs too much money for society. The group of participants who held 
these opinions was very small but our study indicates that these kinds of judgements exist. 
However, revealing these public attitudes is not enough to disprove or prove societal 
pressure. The presence of indicators of pressure within the public attitudes does not mean 
that women indeed experience pressure regarding accepting or declining prenatal screening: 
it is possible that, although there are outspoken opinions regarding prenatal screening being 
indicators for societal pressure, women do not experience that pressure. Therefore the 
follow-up question is to what extent these positive or negative public opinions wou ld 
influence women’s decision-making or lead to a perceived pressure to test. But it will be 
more difficult to measure these experiences of pressure. To measure this personal 
experience other measurement scales for pressure are necessary. However the development 
of these measurement scales or the operationalization of societal pressure might raise 
several problems. Firstly, the way women describe pressure might be very personal  as 
shown in the interviews (chapter 3) and difficult to define in general terms, within a scale. 
Secondly, it is unclear to what extent women might experience pressure concretely: is it also 
possible that societal pressure is more subtle present in women’s decision -making? Related 
to the latter point it might be questionable whether it is still pressure when women do not 
experience pressure and have the feeling that they could make an autonomous choice, while 
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they are maybe unconsciously influenced by for example their social environment. Does it 
still affect the aim of reproductive autonomy, when women do not feel pressure and have 
the feeling that they could make an autonomous choice?   
To conclude, the argument of societal pressure needs at least more specification about its 
sources and related fears. The argument also requires new measures to examine and 
monitor pressure which include as much as possible the possible variability in personal 
experience of pressure.  
Conclusion 
In sum, the main findings of this thesis are that there is a set ethical framework for prenatal 
screening of which the pillars and moral starting points provide ground for the current 
prenatal screening offer and future expansion of its scope, including the possible negative 
consequences such as challenges for women’s informed consent, information overload, 
routine acceptance of prenatal screening and societal pressure to test.  
Reflections on the aim of prenatal screening  
This thesis has shown that there is a well formulated aim of prenatal screening within the 
ethical framework. This framework provides guidance to deal with the challenges of reaching 
the aim of promoting reproductive autonomy. But one new challenge is not mentioned yet 
in this framework, the future availability of foetal treatment for congenital disorders. In this 
section I want to reflect further on the aim, its position within this framework and the 
possible consequences of enabling foetal treatment. 
Offering reproductive options or promoting reproductive autonomy  
The aim of prenatal screening as we have discussed throughout this thesis is formulated as 
‘promoting reproductive autonomy’ or ‘offering reproductive options’. Both definitions of 
the aim refer to offering women the possibility to decide about termination of pregnancy in 
case of a congenital abnormality, or to prepare for the birth of a child with a disability. This 
aim requires autonomous informed decision-making, which is attained by offering sufficient 
information to women and promoting their informed decision-making.(13, 16, 25, 35, 36) 
Therefore, to assess the ‘effectiveness’ of the program of prenatal screening scales are 
developed to measure women’s reproductive autonomy(37) and to measure women’s 
informed consent(38, 39) or informed choice.(40-42) The studies on informedness of 




decision-making provided different conclusions about whether the aim of prenatal screening 
is reached, from high percentages of informed consent or informed choice to relatively low 
percentages.  
However, the analyses of the four pillars of the framework in chapter 2 and in this discussion 
section also refer to other requirements for a responsible offer of prenatal screening. These 
requirements also affect the aim of prenatal screening: proportionality of the offered test 
might restrict the number of courses of action women may have, reimbursement policies 
should minimally influence women’s decision-making and freedom of choice should be 
guaranteed. These requirements of the framework are comprehensive and show that merely 
offering prenatal screening does not promote reproductive autonomy and thus might not 
reach the aim. 
In this paragraph I would therefore argue for a distinction between offering reproductive 
options as the aim of a prenatal screening offer and promoting reproductive autonomy as 
the justification of the prenatal screening offer.  
Future parents make many reproductive choices before and during pregnancy. Prenatal 
screening aims to contribute to having reproductive options, firstly in the offer of a prenatal 
test in order to learn about congenital abnormalities and secondly in opting for termination 
or continuation of the pregnancy in case of a detected abnormality.   
These reproductive options promote women’s autonomy when they are enabled to decide 
about these options personally and well informed, according to the Western perspective on 
autonomy.(43)  
Autonomy is amongst others about self-governing agents who formulate their own ideals 
and undertake actions according to these ideals. Prenatal screening could support women to 
act according their personal ideals by providing courses of action in case of an abnormal ity in 
a foetus and therewith support their reproductive autonomy. However, in the field of 
prenatal screening it is acknowledged that this formulation of the aim meets some 
challenges.(3) Firstly, there are problems with saying that the aim of prenatal screening is 
maximizing the number of options, like the ‘Pure Choice paradigm’ or the pure autonomy 
paradigm’ do.(3, 44) These paradigms advocate for a maximization of choice without 
limitations. But the aim of a public prenatal screening offer cannot be formulated as simply 
maximizing reproductive options because then it is not justifiable to limit the scope to for 
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example severe or untreatable health conditions.(3) Also in the context of the expansion of 
the scope of prenatal screening it is mentioned that the scope should not be determined 
based on the maximization of the choice, but that informed consent, benefits and harms, 
aspects of justice and social consequences should guide the expansion of the scope.(7, 13) 
  
This thesis furthermore showed that reproductive autonomy not only depends on the 
existence of a prenatal screening offer but is also determined by the way pre-test 
counselling is offered and conducted and the extent to which freedom of choice is 
experienced or guaranteed (chapter 2, 5 and 6). The framework for a responsible prenatal 
screening offer also includes absence of societal pressure, availability of equal valuable 
options, and access to care for people with a disability as requirements for a responsible 
implementation of prenatal screening (chapter 2).(7, 13) Offering reproductive options 
without such a framework cannot be seen as a justified and responsible prenatal screeni ng 
offer. A framework for prenatal screening provides guidance and requirements in order to 
justify and regulate this offer and its aim. This justification is especially important when it 
concerns a public prenatal screening programme, with course of options linked to the moral 
sensitive practice of (selective) abortion.(13)  
A distinction between the aim of prenatal screening formulated as offering reproductive 
options and the justification of a prenatal screening programme formulated as promoting 
reproductive autonomy could contribute to the clarification how offering reproductive 
options can be justified.  
According to this distinction the aspects elaborated on within the framework’s first pillar of 
the aim of prenatal screening, including promoting informed decision-making and pre-test 
counselling, would then be part of the requirements for the justification of prenatal 
screening and not requirements for the aim of prenatal screening. Furthermore, the fact that 
a prenatal screening offer also should be justifiable, underlines the importance of 
guaranteeing autonomous reproductive choices by addressing and monitoring continuously 
the four different pillars of the framework.  
Nonetheless, the aim of prenatal screening also should meet certain requirements I think. 
Test results should for example be valid and provide enough clear information to really offer 
reproductive options. These are proportionality requirements related to the second pillar 




which might be on the borderline of the distinction between the aim and the justification of 
prenatal screening.  
Treatment of congenital disorders, just another course of action?  
A new challenge for promoting reproductive autonomy is the finding that in the future 
several congenital abnormalities could be treated with foetal treatment.(45-48) Recently 
researchers have studied in utero surgery for spina bifida, a defect that can be detected with 
the 20-week ultrasound.(49, 50) Another new kind of foetal therapy is therapy for Down’s 
syndrome: it might become possible to improve neurocognitive skills of people with Down's 
syndrome as some pre-clinical studies suggested.(45) A basic science study presented results 
which suggested that it might become possible to inactivate the third copy of chromosome 
21 of the foetus and which therefore could lead to normal development.(51)  
The availability of foetal treatment raises several ethical questions and concerns. It is for 
example argued that the ‘expressivist’ critique on prenatal screening for Down’s syndrome 
also applies to foetal therapy. This argument includes objections against prenatal testing 
because of its discriminatory message to people with a disability. In line with this critique 
someone could argue that offering foetal treatment sends the same discriminatory message 
that lives of people with this disability are less worth living.(46) Besides, foetal treatment 
might affect an individual’s personality which could be seen as a negative consequence of 
this treatment, changing the benefits and harms for this person.(46)  
Another problem is that availability of treatment might challenge women’s decision-making 
regarding prenatal screening and thus challenge promoting reproductive autonomy. Prenatal 
screening is currently offered to provide women with an option to terminate the pregnancy 
in case of an untreatable congenital disorder. How women value this current option differs 
for each person, there is no good or wrong decision in this: in the current framework for 
prenatal screening accepting or declining a test and termination and continuation of 
pregnancy after receiving the diagnosis of Down’s syndrome are seen as moral equal 
options.(7) The availability of treatment for the syndrome might change this. One 
consideration is that if parents choose to decline prenatal screening for Down’s syndrome 
they will not be aware that their child has Down’s syndrome and thus they could deny their 
child with Down’s syndrome a better health. This might put pressure on women to accept 
prenatal screening even when they do not want to be confronted with these decisions. This 
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challenges the freedom to decline prenatal screening and thus women’s autonomy.   
A second challenge of the availability of foetal therapy for women’s freedom of choice is that 
when she receives a test result that her child has a congenital disorder, she might be 
expected to accept treatment rather than forego this, although she might have personal 
reasons to refrain from treatment.   
Treatment could also be seen as a preferable option above termination of the pregnancy, 
while some women might prefer the latter course of action. Although foetal therapy can be 
seen as an ultimate goal of prenatal diagnosis as argued by some authors (52), other authors 
argued that presenting foetal treatment in this way might be ethically problematic.(46) They 
stated that foetal treatment should not be presented as ‘the morally preferred option’ 
because whether it is a morally preferred option depends on the moral status attributed to 
the foetus.(46) On this issue, however, the pro-life and pro-choice visions differ(46) and 
values of pregnant women differ.(53, 54) Taking these differences into account the option to 
accept foetal treatment is then just another course of action after prenatal diagnosis about 
which a woman will decide according her own values. To help women to decide 
autonomously, the explication of values as proposed in chapter 5 might become even more 
important. In the context of decision-making about foetal treatment women might in 
particular need a personal moral ground on the basis of which she can reflect on the 
available information and options of prenatal screening and its possible follow-up. If women 
have the feeling that they are in a rollercoaster after receiving the diagnosis of Down’s 
syndrome and have to think about follow-up diagnose and further steps, it might be helpful 
to her to rely on what they had deliberated in the context of accepting screening.   
A third challenge is that the moral complexity of foetal treatment makes it less easy to 
present it just as another course of action. Professionals might present it as doing everything 
that is possible.(55) Or women might experience pressure because of a sense of 
responsibility and feel they are obliged to accept foetal treatment in the interest of the 
child.(46)   
It is imaginable that the availability of foetal treatment affects the freedom of choice and 
provokes certain judgements in society and increases societal pressure to test. Would the 
result of a new vignette study on the public attitudes towards prenatal screening then st ill 
be that the vast majority indicates that it is someone’s own choice? The plea for monitoring 
effects of offering prenatal screening should receive more attention as well as studying how 




to achieve an environment wherein women can freely choose according to their own values. 
This study would also regard policy measurements including guaranteeing care for  people 
with a disability, ensuring equal access to foetal treatment as well as to safe and affordable 
pregnancy termination services in order to have equal valuable courses of action for women 
who have to decide about prenatal screening.(56) 
In conclusion, there is a set framework for prenatal screening including requirements for a 
responsible implementation of non-invasive prenatal screening. These requirements, 
including informed decision-making, availability of equal valuable options, absence of 
societal pressure, and access to care for people with a disability are essential for the 
justification of offering prenatal screening because they are essential for women’s 
reproductive autonomous decision-making in case of congenital abnormalities.   
Besides, new techniques, which enable an expansion in courses of action including the 
possibility of having better pregnancy outcomes with foetal treatment, raise challenges for 
the aim of promoting reproductive autonomy and for informed and autonomous decision -
making which amongst others can be addressed by a refocus in pre-test counselling.  
Recommendations for further research   
The first unsolved difficulty in this thesis is the determination of the scope of prenatal 
screening based on the justification and proportionality requirements of the ethical 
framework. The question is who should determine the balance between on the one hand 
the benefit of having reproductive options in order to make an informed autonomous 
reproductive choice and on the other hand the burden of having too many options which 
leads to an inability to make an autonomous reproductive choice. Those who offer prenatal 
screening have to decide between guaranteeing personal autonomous choices on the one 
hand and doing no harm with providing too (many) difficult decisions on the other hand, 
without being paternalistic.   
A first step towards addressing this dilemma might be to study whether and how women 
experience these decisions in practice, before and after accepting an expanded test and 
after receiving an abnormal test result. There are for example upcoming studies which will 
evaluate how pregnant women look back on the process of prenatal screening and on 
receiving information about an incidental finding.(57) The findings of this kind of studies 
might provide counsellors with more background information to help pregnant women 
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decide about a broader prenatal test which implies a greater likelihood of incidental findings, 
or choose between a smaller or broader test.  
A second recommendation for further research concerns the clarification of the concept of 
societal pressure as it is used in the arguments for a restricted implementation of NIPT. As 
shown in this discussion, the concept of societal pressure has more than one meaning and 
therefore possibly needs more than one solution. To deal with this possible negative aspect 
of offering prenatal screening and particularly NIPT it is important to clarify what critics 
mean with this concept and what their concerns are. Furthermore, it should be found out 
how best to measure and monitor societal pressure. For this question it is important to 
define societal pressure. Is it something that can be measured through a scale or with a 
questionnaire whereby pregnant women or the public are explicitly asked for their opinions? 
Or should the study design be more implicit like the contrastive vignette method we used in 
our study (chapter 7). A final topic for further study is how societal pressure can be 
counteracted. Is pre-test counselling enough or are there other measures necessary like for 
example a public education programme? 
Finally, because of the increase in possible courses of action after a prenatal diagnos is, 
including having better pregnancy outcomes and availability of foetal treatment more 
reflection on the aim of prenatal screening and on the offer of prenatal screening in general 
is needed.  
It was previously argued that to women the aim of prenatal screening should be clear also 
when it concerns screening for different purposes including prevention or offering 
reproductive options:(13) a distinction should be made between screening for the purpose 
of prevention, for example for the Rhesus D status on the one hand and screening for 
congenital abnormalities, for example for Down’s syndrome on the other ha nd. One of the 
solutions for this distinction is that two separate screening moments are provided, in order 
to make clear to women that it concerns different screening programmes with two different 
aims. In case of foetal treatment for congenital disorders a new course of action is added. 
But as argued above, the decision to consent to this action is not the same decision as to 
terminate a pregnancy in case of an abnormal diagnostic test result or the decision to learn 
about congenital disorders in order to prepare for the birth of a child with a disability. 
Therefore new kinds of these (practical) solutions might become necessary to distinguish 




between the different courses of action. Furthermore, ethical reflection is needed on how 
the availability of foetal treatment could affect the aim of prenatal screening and whether it 
is just a new course of action after prenatal screening or that it should be prese nted apart 
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The ethical and social debate about prenatal screening and particularly about NIPT address 
several recurring and pressing themes concerning informed choice, routine acceptance of a 
prenatal screening offer, societal pressure to test, reimbursement and the expansion of the 
scope of prenatal screening. However, the relevant arguments appeared to need more 
clarification, soundness or evidence. The aim of this thesis is to contribute to the debates 
with explicating arguments and searching for evidence in ethical and empirical literature to 
support or criticize the relevant arguments.  
 
Chapter 2 offers an account of the leading international ethical framework for prenatal 
screening and analyse it in the context of an expansion of the scope of prenatal screening.  A 
comparative analysis was conducted of four authoritative international and national 
statements and position. Furthermore it was examined how this framework is used by 
professionals working in the field of NIPT. 15 professionals in the field of prenatal screening 
in the Netherlands were interviewed. The current ethical framework consists of four pillars: 
the aim of prenatal screening, the proportionality of the test, justice, and societal aspects. 
Respondents recognised and supported this framework but they also expressed some 
concerns. They felt that pregnant women do not always make informed choices, while this is 
seen as central to reproductive autonomy which is the aim of prenatal screening. Pre-test 
counselling practices therefore stand in need of improvement and more attention could be 
paid to women’s personal values. This becomes especially important in the light of the 
expansion of the scope of prenatal screening when more information becomes available. 
New forms of counselling should therefore be studied.  
Related to proportionality respondents believed that the benefits of NIPT outweigh the 
harms. The mentioned harms of an expanded scope were false positive and negative or 
unclear test results. Therefore proportionality might limit the expansion. 
Justice relates to equal access for prenatal screening. Professionals felt that the out-of-
pocket financial contribution currently required by pregnant women on one hand can be a 
helpful barrier for making women aware of the importance of the choice. But o n the other 
hand it constitutes a barrier to access to NIPT which disproportionally affects those of a 
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lower socioeconomic status.  
Social aspects that where mentioned related to the framework were amongst others 
discrimination and stigmatisation of people with a disability and societal pressure to test for 
pregnant women. Professionals recognised but did not share concerns about a rising 
pressure to test or discrimination and stigmatisation. Although it is difficult to predict 
whether these social consequences will occur, the practice of prenatal screening should also 
be evaluated for these social implications.  
Chapter 3 The non-invasive prenatal test (NIPT) as first trimester prenatal screening for 
trisomies 21, 18, and 13 is offered to all pregnant women in the Netherlands. NIPT using 
genome sequencing allows for an expansion of the scope of prenatal screening and the 
introduction of NIPT gives rise to ethical and societal concerns about deliberated decision‐
making of pregnant women, pressure to engage in screening, and possible lack of equal 
access due to the financial contribution (€175) to NIPT. Pregnant women’s opinions were 
explored about these concerns and about the possibility of a broadening the scope of 
prenatal screening. Nineteen pregnant women representing a diversity of backgrounds were 
interviewed using a semi‐structured interview guide. Eight women did not opt for prenatal 
screening while 11 did (NIPT = 4, combined test = 7). Women experienced a free choice to 
accept or decline prenatal screening, despite sometimes receiving advice from others. Prior 
to pre-test counselling, some women had already deliberated about what an abnormal test 
result would mean to them. Others accepted or declined prenatal screening without 
deliberation. The current Dutch policy of requiring a co‐payment was acceptable to those 
who believed that it functioned as a threshold to think carefully about prenatal screening. 
Others were concerned that a financial threshold would lead to unequal access to screening. 
Finally, pregnant women found it difficult to formulate opinions on the scope of prenatal 
screening, because of lacking knowledge about the different disorders. Life expectancy, 
severity, and treatability were considered important criteria for the inclusion of a c ondition 
in NIPT. 
Chapter 4 explored the attitudes of parents of children with Down syndrome towards non -
invasive prenatal testing (NIPT) and widening the scope of prenatal screening. Three focus 
groups of in total sixteen Dutch parents and eleven individual interviews with Dutch parents 
(and two relatives) of children with Down syndrome were conducted. Parents saw safety, 




accuracy and earlier testing as the main advantages of NIPT. Also the reduction of the 
number of invasive procedures, and thus miscarriages was mentioned as great advantage. 
However, many feared uncritical use of NIPT and more abortions for Down syndrome. 
Parents expected unwanted consequences of this uncritical use including a limitation in 
freedom to choose not to have prenatal screening and negative consequences for the 
acceptance of and facilities for children with Down syndrome. They feared that this might 
result in more people who accept screening and termination the pregnancy of a disabled 
child. Participants stressed the importance of good counselling and balanced, accurate 
information about Down syndrome instead of a too negative or too optimistic portrait of 
Down’s syndrome. Testing for more disorders might divert the focus away from Down 
syndrome, but participants worried about “where to draw the line”. They also feared a loss 
of diversity in society. Findings in this chapter showed that, while parents acknowledge that 
NIPT offers a better and safer option to know whether the foetus is affected, they also have 
concerns about NIPT’s impact on the freedom to accept or decline prenatal screening and on 
the acceptance and care of children with Down syndrome.  
Chapter 5 proposes a rethinking for pre-test counselling and provided an ethical analysis of 
informed consent in the context of NIPT. Informed consent is a key condition for prenatal 
screening programs to reach their aim of promoting reproductive autonomy. Reaching this 
aim is currently being challenged with the introduction of non-invasive prenatal testing 
(NIPT) in first-trimester prenatal screening programs: amongst others its procedural ease –it 
only requires a blood draw and reaches high levels of reliability– might hinder women’s 
understanding that they should make a personal, informed decision about screening. We 
offer arguments for a renewed recognition and use of informed consent compared to 
informed choice, and for a focus on value-consistent choices and personalized informational 
preferences. We argue for a three-step counselling model in which three decision moments 
are distinguished and differently addressed. 1) Professionals explore women’s values 
concerning whether and why they wish to know whether their baby has a genetic disorder . 
2) Women receive layered medical-technical information and are asked to make a decision 
about screening. 3) During post-test counselling, women are supported in decision -making 
about follow-up testing and the continuation or termination of their pregnancy. This model 
might also be applicable in other fields of genetic (pre-test) counselling, where techniques 
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for expanding genome analysis and burdensome test-outcomes challenge counselling of 
patients. 
In chapter 6 the concept of routinisation is critically assessed as well as the related 
arguments. In the debate surrounding the introduction of non-invasive prenatal testing 
(NIPT) in prenatal screening programmes, the concept of routinisation is often used to refer 
to concerns and potential negative consequences of the test. A literature analysis shows that 
routinisation has many different meanings, which can be distinguished in three major 
versions of the concept. Each of these versions comprises several inter-related fears and 
concerns regarding prenatal screening and particularly regarding NIPT in three areas: (1) 
informed choice, (2) freedom to choose and (3) consequences for people with a disability. 
Three of the strongest arguments raised under the flag of routinisation are assessed for their 
validity: the threat that NIPT poses to informed choice, the potential increase in uptake of 
first-trimester prenatal screening and its consequences for social pressure to participate in 
screening or terminate affected pregnancies, and the negative consequences for d isabled 
people. These routinisation arguments lack valid empirical or normative ground. How ever, 
the results of this analysis do not imply that no attention should be paid to possible 
problems surrounding the introduction of NIPT. At least two problems remain and should be 
addressed: there should be an ongoing debate about the requirements of in formed choice, 
particularly related to an expanded scope of prenatal screening. Also, reproductive 
autonomy can only be achieved when expecting parents’ options are variegated, real and 
valuable, so that they can continue to choose whether or not to screen  or to terminate a 
pregnancy. 
Chapter 7 provided an insight in public attitudes towards prenatal screening through the 
contrastive vignette method. The introduction of the accurate and procedurally easy non-
invasive prenatal test (NIPT) raises ethical concerns that public attitudes towards prenatal 
screening may change, leading to societal pressure to participate in aneuploidy screening. 
This study examined Dutch citizens’ attitudes towards a pregnant woman’s decision to 1) 
decline NIPT in the context of two different funding policies and 2) to terminate or continue 
a pregnancy affected by different disorders. The attitudes of 1096 respondents were 
assessed with the contrastive vignette method, using two pairs of vignettes about declining 
NIPT and termination of pregnancy. Most respondents either agreed or did not agree or 




disagree with a woman’s decision to decline NIPT stating that this decision is someone’s own 
to make and does not warrant judgment by others. However, funding policies did influence 
respondents’ attitudes: significantly more respondents disagreed with declining NIPT when it 
was fully reimbursed.   
Respondents had similar attitudes to the vignettes on termination and continuation of 
pregnancy in case of Down’s syndrome. In case of Edward’s or Patau’s syndrome, however, 
significantly more respondents disagreed with continuation, citing the severity of the 
disorder and the child’s best interests. This study demonstrates broad acknowledgment of 
women’s freedom of choice in Dutch society; a finding that may help to rebut existing 
concerns about societal pressure for pregnant women to participate in prenatal screening. 
As the reimbursement policy and the scope of NIPT may influence people’s attitudes and 
elicit moral judgements, however, maintaining freedom of choice warrants sustained efforts 
by health professionals and policy-makers. 
Chapter 8 addresses the reimbursement question of prenatal screening. The introduction of 
non-invasive prenatal testing (NIPT) in healthcare systems around the world offers an 
opportunity to reconsider funding policies for prenatal screening. In some countries with 
universal access healthcare systems, pregnant women and their partners are asked to 
(co)pay for NIPT. In this chapter two important rationales for charging women for NIPT were 
discussed: (1) to prevent increased uptake of NIPT and (2) to promote informed choice. First, 
given the aim of prenatal screening (reproductive autonomy), high or low uptake rates are 
not intrinsically desirable or undesirable. Using funding policies to negatively affect uptake, 
however, is at odds with the aim of screening. Furthermore, co-payment disproportionally 
affects those of lower socioeconomic status, which conflicts with justice requirements and 
impedes equal access to prenatal screening. Second, it is argued that although payment 
models may influence pregnant women’s choice behaviours and perceptions of the 
relevance of NIPT, the co-payment requirement does not necessarily lead to better-informed 
choices. On the contrary, external (i.e., financial) influences on women’s personal choices for 
or against prenatal screening should ideally be avoided. To improve informed decision -
making, healthcare systems should instead invest in adequate non-directive, value focused 
pre-test counselling. This chapter concludes that requiring (substantial) co-payments for 
NIPT in universal access healthcare systems fail to promote reproductive autonomy.  
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Concluding remarks   
A set framework for prenatal screening is defined including preconditions for  a responsible 
implementation of non-invasive prenatal screening. New techniques, which enable an 
expansion of the scope prenatal screening including the possibility of having better 
pregnancy outcomes and possibly provide availability of foetal treatment,  raise challenges 
for the aim of promoting reproductive autonomy and how informed and autonomous 
decision-making should be reached. Therefore more reflection on the consequences of these 
new possibilities for the aim of prenatal screening is necessary. Besides, the aim of prenatal 
screening is associated with some preconditions including informed decision -making, 
absence of societal pressure, availability of equal valuable options, and access to care for 
people with a disability. These preconditions, comprised in a framework for prenatal 
screening, are the justification of promoting reproductive autonomy which should be 
distinguished from its aim of offering women reproductive choices in case of congenital 























Het ethische en publieke debat over prenatale screening, in het bijzonder over NIPT, gaat 
over geïnformeerde keuze, routineuze aanvaarding van het aanbod van prenatale screening, 
maatschappelijk druk om te testen, vergoeding van de test en uitbreiding van de reikwijdte 
van prenatale screening. De relevante argumenten vragen echter om meer verheldering of 
bewijs. Het doel van deze thesis is een bijdrage te leveren aan dit debat door middel van het 
expliciteren van argumenten en het zoeken naar bewijs in ethische en empirische literatuur 
om daarmee de relevante argumenten van onderbouwing of kritiek te voorzien. 
Hoofdstuk 2 biedt een uitwerking aan van een toonaangevend internationaal ethisch kader 
voor prenatale screening en analyseert het in de context van een uitbreiding van de scope 
van prenatale screening. Er is een vergelijkende analyse uitgevoerd van vier gezaghebbend e 
nationale en internationale documenten en stellingnamen. Vervolgens is onderzocht hoe het 
kader gebruikt wordt door professionals die werkzaam zijn in het veld van NIPT. Er zijn 
semigestructureerde interviews gehouden onder vijftien professionals uit het  veld van 
prenatale screening in Nederland. Het huidige ethische kader bestaat uit vier pijlers: het doel 
van screening, de proportionaliteit van de test, rechtvaardigheid en maatschappelijke 
aspecten. Respondenten herkenden en onderschreven dit kader in hun praktijk maar uitten 
ook hun zorgen. Ze denken dat zwangere vrouwen niet altijd een geïnformeerde keuze 
maken terwijl dit als cruciaal gezien wordt voor reproductieve autonomie, wat het doel is 
van screening. De counseling voorafgaand aan de test valt dus nog te verbeteren waarbij 
meer aandacht uit zou kunnen gaan naar de persoonlijke waarden van vrouwen. Dit is extra 
belangrijk in het licht van de uitbreiding van de scope van prenatale screening waarbij nog 
meer informatie over de foetus beschikbaar komt. Daarom zou er onderzoek gedaan 
moeten worden naar nieuwe vormen van counseling. Als het gaat om proportionaliteit 
dachten respondenten dat de voordelen van NIPT opwegen tegen de nadelen. De genoemde 
nadelen van een bredere scope waren fout- positieve, fout-negatieve of onduidelijke 
testresultaten. Om die reden zou proportionaliteit de uitbreiding van de scope kunnen 
begrenzen. Rechtvaardigheid gaat over gelijke toegang tot prenatale screening. 
Professionals hadden het gevoel dat de eigen financiële bijdrage die momenteel vereist is 
voor zwangere vrouwen enerzijds een behulpzame drempel kan zijn om vrouwen bewust te 




maken van het belang van de keuze. Anderzijds kan het een drempel opwerpen voor 
toegang tot NIPT die degenen met een lagere sociaaleconomische status onevenredig raakt. 
Maatschappelijke aspecten die genoemd werden in relatie tot het ethisch kader waren 
onder andere discriminatie en stigmatisering van mensen met een aandoening en sociale 
druk voor zwangere vrouwen om te testen. Professionals herkenden de zorgen over 
toenemende druk om te testen of over discriminatie en stigmatisering maar onderschreven 
die niet. Ondanks dat het moeilijk is om te voorspellen of deze maatschappelijke 
consequenties daadwerkelijk voor zullen komen moet de praktijk van prenatale screening 
ook voor deze sociale implicaties tegen het licht gehouden worden. 
Hoofdstuk 3 De niet-invasieve prenatale test (NIPT) voor de trisomiën 21, 18 en 13 wordt 
aangeboden aan alle zwangere vrouwen in Nederland. Omdat NIPT gebruik maakt van 
genoomsequencing is het mogelijk om de scope van de prenatale screening te vergroten. De 
introductie van NIPT geeft aanleiding tot ethische en maatschappelijke zorgen over 
weldoordachte besluitvorming van zwangere vrouwen, druk om deel te nemen aan 
screening en ongelijke toegang tot NIPT vanwege de financiële bijdrage van € 175,-. De 
meningen van zwangere vrouwen over deze zorgen zijn onderzocht, evenals hun 
standpunten over de mogelijke uitbreiding van de scope van prenatale screening. Negentien 
zwangere vrouwen die verschillende achtergronden representeerden zijn geïnterviewd aan 
de hand van een semigestructureerde interviewleidraad. Acht van de vrouwen nam geen 
deel aan de prenatale screening en de andere elf wel (NIPT = 4, combinatietest = 7). De 
vrouwen ervoeren een vrije keuze om de prenatale screening te accepteren of te weigeren, 
hoewel sommigen aangaven advies gekregen te hebben van anderen. Voorafgaand aan de 
pre-test counseling hadden sommige vrouwen al nagedacht over wat een afwijkend 
testresultaat voor hen zou betekenen. Anderen accepteerden of weigerden prenatale 
screening voor de trisomieën zonder erover na te denken. Het huidige Nederlandse beleid 
waarbij een eigen bijdrage gevraagd wordt was voor sommigen acceptabel. Zij dachten dat 
het zou kunnen functioneren als drempel om tot nadenken aan te zetten over prenatale 
screening. Anderen waren bezorgd dat een financiële drempel zou leiden tot ongelijke 
toegang tot screening. Ten slotte vonden de zwangere vrouwen het moeilijk om een mening 
te formuleren over de scope van de prenatale screening vanwege een gebrek aan kennis 
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over de verschillende aandoeningen. Levensverwachting, ernst en behandelmogelijkheden 
werden als belangrijke criteria genoemd voor het includeren van een aandoening in NIPT. 
Hoofdstuk 4 geeft de mening weer van ouders van kinderen met downsyndroom over de 
introductie van de niet-invasieve test en de uitbreiding van de scope van prenatale 
screening. Drie focusgroepen met in totaal 16 deelnemers en 11 individuele interviews zijn 
uitgevoerd met ouders en twee familie leden. Ouders zagen de afwezigheid van een 
miskraamrisico, de mogelijkheid om vroeg te testen en de betrouwbaarheid van de uitkomst 
als belangrijke voordelen van de test. Ze maakten zich wel zorgen over een ondoordacht 
gebruik van NIPT en een afname in keuzevrijheid om de test te weigeren. Verder vreesden ze 
negatieve consequenties voor de acceptatie van kinderen met downsyndroom en een 
afname in de beschikbaarheid van zorg voor deze kinderen. Ze vreesden dat hierdoor meer  
ouders zullen testen en de zwangerschap zullen beëindigen in het geval van een gevonden 
afwijking. Ouders benadrukten het belang van goede counseling en volledige informatie over 
downsyndroom. Met betrekking tot de scope noemden ouders als voordeel dat de  focus op 
downsyndroom minder zou worden. Wel vroegen ze zich af waar de grens getrokken moet 
worden van de scope. Sommige ouders noemden de mogelijkheid van verlies van diversiteit 
in de samenleving als nadeel van een bredere scope van prenatale screening.  
Hoofdstuk 5 introduceert een nieuw model voor pre-test counseling voor prenatale 
screening in de context van NIPT. Pre-test counseling is de manier om geïnformeerde keuze 
te bevorderen. Geïnformeerde keuze is belangrijk voor het bereiken van het doel van 
prenatale screening, het bevorderen van reproductieve autonomie. De introductie van NIPT 
brengt echter uitdagingen met zich mee voor dit doel. De angst is dat een eenvoudige test 
zoals NIPT, die alleen een bloedafname vereist, er toe leidt dat vrouwen niet nadenken ove r 
hun keuze voor prenatale screening. In dit hoofdstuk worden argumenten besproken voor 
het gebruik van het concept geïnformeerde toestemming boven het concept van 
geïnformeerde keuze, omdat dit beter aansluit op de bestaande ethische literatuur over 
besluitvorming en autonomie. Verder wordt er een nieuw counselingmodel voorgesteld dat 
focust op de waarden van de zwangere vrouw in plaats van op informatievoorziening. Dit 
model bestaat uit drie stappen. 1) de counselor bespreekt met de zwangere vrouw wat haa r 
waarden met betrekking tot prenatale screening zijn. 2) vrouwen ontvangen informatie over 
prenatale screening, op basis van hun informatiebehoefte en ze besluiten of ze prenatale 




screening willen. 3) in de post-test counseling worden vrouwen begeleid in de beslissing om 
al dan niet vervolgtesten te ondergaan en de zwangerschap te beëindigen of uit te dragen. 
Dit model maakt het ook mogelijk om vrouwen te ondersteunen in een beslissing over een 
NIPT wanneer meer aandoeningen zijn toegevoegd aan de test. Dit model is niet alleen 
geschikt voor prenatale screening maar zou mogelijk ook in andere gebieden van genetische 
counseling gebruikt kunnen worden. 
Hoofdstuk 6 biedt een analyse van het concept van routinisatie van prenatale screening. Dit 
concept wordt vaak gebruikt om zorgen aan te duiden met betrekking tot mogelijk negatieve 
gevolgen van de introductie van NIPT. Een literatuuranalyse laat drie verschillende 
betekenissen van dit concept zien die allen verschillende zorgen omvatten met betrekking 
tot NIPT. 1) NIPT zou de geïnformeerde keuze van vrouwen kunnen beïnvloeden. 2) NIPT zou 
de keuzevrijheid van vrouwen kunnen aantasten. 3) NIPT zou negatieve consequenties 
kunnen hebben voor mensen met een (chromosomale) aandoening. Deze drie zorgen en 
gerelateerde argumenten zijn in dit hoofdstuk onderzocht op hun validiteit en beschikbare 
empirische of conceptuele bewijs. Hoewel de resultaten laten zien dat er maar beperkt 
bewijs is voor deze zorgen neemt dat niet weg dat er aandacht aan besteed moet worden. In 
de eerste plaats moet er blijvend aandacht geschonken worden aan het bereiken van 
geïnformeerde keuze in het bijzonder met het oog op de uitbreiding van prenatale 
screening. En alle opties voor zwangere vrouwen, zowel het accepteren als afwijzen van 
prenatale screening en het beëindigen of uitdragen van de zwangerschap moeten 
gelijkwaardige opties zijn. Vrouwen moeten te allen tijde emotionele en materiële steun 
ontvangen bij de keuze die ze maken.  
Hoofdstuk 7 geeft inzicht in de mening van de Nederlandse bevolking over prenatale 
screening. De zorg is dat de NIPT, die eenvoudig uit te voeren is er voor zorgt dat vrouwen 
sociale druk zullen ervaren om de test te accepteren en daaraan gerelateerd om de 
zwangerschap af te breken. Om te onderzoeken of deze zorg terecht is moet er eerst 
gekeken worden naar hoe het Nederlandse publiek denkt over prenatale screening en 
zwangerschapsafbreking na prenatale screening. Dit hoofdstuk onderzoekt ten eerste de 
houding van een representatieve onderzoeksgroep ten opzichte van het afwijzen van NIPT in 
de context van verschillende vergoedingen: helemaal vergoed of inclusief een eigen bijdrage 
van €175,-. Ten tweede wordt onderzocht hoe deze groep staat tegenover 
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zwangerschapsafbreking. Deze houding is in kaart gebracht met de contrastieve vignetten 
methode die is ontwikkeld om sociaal wenselijke antwoorden te voorkomen.  
De grootste groep van de deelnemers gaf aan geen mening te hebben over de keuze van een 
ander om NIPT af te wijzen of de zwangerschap af te breken omdat dit iemands eigen keuze 
is die niet beoordeeld moet worden door anderen. Verder bleek dat het vragen van een 
eigen bijdrage wel invloed heeft op de mening van een aantal respondenten: significant 
meer respondenten waren het niet eens met het afwijzen van NIPT wanneer deze volledig 
vergoed werd vergeleken met een afwijzing van NIPT in het geval van een eigen bijdrage. 
Met betrekking tot het afbreken of uitdragen van de zwangerschap was er geen verschil in 
de houding van de respondenten tussen deze twee opties. Wel waren er meer respondenten 
die het niet eens waren met het uitdragen van de zwangerschap in het geval van edwards- of 
patausyndroom omdat dit niet in het belang van het kind is. De keuzevrijheid die in dit 
onderzoek hoog gewaardeerd wordt moet wel actief in stand gehouden worden en 
mogelijke negatieve invloeden van het vergoedingsbeleid of morele oordelen ten aanzien 
van de ernst van de ziekte moeten actief worden voorkomen door degenen die NIPT 
aanbieden.  
Hoofdstuk 8 behandelt de vraag met betrekking tot de vergoeding van prenatale screening. 
In sommige landen, waaronder Nederland, wordt aan zwangere vrouwen een eigen bijdrage 
gevraagd voor prenatale screening. Hiervoor zijn twee redenen te geven. Ten eerste zou een 
eigen bijdrage de toename in uptake van prenatale screening kunnen tegengaan en ten 
tweede zou een eigen bijdrage de geïnformeerde besluitvorming kunnen bevorderen. Het 
doel van prenatale screening, het bevorderen van reproductieve autonomie, geeft echter 
geen aanleiding om een hoge uptake te willen voorkomen of te bevorderen. Het vragen van 
een eigen bijdrage om de uptake te beïnvloeden kan juist niet samen gaan met dit doel. 
Verder heeft het vragen van een eigen bijdrage vooral effect op diegenen met een lagere 
sociaal economische status of een lager inkomen. Dit is in strijd met het principe van 
rechtvaardigheid en gelijke toegang tot prenatale screening. Daarnaast leidt het vragen van 
een eigen bijdrage niet tot een geïnformeerde keuze. In tegendeel, zowel het vragen van een 
bijdrage als een volledige vergoeding van NIPT zou geen invloed moeten hebben op de 
keuze van een zwangere vrouw.  




Concluderende opmerkingen  
Een vastgesteld kader voor prenatale screening omvat verschillende voorwaarden voor een 
verantwoorde implementatie van de niet-invasieve prenatale test. Nieuwe technieken die de 
uitbreiding van de scope van prenatale screening mogelijk maken en daarnaast ook de 
mogelijkheid gaan bieden om onder andere neurocognitieve kenmerken van downsyndroom 
foetaal te behandelen roepen vragen op ten aanzien van het doel van prenatale screening. 
De vraag is hoe vrouwen voor deze nieuwe mogelijkheden een geïnformeerde, persoonlijke 
en autonome keuze kunnen maken. Daarom moet er meer onderzoek gedaan worden naar 
hoe deze technieken het doel kunnen beïnvloeden en hoe een autonome keuze 
gewaarborgd kan worden.   
Daarnaast zijn er in het ethisch kader verschillende voorwaarden geformuleerd voor het 
aanbod van prenatale screening en het bereiken van het doel van het bieden van 
reproductieve keuzeopties. Dit kader vormt de rechtvaardiging van het doel van prenatale 
screening en moet onderscheiden worden van het doel vrouwen reproductieve keuzeopties 
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